Agilent (A) 10-K 21 Dec 15 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Billions	12 Months Ended
	Oct. 31, 2015	Dec. 01, 2015	Apr. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	AGILENT TECHNOLOGIES INC
Entity Central Index Key	1,090,872
Current Fiscal Year End Date	--10-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 9.6
Entity Common Stock, Shares Outstanding		332,170,890
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Oct. 31, 2015

CONSOLIDATED STATEMENT OF OPERA

CONSOLIDATED STATEMENT OF OPERATIONS - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Net revenue:
Products	$ 3,146	$ 3,185	$ 3,083
Services and other	892	863	811
Total net revenue	4,038	4,048	3,894
Costs and expenses:
Cost of products	1,496	1,568	1,525
Cost of services and other	501	504	462
Total costs	1,997	2,072	1,987
Research and development	330	358	337
Selling, general and administrative	1,189	1,199	1,184
Total costs and expenses	3,516	3,629	3,508
Income from operations	522	419	386
Interest income	7	9	7
Interest expense	(66)	(110)	(107)
Other income (expense), net	17	(89)	7
Income from continuing operations before taxes	480	229	293
Provision (benefit) for income taxes	42	(3)	68
Income from continuing operations	438	232	225
Income (loss) from discontinued operations, net of tax expense (benefit) of $(2), $100 and $57	(37)	317	509
Net income	$ 401	$ 549	$ 734
Net income per share - basic:
Income from continuing operations	$ 1.32	$ 0.70	$ 0.66
Income (loss) from discontinued operations	(0.12)	0.95	1.49
Net income per share - basic	1.20	1.65	2.15
Net income per share - diluted:
Income from continuing operations	1.31	0.69	0.65
Income (loss) from discontinued operations	(0.11)	0.93	1.48
Net income per share - diluted	$ 1.20	$ 1.62	$ 2.13
Weighted Averge Shares Used In Computing Net Income Per Share
Basic (in shares)	333	333	341
Diluted (in shares)	335	338	345
Cash dividends declared per common share	$ 0.400	$ 0.528	$ 0.460

CONSOLIDATED STATEMENT OF OPER3

CONSOLIDATED STATEMENT OF OPERATIONS (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Income tax expense (benefit) from discontinued operations	$ (2)	$ 100	$ 57

CONSOLIDATED STATEMENT OF COMPR

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Statement of Comprehensive Income [Abstract]
Net income	$ 401	$ 549	$ 734
Other comprehensive income (loss):
Unrealized gain on investments, net of tax (expense) benefit of $0, $(1) and $(2)	0	11	7
Amounts reclassified into earnings related to investments, net of tax of $0,$0,$0	0	(1)	0
Gain on derivative instruments, net of tax (expense) of $(3), $(5) and $(2)	8	8	8
Amounts reclassified into earnings related to derivative instruments, net of tax benefit of $6, $0 and $3	(12)	1	(10)
Foreign currency translation, net of tax benefit of $24, $8 and $8	(336)	(269)	1
Net defined benefit pension cost and post retirement plan costs:
Change in actuarial net loss, net of tax (expense) benefit of $17, $65 and $(114)	(38)	(143)	228
Change in net prior service benefit, net of tax benefit of $6, $16 and $16	(11)	(32)	(32)
Other comprehensive income (loss)	(389)	(425)	202
Total comprehensive income	$ 12	$ 124	$ 936

CONSOLIDATED STATEMENT OF COMP5

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Unrealized gain on investments, tax expense (benefit)	$ 0	$ 1	$ 2
Amounts reclassified into earnings related to investments, tax	0	0	0
Gain on derivative instruments, tax expense (benefit)	3	5	2
Amounts reclassified into earnings related to derivative instruments, tax expense (benefit)	(6)	0	(3)
Foreign currency translation, tax expense ( benefit)	(24)	(8)	(8)
Change in actuarial net loss, tax expense (benefit)	(17)	(65)	114
Change in net prior service benefit, tax expense (benefit)	$ (6)	$ (16)	$ (16)

CONSOLIDATED BALANCE SHEET

CONSOLIDATED BALANCE SHEET - USD ($) $ in Millions	Oct. 31, 2015	Oct. 31, 2014
Current assets:
Cash and cash equivalents	$ 2,003	$ 2,218
Short-term restricted cash and cash equivalents	242	0
Accounts receivable, net	606	626
Inventory	541	574
Other current assets	294	263
Current assets of discontinued operations	0	1,828
Total current assets	3,686	5,509
Property, plant and equipment, net	604	631
Goodwill	2,366	2,507
Other intangible assets, net	445	649
Long-term investments	86	96
Other assets	292	268
Non-current assets of discontinued operations	0	1,155
Total assets	7,479	10,815
Current liabilities:
Accounts payable	279	302
Employee compensation and benefits	221	228
Deferred revenue	258	260
Other accrued liabilities	218	279
Current liabilities of discontinued operations	0	623
Total current liabilities	976	1,692
Long-term debt	1,655	1,663
Retirement and post-retirement benefits	264	209
Other long-term liabilities	414	513
Long-term liabilities of discontinued operations	0	1,434
Total liabilities	$ 3,309	$ 5,511
Commitments and contingencies (Note 18)
Stockholders' equity:
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding	$ 0	$ 0
Common stock; $0.01 par value; 2 billion shares authorized; 611 million shares at October 31, 2015 and 608 million shares at October 31, 2014 issued	6	6
Treasury stock at cost; 279 million shares at October 31, 2015 and 273 million shares at October 31, 2014	(10,074)	(9,807)
Additional paid-in-capital	9,045	8,967
Retained earnings	5,581	6,469
Accumulated other comprehensive loss	(391)	(334)
Total stockholders' equity	4,167	5,301
Non-controlling interest	3	3
Total equity	4,170	5,304
Total liabilities and equity	$ 7,479	$ 10,815

CONSOLIDATED BALANCE SHEET (Par

CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares shares in Millions	Oct. 31, 2015	Oct. 31, 2014
Stockholders' equity:
Preferred stock par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock shares authorized (in shares)	125	125
Preferred Stock, Shares Issued (in shares)	0	0
Preferred Stock, Shares Outstanding (in shares)	0	0
Common stock par value (in dollars per share)	$ 0.01	$ 0.01
Common stock shares authorized (in shares)	2,000	2,000
Common stock issued (in shares)	611	608
Treasury stock, at cost (in shares)	279	273

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Cash flows from operating activities:
Net income	$ 401	$ 549	$ 734
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	253	384	372
Accelerated amortization of interest rate swap gain (due to early redemption of debt)	0	(22)	0
Share-based compensation	54	96	85
Excess tax benefit from share-based plans	(8)	(1)	(2)
Deferred taxes	70	(192)	(4)
Excess and obsolete inventory and inventory related charges	30	79	48
Non-cash restructuring and asset impairment charges	3	23	3
Net gain on sale of investments	0	(1)	(1)
Net (gain) loss on sale of assets and divestitures	3	(10)	3
Other	13	10	3
Changes in assets and liabilities:
Accounts receivable, net	(24)	(119)	14
Inventory	(24)	(99)	(100)
Accounts payable	(26)	50	(27)
Employee compensation and benefits	8	9	16
Other assets and liabilities	(262)	(45)	8
Net cash provided by operating activities	491	711	1,152
Cash flows from investing activities:
Investments in property, plant and equipment	(98)	(205)	(195)
Proceeds from the sale of property, plant and equipment	12	14	2
Proceeds from the sale of investment securities	0	1	12
Proceeds from divestitures	3	2	0
Payment to acquire equity method investment	(1)	(25)	(21)
Payment in exchange for convertible note	(2)	0	0
Purchase of other investments	0	0	(25)
Change in restricted cash, cash equivalents and investments, net	(240)	(4)	0
Acquisitions of businesses and intangible assets, net of cash acquired	(74)	(13)	(21)
Net cash used in investing activities	(400)	(230)	(248)
Cash flows from financing activities:
Issuance of common stock under employee stock plans	58	188	161
Treasury stock repurchases	(267)	(200)	(900)
Payment of dividends	(133)	(176)	(156)
Issuance of senior notes	0	1,099	597
Debt issuance costs	0	(9)	(5)
Repayments of Senior notes	0	(1,000)	(250)
Purchase of non-controlling interest	0	0	(3)
Proceeds from debts and credit facility	0	87	0
Net transfer of cash and cash equivalents to Keysight	(734)	0	0
Repayments of debt and credit facility	0	87	0
Excess tax benefit from share-based plans	8	1	2
Net cash used in financing activities	(1,068)	(97)	(554)
Effect of exchange rate movements	(48)	(31)	(26)
Net increase (decrease) in cash and cash equivalents	(1,025)	353	324
Cash and cash equivalents at beginning of year	3,028	2,675	2,351
Change in cash and cash equivalents within current assets of discontinued operations	810
Cash and cash equivalents at beginning of year	2,218
Cash and cash equivalents at end of year		3,028	$ 2,675
Cash and cash equivalents at end of year	$ 2,003	$ 2,218

CONSOLIDATED STATEMENT OF EQUIT

CONSOLIDATED STATEMENT OF EQUITY - USD ($) shares in Thousands, $ in Millions	Total	Total Stockholders Equity [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]
Treasury Stock, Number of shares					(248,786)
Treasury Stock, Value					$ (8,707)
Adjustments to Additional Paid in Capital, Other	$ 12			$ (12)
Income Tax Effects Allocated Directly to Equity, Prior Period Adjustment						$ 13
Prior Period Reclassification Adjustment	1	$ 1
Balance (As Previously Reported) at Oct. 31, 2012	5,185	5,182		8,489		5,505
Balance at Oct. 31, 2012	5,186	5,183	$ 6	8,477		5,518	$ (111)	$ 3
Balance (in shares) at Oct. 31, 2012			(595,259)
Components of comprehensive income:
Net income | As Previously Reported	724
Net income	734	734				734
Other Comprehensive Income (Loss)	202	202					202
Total comprehensive income	936	936
Cash dividends declared	(156)	(156)				(156)
Share-based awards issued	147	147		147
Share-based awards issued (in shares)			6,370
Cumulative excess tax benefits realized from share-based awards	2	2		2
Repurchase of common stock	(900)	(900)			$ (900)
Repurchase of common stock (in shares)					(20,544)
Share-based compensation	85	85		85
Balance at Oct. 31, 2013	5,300	5,297	$ 6	8,711		6,096	91	3
Balance (in shares) at Oct. 31, 2013			(601,629)
Treasury Stock, Number of shares					(269,330)
Treasury Stock, Value					$ (9,607)
Components of comprehensive income:
Net income | As Previously Reported	504
Net income	549	549				549
Other Comprehensive Income (Loss)	(425)	(425)					(425)
Total comprehensive income	124	124
Cash dividends declared	(176)	(176)				(176)
Change in non-controlling interest	0							0
Share-based awards issued	170	170		170
Adjustment to cumulative excess tax benefits realized from share based awards issued	(11)	(11)		(11)
Share-based awards issued (in shares)			6,261
Cumulative excess tax benefits realized from share-based awards	1	1		1
Repurchase of common stock	(200)	(200)			$ (200)
Repurchase of common stock (in shares)					(3,594)
Share-based compensation	96	96		96
Balance at Oct. 31, 2014	$ 5,304	5,301	$ 6	8,967		6,469	(334)	3
Balance (in shares) at Oct. 31, 2014			(607,890)
Treasury Stock, Number of shares	(273,000)				(272,924)
Treasury Stock, Value	$ (9,807)				$ (9,807)
Components of comprehensive income:
Net income	401	401				401
Other Comprehensive Income (Loss)	(389)	(389)					(389)
Total comprehensive income	12	12
Cash dividends declared	(133)	(133)				(133)
Distribution of Keysight	(852)	(852)		(28)		(1,156)	332
Share-based awards issued	44	44		44
Share-based awards issued (in shares)			2,964
Tax benefit from share based awards issued	8	8		8
Repurchase of common stock	(267)	(267)			$ (267)
Repurchase of common stock (in shares)					(6,471)
Share-based compensation	54	54		54
Balance at Oct. 31, 2015	$ 4,170	$ 4,167	$ 6	$ 9,045		$ 5,581	$ (391)	$ 3
Balance (in shares) at Oct. 31, 2015			(610,854)
Treasury Stock, Number of shares	(279,000)				(279,395)
Treasury Stock, Value	$ (10,074)				$ (10,074)

CONSOLIDATED STATEMENT OF EQU10

CONSOLIDATED STATEMENT OF EQUITY (Parenthetical) - $ / shares	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Statement of Stockholders' Equity [Abstract]
Cash Dividends Declared (per common share)	$ 0.400	$ 0.528	$ 0.460

OVERVIEW AND SUMMARY OF SIGNIFI

OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Oct. 31, 2015
Accounting Policies [Abstract]
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Overview. Agilent Technologies Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that includes instruments, software, services and consumables for the entire laboratory workflow. Keysight Separation. On November 1, 2014, we completed the distribution of 100% of the outstanding common shares of Keysight Technologies, Inc. ("Keysight") to Agilent stockholders who received one share of Keysight common stock for every two shares of Agilent held as of the close of business on the record date, October 22, 2014. The historical results of operations and the financial position of Keysight are included in the consolidated financial statements of Agilent and are reported as discontinued operations within this Form 10-K. Exit of Nuclear Magnetic Resonance Business. During the fourth quarter of fiscal year 2014, we made the decision to cease the manufacture and sale of our nuclear magnetic resonance (“NMR”) product line within our life sciences and applied markets segment. In connection with the exit from this business, we recorded approximately $6 million and $68 million in restructuring and other related costs in 2015 and 2014, respectively. For additional details related to the exit of the NMR business see Note 15, "Exit of NMR Business". We will continue to provide service support to the NMR installed base. New Segment Structure. In November 2014, we announced a change in organizational structure designed to better serve our customers. Our life sciences business, excluding the nucleic acid solutions division, together with the chemical analysis business combined to form a new segment called life sciences and applied markets business. Our diagnostics and genomics businesses combined with the nucleic acid solutions division from our life sciences business and became the diagnostics and genomics segment. Finally, the Agilent CrossLab segment was formed from the services and consumables businesses previously part of the life sciences and chemicals analysis businesses. Financial reporting under this new structure is included within this report on Form 10-K and historical financial segment information has been recast to conform to this new presentation within our financial statements. Basis of presentation. The accompanying financial data has been prepared by us pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") and is in conformity with U.S. generally accepted accounting principles ("GAAP"). Our fiscal year end is October 31. Unless otherwise stated, all years and dates refer to our fiscal year. Principles of consolidation. The consolidated financial statements include the accounts of the company and our wholly- and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Revision of Services and other and Product Net Revenues and related Cost of Sales. In 2015 we revised amounts shown in our consolidated statement of operations to more accurately reflect the character of items delivered to customers. Our diagnostic and genomics segment identified a stream of service revenues that had been presented as product revenue in previous years. We have now revised those years’ presentation to show the revenue within services and other. The cost of sales associated with these newly identified service revenues has also been revised to align with the new presentation. For the year ended October 31, 2014 service and other revenue increased $21 million and service and other cost of sales increased $19 million with corresponding reductions in product revenue and cost of sales. For the year ended October 31, 2013 service and other revenue increased $17 million and service and other cost of sales increased $12 million with corresponding reductions in product revenue and cost of sales.These corrections to the classifications are not considered to be material to current or prior periods and had no impact to our consolidated statement of operations. Use of estimates. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, share-based compensation, retirement and post-retirement plan assumptions, restructuring and accounting for income taxes. Revenue recognition. We enter into agreements to sell products (hardware and/or software), services and other arrangements (multiple element arrangements) that include combinations of products and services. We recognize revenue, net of trade discounts and allowances, provided that (1) persuasive evidence of an arrangement exists, (2) delivery has occurred, (3) the price is fixed or determinable and (4) collectability is reasonably assured. Delivery is considered to have occurred when title and risk of loss have transferred to the customer for products, or when the service has been provided. We consider the price to be fixed or determinable when the price is not subject to refund or adjustments. We consider arrangements with extended payment terms not to be fixed or determinable, and accordingly we defer revenue for these sales arrangements for which the payment is not yet due. At the time of the transaction, we evaluate the creditworthiness of our customers to determine the appropriate timing of revenue recognition. Product revenue. Our product revenue is generated predominantly from the sales of various types of analytical instrumentation. Product revenue, including sales to resellers and distributors, is reduced for estimated returns when appropriate. For sales or arrangements that include customer-specified acceptance criteria, including those where acceptance is required upon achievement of performance milestones, revenue is recognized after the acceptance criteria have been met. For products that include installation, if the installation meets the criteria to be considered a separate element, product revenue is recognized upon delivery, and recognition of installation revenue is delayed until the installation is complete. Otherwise, neither the product nor the installation revenue is recognized until the installation is complete. Where software is licensed separately, revenue is recognized when the software is delivered and has been transferred to the customer or, in the case of electronic delivery of software, when the customer is given access to the licensed software programs. We also evaluate whether collection of the receivable is probable, the fee is fixed or determinable and whether any other undelivered elements of the arrangement exist on which a portion of the total fee would be allocated based on vendor-specific objective evidence. Service revenue. Revenue from services includes extended warranty, customer and software support, consulting including companion diagnostics and training and education. Service revenue is deferred and recognized over the contractual period or as services are rendered and accepted by the customer. For example, customer support contracts are recognized ratably over the contractual period, while training revenue is recognized as the training is provided to the customer. In addition the four revenue recognition criteria described above must be met before service revenue is recognized. Revenue Recognition for Arrangements with Multiple Deliverables. Our multiple-element arrangements are generally comprised of a combination of measurement instruments, installation or other start-up services, and/or software and/or support or services. Hardware and software elements are typically delivered at the same time and revenue is recognized upon delivery once title and risk of loss pass to the customer. Delivery of installation, start-up services and other services varies based on the complexity of the equipment, staffing levels in a geographic location and customer preferences, and can range from a few days to a few months. Service revenue is deferred and recognized over the contractual period or as services are rendered and accepted by the customer. Revenue from the sale of software products that are not required to deliver the tangible product's essential functionality are accounted for under software revenue recognition rules which require vendor specific objective evidence (VSOE) of fair value to allocate revenue in a multiple element arrangement. Our arrangements generally do not include any provisions for cancellation, termination, or refunds that would significantly impact recognized revenue. We have evaluated the deliverables in our multiple-element arrangements and concluded that they are separate units of accounting if the delivered item or items have value to the customer on a standalone basis and for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in our control. We allocate revenue to each element in our multiple-element arrangements based upon their relative selling prices. We determine the selling price for each deliverable based on a selling price hierarchy. The selling price for a deliverable is based on VSOE if available, third-party evidence (TPE) if VSOE is not available, or estimated selling price (ESP) if neither VSOE nor TPE is available. Revenue allocated to each element is then recognized when the basic revenue recognition criteria for that element have been met. We use VSOE of selling price in the selling price allocation in all instances where it exists. VSOE of selling price for products and services is determined when a substantial majority of the selling prices fall within a reasonable range when sold separately. TPE of selling price can be established by evaluating largely interchangeable competitor products or services in standalone sales to similarly situated customers. As our products contain a significant element of proprietary technology and the solution offered differs substantially from that of competitors, it is difficult to obtain the reliable standalone competitive pricing necessary to establish TPE. ESP represents the best estimate of the price at which we would transact a sale if the product or service were sold on a standalone basis. We determine ESP for a product or service by using historical selling prices which reflect multiple factors including, but not limited to customer type, geography, market conditions, competitive landscape, gross margin objectives and pricing practices. The determination of ESP is made through consultation with and approval by management. We may modify or develop new pricing practices and strategies in the future. As these pricing strategies evolve changes may occur in ESP. The aforementioned factors may result in a different allocation of revenue to the deliverables in multiple element arrangements, which may change the pattern and timing of revenue recognition for these elements but will not change the total revenue recognized for the arrangement. Deferred revenue. Deferred revenue represents the amount that is allocated to undelivered elements in multiple element arrangements. We limit the revenue recognized to the amount that is not contingent on the future delivery of products or services or meeting other specified performance conditions. Accounts receivable, net. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Such accounts receivable has been reduced by an allowance for doubtful accounts, which is our best estimate of the amount of probable credit losses in our existing accounts receivable. We determine the allowance based on customer specific experience and the aging of such receivables, among other factors. The allowance for doubtful accounts as of October 31, 2015 and 2014 was not material. We do not have any off-balance-sheet credit exposure related to our customers. Accounts receivable are also recorded net of product returns. Shipping and handling costs. Our shipping and handling costs charged to customers are included in net revenue, and the associated expense is recorded in cost of products for all periods presented. Inventory. Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with manufacturing to maximize recovery of excess inventory. Goodwill and Purchased Intangible Assets. Under the authoritative guidance we have the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The accounting standard gives an entity the option to first assess qualitative factors to determine whether performing the two-step test is necessary. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e. greater than 50% chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test will be required. Otherwise, no further testing will be required. The guidance includes examples of events and circumstances that might indicate that a reporting unit's fair value is less than its carrying amount. These include macro-economic conditions such as deterioration in the entity's operating environment or industry or market considerations; entity-specific events such as increasing costs, declining financial performance, or loss of key personnel; or other events such as an expectation that a reporting unit will be sold or a sustained decrease in the stock price on either an absolute basis or relative to peers. If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, the provisions of authoritative guidance require that we perform a two-step impairment test on goodwill. In the first step, we compare the fair value of each reporting unit to its carrying value. The second step (if necessary) measures the amount of impairment by applying fair-value-based tests to the individual assets and liabilities within each reporting unit. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. We aggregate components of an operating segment that have similar economic characteristics into our reporting units. In fiscal year 2015, we assessed goodwill impairment for our three reporting units which consisted of three segments: life sciences and applied markets, diagnostics and genomics and Agilent CrossLab. Due to the new segment structure in November 2014 we performed a quantitative test for goodwill impairment of the three reporting units, as of September 30, 2015. Based on the results of our testing, the fair value of these reporting units are greater than their respective carrying values. Each quarter we review the events and circumstances to determine if goodwill impairment is indicated. There was no impairment of goodwill during the years ended October 31, 2015, 2014 and 2013. Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how, trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that reflect the pattern in which the economic benefits are consumed or used up or a straight-line method ranging from 6 months to 15 years. In-process research and development ("IPR&D") is initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When the IPR&D project is complete, it is reclassified as an amortizable purchased intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, Agilent will record a charge for the value of the related intangible asset to Agilent's condensed consolidated statement of operations in the period it is abandoned. Agilent's indefinite-lived intangible assets are IPR&D intangible assets. The accounting guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to determine whether it is more-likely-than-not (i.e. greater than 50% chance) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. We performed a qualitative test for impairment of indefinite-lived intangible assets as of September 30, 2015. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of these indefinite-lived intangible assets is greater than their respective carrying values. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible asset is indicated. In the years ended October 31, 2015, 2014 and 2013, we recorded an impairment of $3 million , $4 million and zero , respectively due to the cancellation of certain IPR&D projects. In addition, in the year ended October 31, 2014, we also recorded $12 million of impairment of other intangibles due to the exit of our NMR business. Share-based compensation. For the years ended 2015 , 2014 and 2013 , we accounted for share-based awards made to our employees and directors including employee stock option awards, restricted stock units, employee stock purchases made under our Employee Stock Purchase Plan ("ESPP") and performance share awards under Agilent Technologies, Inc. Long-Term Performance Program ("LTPP") using the estimated grant date fair value method of accounting. Under the fair value method, we recorded compensation expense, in continuing operations, for all share-based awards of $55 million in 2015 , $59 million in 2014 and $51 million in 2013 . For the stock option and long term performance plan grants in 2015 we are now using a volatility measure derived from a selection of our peer companies. In prior periods, we used Agilent stock historical volatility. We currently consider this method to not be reflective of our future volatility due to the separation of Keysight. See Note 5, "Share-based compensation" for additional information. Retirement and post-retirement plans. Substantially all of our employees are covered under various defined benefit and/or defined contribution retirement plans. Additionally we sponsor post-retirement health care benefits for our eligible U.S. employees. Assumptions used to determine the benefit obligations and the expense for these plans are derived annually. See Note 16, “Retirement plans and post-retirement pension plans” for additional information. Restructuring and exit of NMR business. The main components of expenses are related to workforce reductions, assets impairments and write-downs and special charges to inventory, which mainly relates to exiting of one of our businesses. Workforce reduction charges are accrued when payment of benefits that the employees are entitled to becomes probable and the amounts can be estimated. We have also assessed the recoverability of our long-lived assets, by determining whether the carrying value of such assets will be recovered through undiscounted future cash flows. Asset impairments primarily consist of property, plant and equipment and are based on an estimate of the amounts and timing of future cash flows related to the expected future remaining use and ultimate sale or disposal of buildings and equipment net of costs to sell. The charges related to inventory include estimated future inventory disposal payments that we are contractually obliged to make to our suppliers and inventory written-down to net realizable value. If the amounts and timing of cash flows from restructuring activities are significantly different from what we have estimated, the actual amount of restructuring and asset impairment charges could be materially different, either higher or lower, than those we have recorded. Taxes on income. Income tax expense or benefit is based on income or loss before taxes. Deferred tax assets and liabilities are recognized principally for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. See Note 6, "Income Taxes" for more information. Warranty. Our standard warranty terms typically extend for one year from the date of delivery. We accrue for standard warranty costs based on historical trends in warranty charges as a percentage of net product revenue. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost estimates. Estimated warranty charges are recorded within cost of products at the time products are sold. See Note 17, "Guarantees". Advertising. Advertising costs are generally expensed as incurred and amounted to $25 million in 2015 , $31 million in 2014 and $28 million in 2013 . Research and development. Costs related to research, design and development of our products are charged to research and development expense as they are incurred. Sales Taxes. Sales taxes collected from customers and remitted to governmental authorities are not included in our revenue. Net income per share. Basic net income per share is computed by dividing net income - the numerator - by the weighted average number of common shares outstanding - the denominator - during the period excluding the dilutive effect of stock options and other employee stock plans. Diluted net income per share gives effect to all potential common shares outstanding during the period unless the effect is anti-dilutive. The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense, the tax benefits and shortfalls charged to additional paid-in capital and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options, unamortized share-based compensation expense and tax benefits or shortfalls are assumed proceeds to be used to repurchase hypothetical shares. See Note 7, "Net Income Per Share". Cash, cash equivalents and short term investments. We classify investments as cash equivalents if their original or remaining maturity is three months or less at the date of purchase. Cash equivalents are stated at cost, which approximates fair value. As of October 31, 2015 , approximately $1,780 million of our cash and cash equivalents is held outside of the U.S. in our foreign subsidiaries. Under current tax laws, the cash could be repatriated to the U.S. but most of it would be subject to U.S. federal and state income taxes, less applicable foreign tax credits. Our cash and cash equivalents mainly consist of short term deposits held at major global financial institutions, institutional money market funds, and similar short duration instruments with original maturities of 90 days or less. We continuously monitor the creditworthiness of the financial institutions and institutional money market funds in which we invest our funds. We classify investments as short-term investments if their original maturities are greater than three months and their remaining maturities are one year or less. Currently, we have no short-term investments. Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments is determined using quoted market prices for those securities when available. For those long-term equity investments accounted for under the cost or equity method, their carrying value approximates their estimated fair value. Equity method investments are reported at the amount of the company’s initial investment and adjusted each period for the company’s share of the investee’s income or loss and dividend paid. The fair value of our long-term debt, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy, exceeds the carrying value by approximately $30 million and $53 million as of October 31, 2015 and 2014, respectively. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 13, "Fair Value Measurements" for additional information on the fair value of financial instruments. Concentration of credit risk. Financial instruments that potentially subject Agilent to significant concentration of credit risk include money market fund investments, time deposits and demand deposit balances. These investments are categorized as cash and cash equivalents. In addition, Agilent has credit risk from derivative financial instruments used in hedging activities and accounts receivable. We invest in a variety of financial instruments and limit the amount of credit exposure with any one financial institution. We have a comprehensive credit policy in place and credit exposure is monitored on an ongoing basis. Credit risk with respect to our accounts receivable is diversified due to the large number of entities comprising our customer base and their dispersion across many different industries and geographies. Credit evaluations are performed on customers requiring credit over a certain amount and we sell the majority of our products through our direct sales force. Credit risk is mitigated through collateral such as letter of credit, bank guarantees or payment terms like cash in advance. No single customer accounted for more than 10 percent of combined accounts receivable as of October 31, 2015 , or 2014 . Derivative instruments. Agilent is exposed to global foreign currency exchange rate and interest rate risks in the normal course of business. We enter into foreign exchange hedging contracts, primarily forward contracts and purchased options and, in the past, interest rate swaps to manage financial exposures resulting from changes in foreign currency exchange rates and interest rates. In the vast majority of cases, these contracts are designated at inception as hedges of the related foreign currency or interest exposures. Foreign currency exposures include committed and anticipated revenue and expense transactions and assets and liabilities that are denominated in currencies other than the functional currency of the subsidiary. Interest rate exposures are associated with the company's fixed-rate debt. For option contracts, we exclude time value from the measurement of effectiveness. To qualify for hedge accounting, contracts must reduce the foreign currency exchange rate and interest rate risk otherwise inherent in the amount and duration of the hedged exposures and comply with established risk management policies; foreign exchange hedging contracts generally mature within twelve months and interest rate swaps, if any, mature at the same time as the maturity of the debt. In order to manage foreign currency exposures in a few limited jurisdictions we may enter into foreign exchange contracts that do not qualify for hedge accounting. In such circumstances, the local foreign currency exposure is offset by contracts owned by the parent company. We do not use derivative financial instruments for speculative trading purposes. All derivatives are recognized on the balance sheet at their fair values. For derivative instruments that are designated and qualify as a fair value hedge, changes in value of the derivative are recognized in the consolidated statement of operations in the current period, along with the offsetting gain or loss on the hedged item attributable to the hedged risk. For derivative instruments that are designated and qualify as a cash flow hedges, changes in the value of the effective portion of the derivative instrument is recognized in comprehensive income (loss), a component of stockholders' equity. Amounts associated with cash flow hedges are reclassified and recognized in income when either the forecasted transaction occurs or it becomes probable the forecasted transaction will not occur. Derivatives not designated as hedging instruments are recorded on the balance sheet at their fair value and changes in the fair values are recorded in the income statement in the current period. Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet. Changes in the fair value of the ineffective portion of derivative instruments are recognized in earnings in the current period. Ineffectiveness in 2015 , 2014 and 2013 was not material. Cash flows from derivative instruments are classified in the statement of cash flows in the same category as the cash flows from the hedged or economically hedged item, primarily in operating activities. Property, plant and equipment. Property, plant and equipment are stated at cost less accumulated depreciation. Additions, improvements and major renewals are capitalized; maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation and amortization are removed from our general ledger, and the resulting gain or loss is reflected in the consolidated statement of operations. Buildings and improvements are depreciated over the lesser of their useful lives or the remaining term of the lease and machinery and equipment over three to ten years. We use the straight-line method to depreciate assets. Leases. We lease buildings, machinery and equipment under operating leases for original terms ranging generally from one year to twenty years. Certain leases contain renewal options for periods up to six years. In addition, we lease equipment to customers in connection with our diagnostics business using both capital and operating leases. As of October 31, 2015 and 2014 our diagnostics and genomics segment has approximately $11 million and $8 million , respectively, of lease receivables related to capital leases and approximately $31 million and $33 million , respectively, of net assets for operating leases. We depreciate the assets related to the operating leases over their estimated useful lives. Capitalized software. We capitalize certain internal and external costs incurred to acquire or create internal use software. Capitalized software is included in property, plant and equipment and is depreciated over three to five years once development is complete. Impairment of long-lived assets. We continually monitor events and changes in circumstances that could indicate carrying amounts of long-lived assets, including intangible assets, may not be recoverable. When such events or changes in circumstances occur, we assess the recoverability of l

REVISION OF PRIOR PERIOD FINANC

REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS	12 Months Ended
	Oct. 31, 2015
Income Tax Disclosure [Abstract]
Error Corrections and Revision of prior period Financial Statements[Text Block]	2. REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS During the year ended October 31, 2014 the company identified and recorded various out of period income tax adjustments. Specifically, $13 million tax expense for corrections to U.S. deferred taxes, $12 million tax expense for the correction of transfer pricing for prior years, $9 million tax benefit related to the correction of the tax basis of land in the U.K. and $3 million of tax expense to correct tax related balance sheet accounts. During the year ended October 31, 2015 the company identified additional income tax out of period adjustments. Specifically, $13 million of tax benefit from the reduction in deferred tax liabilities due to tax rate changes in Denmark occurring in the prior year, $10 million of tax benefit to correct the overstatement of U.S. income taxes payable, $7 million of tax benefit to correct the understatement of international prepaid income taxes, $17 million of tax expense to correct deferred tax liabilities associated with unremitted foreign earnings, $4 million of tax expense attributable to an error discovered on a prior year U.S. tax return, $4 million tax expense related to foreign deferred tax assets, and a $2 million net tax benefit associated with errors in prior year international income tax provisions. The aggregated impact of the out of period income tax adjustments identified, including the reversing effect of prior year errors, resulted in the provision for income taxes in 2014 and 2013 to be overstated by $45 million and $10 million , respectively. We evaluated the aggregate effects of the errors to our previously issued financial statements in accordance with SEC Staff Accounting Bulletins No. 99 and No. 108 and, based upon quantitative and qualitative factors, determined that the errors were not material to the previously issued financial statements and disclosures included in our Annual Report on Form 10-K for the year ended October 31, 2014 or for any quarterly periods included therein or through our most recent Quarterly Report on Form 10-Q. As part of this evaluation, we considered a number of qualitative factors, including, among others, that the errors did not change a net loss into net income or vice versa, did not have an impact on our long-term debt covenant compliance, and did not mask a change in earnings or other trends when considering the overall competitive and economic environment within the industry during the periods. However, as a result of the Company presenting continuing operations and discontinued operations for the first time in our Annual Report on Form 10-K, we determined the effect of the errors is significant to our financial results for the year ending October 31, 2014 and 2013. Accordingly, we are revising our historical financial statements. Due to the immaterial nature of the misstatement corrections, the cumulative adjustments required to correct the misstatements in the financial statements prior to the fiscal year ended October 31, 2013 are reflected in the revised stockholders’ equity as of October 31, 2012. The cumulative effect of those adjustments increased previously reported retained earnings by $13 million and reduced additional paid in capital by $12 million . The cumulative effect to retained earnings includes the $65 million related to adjusting the cumulative effect of a change in accounting principle to reduce our long-term tax liabilities that was previously recorded in 2014. These adjustments also cumulatively impacted the following balance sheet line items as of October 31, 2014: October 31, 2014 As Reported Adjustments As Revised (in millions) Other current assets $ 261 $ 2 $ 263 Current assets of discontinued operations $ 1,821 7 $ 1,828 Total current assets $ 5,500 9 $ 5,509 Other assets $ 283 (15 ) $ 268 Non-current assets of discontinued operations $ 1,165 (10 ) $ 1,155 Total assets $ 10,831 $ (16 ) $ 10,815 Other accrued liabilities $ 289 $ (10 ) $ 279 Total current liabilities $ 1,702 $ (10 ) $ 1,692 Other long-term liabilities $ 522 $ (9 ) $ 513 Total liabilities $ 5,530 $ (19 ) $ 5,511 Retained earnings $ 6,466 $ 3 $ 6,469 Total stockholders equity $ 5,298 $ 3 $ 5,301 The errors discussed above resulted in an understatement of net income of $45 million and $10 million relating to the provision for income taxes for the years ended October 31, 2014 and 2013, respectively. Year Ended October 31, 2014 As Reported Adjustments Revised Reclassified for Discontinued Operations (in millions, except per share data) Income before taxes $ 646 $ 646 Provision (benefit) for income taxes 142 (45 ) 97 Income from continuing operations before taxes 229 Provision for income taxes on continuing operations (3 ) Income from continuing operations 232 Income from discontinued operations, net of tax expense of $100 317 Net income $ 504 $ 45 $ 549 $ 549 Net income per share: Basic $ 1.51 $ 0.14 $ 1.65 Diluted $ 1.49 $ 0.13 $ 1.62 Net income per share - basic Income from continuing operations $ 0.70 Income from discontinued operations $ 0.95 Net income per share - basic $ 1.65 Net income per share - diluted Income from continuing operations $ 0.69 Income from discontinued operations $ 0.93 Net income per share - diluted $ 1.62 Total comprehensive income $ 79 $ 45 $ 124 Year Ended October 31, 2013 As Reported Adjustments Revised Reclassified for Discontinued Operations (in millions, except per share data) Income before taxes $ 859 $ 859 Provision (benefit) for income taxes 135 (10 ) 125 Income from continuing operations before taxes 293 Provision for income taxes on continuing operations 68 Income from continuing operations 225 Income from discontinued operations, net of tax expense of $57 509 Net income $ 724 $ 10 $ 734 $ 734 Net income per share: Basic $ 2.12 $ 0.03 $ 2.15 Diluted $ 2.10 $ 0.03 $ 2.13 Net income per share - basic Income from continuing operations $ 0.66 Income form discontinued operations $ 1.49 Net income per share - basic $ 2.15 Net income per share - diluted Income from continuing operations $ 0.65 Income form discontinued operations $ 1.48 Net income per share - diluted $ 2.13 Total comprehensive income $ 926 $ 10 $ 936 The adjustments resulted in the following revisions to our consolidated cash flow statements. Year Ended October 31, 2014 As Reported Adjustments As Revised (in millions) Net income $ 504 $ 45 $ 549 Deferred taxes $ (132 ) $ (60 ) $ (192 ) Changes in assets and liabilities: Other assets and liabilities $ (60 ) $ 15 $ (45 ) Year Ended October 31, 2013 As Reported Adjustments As Revised (in millions) Net income $ 724 $ 10 $ 734 Deferred taxes $ 31 (35 ) $ (4 ) Changes in assets and liabilities: Other assets and liabilities $ (17 ) 25 $ 8 All financial information presented in the accompanying notes to these consolidated financial statements was revised to reflect the correction of these errors.

NEW ACCOUNTING PRONOUNCEMENTS

NEW ACCOUNTING PRONOUNCEMENTS	12 Months Ended
	Oct. 31, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
NEW ACCOUNTING PRONOUNCEMENTS	3. NEW ACCOUNTING PRONOUNCEMENTS In April 2014, Financial Accounting Standards Board ("FASB") issued amendments to the guidance on discontinued operations. The guidance changes the criteria for reporting discontinued operations while enhancing disclosures in this area. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. Additionally, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, expenses of discontinued operations and of the pre-tax income attributable to a disposal of a significant part of an organization that does not qualify for discontinued operations reporting. The new guidance is effective for Agilent prospectively for all disposals (or classifications as held for sale) of components of an entity that occur after November 1, 2016. The disposal of Keysight meets the definition of a discontinued operation under both the existing and amended accounting guidance. The historical results of operations and the financial position of Keysight are included in the consolidated financial statements of Agilent and are reported as discontinued operations within this Form 10-K. In May 2014, the FASB issued an amendment to the accounting guidance related to revenue recognition. The amendment was the result of a joint project between the FASB and the International Accounting Standards Board ("IASB") to clarify the principles for recognizing revenue and to develop common revenue standards for U.S. GAAP and International Financial Reporting Standards ("IFRS"). To meet those objectives, the FASB is amending the FASB Accounting Standards Codification and creating a new Topic 606, Revenue from Contracts with Customers, and the IASB is issuing IFRS 15, Revenue from Contracts with Customers. We are evaluating the impact of adopting this guidance to our consolidated financial statements. In January 2015, FASB issued guidance on simplifying income statement presentation by eliminating the concept of extraordinary items from U.S. GAAP. The amendments in this update are effective for us from November 1, 2016, and in interim periods during that year. A reporting entity may apply the amendments prospectively and retrospectively to all periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. We have evaluated the accounting guidance and determined that there is no impact of this update to our consolidated financial statements. In February 2015, FASB issued an amendment to the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. All legal entities are subject to reevaluation under the revised consolidation model. The amendments in this update are effective for us from November 1, 2016, and for interim periods within that year. We do not expect that adopting this guidance will have an impact to our consolidated financial statements. In April 2015, FASB issued an amendment to simplify the presentation of debt issuance costs. The amendments in this update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs remain unchanged. The amendments in this update are effective for us from November 1, 2016, and for interim periods within that year. Earlier adoption is permitted and we are currently evaluating when we will implement the guidance. We do not expect the impact of adopting this guidance to be material to our consolidated financial statements. In July 2015, FASB issued guidance to simplify the accounting for inventory and to more closely align their guidance with international accounting standards. The amendments in this update apply to companies which use inventory valuation methods other than last in, first-out and the retail inventory method to change the way that they subsequently measure the value of inventory on their balance sheet. Under the new guidance, inventory should be valued at the lower of cost and net realizable value rather than the lower of cost and market. The amendments in this update are effective for us from November 1, 2017, and for interim periods in the following year. We do not expect this amended guidance to have an impact to our consolidated financial statements, as the new guidance aligns with our current practice of using net realizable value as our estimate of market value. In July 2015, FASB announced that the implementation date of Topic 606, Revenue from Contracts with Customers, would be delayed by one year. It will now be effective for us in fiscal 2019, with early adoption permitted for us from November 1, 2017. We are evaluating the timing of our adoption and the impact of this guidance to our consolidated financial statements. In September 2015, FASB issued guidance intended to simplify accounting for adjustments to provisional amounts recorded in connection with business combinations. Beginning in November 1, 2017 and in the interim periods from November 1, 2018, adjustments will be recorded in the period that they are determined rather than applied retrospectively via revision to the period of acquisition and each period thereafter. Early adoption is permitted. We do not expect this guidance to have a material impact to our consolidated financial statements, but we are currently evaluating the timing of our adoption. In November 2015, FASB issued guidance intended to simplify accounting for deferred taxes. Beginning on November 1, 2017 including the interim periods following that date we will present all deferred tax balances as non-current. Existing GAAP guidance requires us to record deferred tax balances as either current or non-current in accordance with the classification of the underlying attributes. Early adoption is permitted. We are still evaluating when we will adopt this guidance as we expect adoption will cause significant balance sheet reclassifications. See Note 6, “Income Taxes” for details of the current and non-current deferred tax liability balances. Other amendments to GAAP in the U.S. that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.

DISCONTINUED OPERATIONS (Notes)

DISCONTINUED OPERATIONS (Notes)	12 Months Ended
	Oct. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations Disclosure	4. DISCONTINUED OPERATIONS On September 19, 2013, Agilent announced its intention to separate its electronic measurement business, Keysight, which was previously a separate reportable segment, into a stand-alone publicly traded company. Keysight was incorporated in Delaware as a wholly-owned subsidiary of Agilent on December 6, 2013. On November 1, 2014, we completed the distribution of 100% of the outstanding common stock of Keysight to Agilent stockholders, who received one share of Keysight common stock for every two shares of Agilent common stock held as of the close of business on the record date, October 22, 2014. The separation agreement ensured that Keysight had approximately $700 million of total cash and cash equivalents immediately following distribution. For the year ended October 31, 2015, we transferred a total amount of cash and cash equivalents of $734 million to Keysight. The historical results of operations and statement of financial position of Keysight have been presented as discontinued operations in the consolidated financial statements and prior periods have been restated. Discontinued operations include results of Keysight's business except for certain allocated corporate overhead costs and certain costs associated with transition services provided by Agilent to Keysight. Discontinued operations also includes other costs incurred by Agilent to separate Keysight. These costs include transaction charges, advisory and consulting fees and information system expenses. The following table summarizes results from discontinued operations of Keysight included in the consolidated statement of operations: Years Ended October 31, 2015 2014 2013 (in millions) Net revenue $ — $ 2,933 $ 2,888 Costs and expenses 39 2,521 2,323 Operating income (loss) (39 ) 412 565 Other income (expense), net — 5 1 Income (loss) from discontinued operations before tax (39 ) 417 566 Provision (benefit) for income taxes (2 ) 100 57 Net income (loss) from discontinued operations $ (37 ) $ 317 $ 509 Net income (loss) from discontinued operations includes transaction, information systems and other costs to effect the separation of $39 million and $178 million for the years ended October 31, 2015 and 2014, respectively. In the year ended October 31, 2015 only those costs incurred to effect the separation have been included. No income or expense has been recorded for the Keysight business after separation from Agilent on November 1, 2014. The following table presents Agilent's electronic measurement business assets and liabilities removed from the consolidated balance sheet as of November 1, 2014 and presented as discontinued operations as of October 31, 2014: October 31, 2014 (in millions) Assets: Cash and cash equivalents $ 810 Accounts receivable, net 357 Inventory 498 Other current assets 163 Current assets of discontinued operations 1,828 Property, plant and equipment, net 470 Goodwill 392 Other intangible assets, net 18 Long-term investments 63 Other assets 212 Non-current assets of discontinued operations 1,155 Total assets of discontinued operations $ 2,983 Liabilities: Accounts payable $ 173 Employee compensation and benefits 167 Deferred revenue 175 Other accrued liabilities 108 Current liabilities of discontinued operations 623 Long-term debt 1,099 Retirement and post-retirement benefits 213 Other long-term liabilities 122 Long-term liabilities of discontinued operations 1,434 Total liabilities of discontinued operations $ 2,057 In addition, $332 million of accumulated other comprehensive loss, net of income taxes, primarily related to pension and other post-retirement benefits plans and currency translation was also transferred to Keysight together with $28 million of additional paid in capital related to share based compensation windfall tax benefits. The removal of Keysight net assets and equity related adjustments is presented as a reduction in Agilent's retained earnings and represents a non cash financing activity excluding cash transferred. See Note 6 “Income Taxes” for tax implications and adjustments due to the distribution and Note 5 “Share Based Compensation” for changes to share based compensation awards as a result of the distribution of Keysight. In order to effect the separation and govern our relationship with Keysight after the separation, we entered into a Separation and Distribution Agreement and other agreements including a Tax Matters Agreement, an Employee Matters Agreement and a Transition Services Agreement. The Separation and Distribution Agreement governs the separation of the electronic measurement business, the transfer of assets and other matters related to our relationship with Keysight. Any costs incurred by Agilent in respect of these agreements after separation are recorded in the continuing operations of Agilent. The Tax Matters Agreement governs the respective rights, responsibilities and obligations of Keysight and Agilent with respect to taxes, tax attributes, tax returns, tax proceedings and certain other tax matters. The Employee Matters Agreement governs the compensation and employee benefit obligations with respect to the current and former employees and non-employee directors of Keysight and Agilent, and generally allocates liabilities and responsibilities relating to employee compensation, benefit plans and programs. The Employee Matters Agreement provides that employees of Keysight will no longer participate in benefit plans sponsored or maintained by Agilent. In addition, the Employee Matters Agreement provides that each of the parties will be responsible for their respective former and current employees and compensation plans for such current employees. Under the terms of the Transition Services Agreement, we agreed to provide administrative, site services, information technology systems and various other corporate and support services to Keysight over the period of 12-18 months after the separation on a cost or cost-plus basis. The most significant component of the service income is the provision of IT services that was completed by the end of the second quarter of 2015. In total we have recorded income for all services provided to Keysight of approximately $12 million . In addition, Agilent expects to receive lease income together with site service income from Keysight over the next 4-5 years of approximately $13 million per year. In the year ended October 31, 2015 other income (expense), net includes $25 million of income in respect of the provision of services to, and lease income from Keysight.

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	12 Months Ended
	Oct. 31, 2015
Share-based Compensation [Abstract]
SHARE-BASED COMPENSATION	5. SHARE-BASED COMPENSATION Agilent accounts for share-based awards in accordance with the provisions of the accounting guidance which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including employee stock option awards, restricted stock units, employee stock purchases made under our ESPP and performance share awards granted to selected members of our senior management under the LTPP based on estimated fair values. Description of Share-Based Plans Employee stock purchase plan. Effective November 1, 2000, we adopted the ESPP. The ESPP allows eligible employees to contribute up to ten percent of their base compensation to purchase shares of our common stock at 85 percent of the closing market price at purchase date. Shares authorized for issuance in connection with the ESPP are subject to an automatic annual increase of the lesser of one percent of the outstanding shares of common stock of Agilent on November 1, or an amount determined by the Compensation Committee of our Board of Directors. Under the terms of the ESPP, in no event shall the number of shares issued under the ESPP exceed 75 million shares. Under our ESPP, employees purchased 346,472 shares for $12 million in 2015 , 1,604,406 shares for $73 million in 2014 and 1,454,724 shares for $48 million in 2013 . As of October 31, 2015 , the number of shares of common stock authorized and available for issuance under our ESPP was 42,605,407 . Incentive compensation plans. On November 19, 2008 and March 11, 2009, the Compensation Committee of Board of Directors and the stockholders, respectively, approved the Agilent Technologies, Inc. 2009 Stock Plan (the "2009 Stock Plan") to replace the Company's 1999 Stock Plan and 1999 Stock Non-Employee Director Stock Plan and subsequently reserved 25 million shares of Company common stock that may be issued under the 2009 Plan, plus any shares forfeited or cancelled under the 1999 Stock Plan. The 2009 Stock Plan provides for the grant of awards in the form of stock options, stock appreciation rights ("SARs"), restricted stock, restricted stock units ("RSUs"), performance shares and performance units with performance-based conditions on vesting or exercisability, and cash awards. The 2009 Plan has a term of ten years . As of October 31, 2015 , 13,524,407 shares were available for future awards under the 2009 Stock Plan. Stock options granted under the 2009 Stock Plans may be either "incentive stock options", as defined in Section 422 of the Internal Revenue Code, or non-statutory. Options generally vest at a rate of 25 percent per year over a period of four years from the date of grant and generally have a maximum contractual term of ten years . The exercise price for stock options is generally not less than 100 percent of the fair market value of our common stock on the date the stock award is granted. Effective November 1, 2003, the Compensation Committee of the Board of Directors approved the LTPP, which is a performance stock award program administered under the 2009 Stock Plan, for the company's executive officers and other key employees. Participants in this program are entitled to receive unrestricted shares of the company's stock after the end of a three-year period, if specified performance targets are met. LTPP awards are generally designed to meet the criteria of a performance award with the performance metrics and peer group comparison set at the beginning of the performance period. Based on the performance metrics the final award may vary from zero to 200 percent of the target award. The maximum contractual term for awards under the LTPP program is three years . We consider the dilutive impact of this program in our diluted net income per share calculation only to the extent that the performance conditions are met. In March 2007, we began to issue restricted stock units under our share-based plans. The estimated fair value of the restricted stock unit awards granted under the Stock Plans is determined based on the market price of Agilent's common stock on the date of grant adjusted for expected dividend yield. Restricted stock units generally vest, with some exceptions, at a rate of 25 percent per year over a period of four years from the date of grant. In connection with the separation of Keysight Technologies on November 1, 2014 and in accordance with the Employee Matters Agreement we made certain adjustments to the exercise price and number of our share-based compensation awards with the intention of preserving the intrinsic value of the awards prior to the separation. Exercisable and non-exercisable stock options converted to those of the entity where the employee is working post-separation. Restricted stock units awards and long-term performance plan grants were adjusted to provide holders restricted stock units and long-term performance plan grants in the company that employs such employee following the separation. These adjustments to our stock-based compensation awards did not have a material impact on compensation expense. Impact of Share-based Compensation Awards We have recognized compensation expense based on the estimated grant date fair value method under the authoritative guidance. For all share-based awards we have recognized compensation expense using a straight-line amortization method. As the guidance requires that share-based compensation expense be based on awards that are ultimately expected to vest, estimated share-based compensation has been reduced for estimated forfeitures. The impact on our results for share-based compensation was as follows: Years Ended October 31, 2015 2014 2013 (in millions) Cost of products and services $ 11 $ 13 $ 12 Research and development 5 7 5 Selling, general and administrative 39 39 34 Share-based compensation expense in continuing operations 55 59 51 Share-based compensation expense in discontinued operations — 39 37 Total share-based compensation expense $ 55 $ 98 $ 88 At October 31, 2015 and 2014 there was no share-based compensation capitalized within inventory. The windfall income tax benefit realized from the exercised stock options and similar awards recognized was $8 million in 2015 , $1 million in 2014 and $2 million in 2013 , respectively. Approximately $11 million of previously recognized windfall tax benefits was reversed due to the favorable settlement of a tax authority examination in first quarter of 2014. The weighted average grant date fair value of options, granted in 2015 , 2014 and 2013 was $10.58 , $18.73 and $12.18 per share, respectively. Included in the 2015, 2014 and 2013 expense is incremental expense for acceleration of share-based compensation related to the announced workforce reduction plan of $2 million , $1 million and $2 million , respectively. Upon termination of the employees impacted by workforce reduction, the non-vested Agilent awards held by these employees immediately vests. Employees have a period of up to three months in which to exercise the Agilent options before such options are cancelled. Valuation Assumptions For all periods presented, the fair value of share based awards for employee stock option awards was estimated using the Black-Scholes option pricing model. For all periods presented, shares granted under the LTPP were valued using a Monte Carlo simulation. The estimated fair value of restricted stock unit awards was determined based on the market price of Agilent's common stock on the date of grant adjusted for expected dividend yield. The ESPP allows eligible employees to purchase shares of our common stock at 85 percent of the fair market value at the purchase date. The following assumptions were used to estimate the fair value of employee stock options and LTPP grants. Years Ended October 31, 2015 2014 2013 Stock Option Plans: Weighted average risk-free interest rate 1.75% 1.69% 0.86% Dividend yield 1% 1% 1% Weighted average volatility 28% 39% 39% Expected life 5.5 years 5.8 years 5.8 years LTPP: Volatility of Agilent shares 25% 36% 37% Volatility of selected peer-company shares 12%-57% 13%-57% 6%-64% Price-wise correlation with selected peers 37% 47% 49% Both the Black-Scholes and Monte Carlo simulation fair value models require the use of highly subjective and complex assumptions, including the option’s expected life and the price volatility of the underlying stock. Due to the separation of Keysight on November 1, 2014, expected volatility for grants of options in fiscal 2015 was based on a 5.5 year average historical stock price volatility of a group of our peer companies. For the volatility of our 2015 LTPP grants, we used the 3 year average historical stock price volatility of a group of our peer companies. We believe our historical volatility prior to the separation of Keysight is no longer relevant to use. For the grants of options and LTPP prior to November 1, 2014, the expected stock price volatility assumption was determined using the historical volatility of Agilent’s stock over the most recent historical period equivalent to the expected life of the stock options and LTPP. In developing our estimated life of our employees' stock options of 5.5 years , we considered the separation of Keysight and the historical option exercise behavior for our executive employees who were granted the majority of the options in the annual grants made which we believe is representative of future behavior. In developing our estimated life of our employee stock options of 5.8 years for 2013 to 2014, we considered the historical option exercise behavior of our executive employees who were granted the majority of the options in the annual grants made which we believe is representative of future behavior. Share-based Payment Award Activity Employee Stock Options The following table summarizes employee stock option award activity made to our employees and directors for 2015 . The amount of options outstanding and the weighted average exercise price at October 31, 2014, have been revised to reflect the impact of the Keysight separation. Options Outstanding Weighted Average Exercise Price (in thousands) Outstanding at October 31, 2014 6,584 $ 27 Granted 1,347 $ 41 Exercised (1,925 ) $ 24 Cancelled/Forfeited/Expired (294 ) $ 35 Outstanding at October 31, 2015 5,712 $ 31 Forfeited and expired options from total cancellations in 2015 were as follows: Options Cancelled Weighted Average Exercise Price (in thousands) Forfeited 277 $ 36 Expired 17 $ 20 Total Options Cancelled during 2015 294 $ 35 The options outstanding and exercisable for equity share-based payment awards at October 31, 2015 were as follows: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life Weighted Average Exercise Price Aggregate Intrinsic Value Number Exercisable Weighted Average Remaining Contractual Life Weighted Average Exercise Price Aggregate Intrinsic Value (in thousands) (in years) (in thousands) (in thousands) (in years) (in thousands) $0 - 25 1,120 1.9 $ 21 $ 18,873 1,120 1.9 $ 21 $ 18,873 $25.01 - 30 2,425 6.1 $ 26 27,504 1,539 5.7 $ 26 17,545 $30.01 - 40 921 8.1 $ 39 — 224 8.1 $ 39 — $40.01 - over 1,246 9.1 $ 41 — 13 8.6 $ 41 — 5,712 6.2 $ 31 $ 46,377 2,896 4.4 $ 25 $ 36,418 The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value, based on the company's closing stock price of $37.76 at October 31, 2015 , which would have been received by award holders had all award holders exercised their awards that were in-the-money as of that date. The total number of in-the-money awards exercisable at October 31, 2015 was approximately 2.7 million . The following table summarizes the aggregate intrinsic value of options exercised and the fair value of options granted in 2015 , 2014 and 2013 : Aggregate Intrinsic Value Weighted Average Exercise Price Per Share Value Using Black-Scholes Model (in thousands) Options exercised in fiscal 2013 $ 71,499 $ 28 Black-Scholes per share value of options granted during fiscal 2013 $ 12 Options exercised in fiscal 2014 $ 98,075 $ 30 Black-Scholes per share value of options granted during fiscal 2014 $ 19 Options exercised in fiscal 2015 $ 33,258 $ 24 Black-Scholes per share value of options granted during fiscal 2015 $ 11 As of October 31, 2015 , the unrecognized share-based compensation costs for outstanding stock option awards, net of expected forfeitures, was approximately $5 million which is expected to be amortized over a weighted average period of 2.0 years. The amount of cash received from the exercise of share-based awards granted was $58 million in 2015 , $188 million in 2014 and $161 million in 2013 . See Note 6, "Income Taxes" for the tax impact on share-based award exercises. Non-vested Awards The following table summarizes non-vested award activity in 2015 primarily for our LTPP and restricted stock unit awards. The amount of non-vested awards and the weighted average grant price at October 31, 2014, have been revised to reflect the impact of the Keysight separation. Shares Weighted Average Grant Price (in thousands) Non-vested at October 31, 2014 2,750 $ 32 Granted 955 $ 42 Vested (1,016 ) $ 30 Forfeited (159 ) $ 36 Change in LTPP shares vested in the year due to performance conditions (113 ) $ — Non-vested at October 31, 2015 2,417 $ 36 As of October 31, 2015 , the unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures, was approximately $32 million which is expected to be amortized over a weighted average period of 2.3 years. The total fair value of restricted stock awards vested was $31 million for 2015 , $54 million for 2014 and $44 million for 2013 .

INCOME TAXES

INCOME TAXES	12 Months Ended
	Oct. 31, 2015
Income Tax Disclosure [Abstract]
PROVISION FOR INCOME TAXES	6. INCOME TAXES The domestic and foreign components of income from continuing operations before taxes are: Years Ended October 31, 2015 2014 2013 (in millions) U.S. operations $ 77 $ (72 ) $ 5 Non-U.S. operations 403 301 288 Total income from continuing operations before taxes $ 480 $ 229 $ 293 The provision (benefit) for income taxes is comprised of: Years Ended October 31, 2015 2014 2013 (in millions) U.S. federal taxes: Current $ (91 ) $ 17 $ 13 Deferred 97 (80 ) 3 Non-U.S. taxes: Current 62 176 88 Deferred (27 ) (111 ) (43 ) State taxes, net of federal benefit: Current 1 — 2 Deferred — (5 ) 5 Total provision (benefit) $ 42 $ (3 ) $ 68 The income tax provision (benefit) does not reflect potential future tax savings resulting from excess deductions associated with our various share-based award plans. The significant components of deferred tax assets and deferred tax liabilities included on the consolidated balance sheet are: October 31, 2015 2014 Deferred Tax Assets Deferred Tax Liabilities Deferred Tax Assets Deferred Tax Liabilities (in millions) Inventory $ 13 $ — $ 18 $ — Intangibles — 95 — 142 Property, plant and equipment 17 — 18 — Warranty reserves 11 — 9 — Pension benefits and retiree medical benefits 93 — 85 — Employee benefits, other than retirement 26 — 27 — Net operating loss, capital loss, and credit carryforwards 173 — 176 — Unremitted earnings of foreign subsidiaries — 33 — 44 Share-based compensation 39 — 41 — Deferred revenue 41 — 41 — Other 4 — 9 3 Subtotal 417 128 424 189 Tax valuation allowance (131 ) — (134 ) — Total deferred tax assets or deferred tax liabilities $ 286 $ 128 $ 290 $ 189 The increase in 2015 as compared to 2014 for the deferred tax asset relating to pension benefits is due mainly to the tax effect of changes in pension plans recognized in other comprehensive income (loss). The decrease in the deferred tax liability relating to intangible assets is due primarily to amortization of acquired intangible assets from Dako. The amortization expenses associated with acquired intangible assets are not deductible for tax purposes. Agilent records U.S. income taxes on the undistributed earnings of foreign subsidiaries unless the subsidiaries' earnings are considered indefinitely reinvested outside the U.S. As of October 31, 2015 the Company recognized a $33 million deferred tax liability for the overall residual tax expected to be imposed upon the repatriation of unremitted foreign earnings that are not considered permanently reinvested. As of October 31, 2015 , the cumulative amount of undistributed earnings considered indefinitely reinvested was $5 billion . No deferred tax liability has been recognized on the basis difference created by such earnings since it is our intention to utilize those earnings in the company’s foreign operations. Because of the availability of U.S. foreign tax credits, the determination of the unrecognized deferred tax liability on these earnings is not practicable. The breakdown between current and long-term deferred tax assets and deferred tax liabilities was as follows for the years 2015 and 2014 : October 31, 2015 2014 (in millions) Current deferred tax assets (included within other current assets) $ 84 $ 88 Long-term deferred tax assets (included within other assets) 180 145 Current deferred tax liabilities (included within other accrued liabilities) (10 ) (7 ) Long-term deferred tax liabilities (included within other long-term liabilities) (96 ) (125 ) Total $ 158 $ 101 Valuation allowances require an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction by jurisdiction basis. As of October 31, 2015, we continued to maintain a valuation allowance of $131 million until sufficient positive evidence exists to support reversal. The valuation allowance is mainly related to deferred tax assets for California R&D credits, net operating losses in the Netherlands and capital losses in Australia. At October 31, 2015 , we had federal net operating loss carryforwards of approximately $7 million and zero tax credit carryforwards. The federal net operating losses expire in years beginning 2022 through 2026. At October 31, 2015 , we had state net operating loss carryforwards of approximately $228 million which expire in years beginning 2016 through 2031, if not utilized. In addition, we had net state tax credit carryforwards of $36 million that do not expire. All of the federal and some of the state net operating loss carryforwards are subject to change of ownership limitations provided by the Internal Revenue Code and similar state provisions. At October 31, 2015 , we also had foreign net operating loss carryforwards of approximately $358 million . Of this foreign loss, $234 million will expire in years beginning 2016 through 2024, if not utilized. The remaining $124 million has an indefinite life. Some of the foreign losses are subject to annual loss limitation rules. These annual loss limitations in the U.S. and foreign jurisdictions may result in the expiration or reduced utilization of the net operating losses. The authoritative guidance prohibits recognition of a deferred tax asset for excess tax benefits related to stock and stock option plans that have not yet been realized through reduction in income taxes payable. Such unrecognized deferred tax benefit totals $193 million as of October 31, 2015 and will be accounted for as a credit to shareholders' equity, if and when realized, through a reduction in income taxes payable. The Company recognized approximately $28 million as a credit to shareholders' equity for cumulative excess tax benefits related to stock and stock option plans that have been realized as of October 31, 2015 . The differences between the U.S. federal statutory income tax rate and our effective tax rate are: Years Ended October 31, 2015 2014 2013 (in millions) Profit before tax times statutory rate $ 167 $ 80 $ 103 State income taxes, net of federal benefit (8 ) (7 ) 5 Non-U.S. income taxed at different rates (72 ) (39 ) (34 ) Change in unrecognized U.S. tax benefits (116 ) (111 ) — Repatriation of foreign earnings 68 75 — Valuation allowances (2 ) 2 (8 ) Transfer pricing adjustments for prior years — — 8 Adjustment to income taxes payable — (6 ) — Other, net 5 3 (6 ) Provision (benefit) for income taxes $ 42 $ (3 ) $ 68 Effective tax rate 8.7 % (1.3 )% 23.4 % Agilent enjoys tax holidays in several different jurisdictions, most significantly in Singapore. The tax holidays provide lower rates of taxation on certain classes of income and require various thresholds of investments and employment or specific types of income in those jurisdictions. The tax holidays are due for renewal between 2016 and 2023. As a result of the incentives, the impact of the tax holidays decreased income taxes by $65 million , $27 million , and $44 million in 2015 , 2014 , and 2013 , respectively. The benefit of the tax holidays on net income per share (diluted) was approximately $0.19 , $0.08 , and $0.13 in 2015 , 2014 and 2013 , respectively. For 2015, the company’s effective tax rate from continuing operations was 8.7 percent . The income tax expense from continuing operations was $42 million . The income tax provision from continuing operations for the year ended October 31, 2015 included net discrete tax benefits of $55 million . The net discrete tax benefit for the year ended October 31, 2015 included $32 million of net tax benefit primarily due to the settlement of an Internal Revenue Service (“IRS) audit in the U.S. and the recognition of tax expense related to the repatriation of dividends to the U.S. The remaining $23 million net tax benefit for the year ended October 31, 2015 included $16 million of tax benefit related to the de-registration of certain foreign branches and statutue of limitations lapses, $6 million of tax benefit for the extension of the U.S. research and development tax credit attributable to the company's prior fiscal year and $1 million of other discrete benefits. For 2014, the company's effective tax rate from continuing operations was (1.3) percent . The income tax benefit from continuing operations was $3 million . The income tax benefit for the year ended October 31, 2014 included a net discrete benefit of $33 million Internal Revenue Service ("IRS") audit in the U.S. and the recognition of tax expense related to the repatriation of dividends. For 2013, the effective tax rate from continuing operations was 23.4 percent . The 23.4 percent effective tax rate is lower than the U.S. statutory rate primarily due to the mix of earnings in non-U.S. jurisdictions taxed at lower statutory rates; in particular Singapore where we enjoy tax holidays. The breakdown between current and long-term income tax assets and liabilities, excluding deferred tax assets and liabilities, was as follows for the years 2015 and 2014 : October 31, 2015 2014 (in millions) Current income tax assets (included within other current assets) $ 104 $ 82 Long-term income tax assets (included within other assets) 20 45 Current income tax liabilities (included within other accrued liabilities) (62 ) (100 ) Long-term income tax liabilities (included within other long-term liabilities) (227 ) (285 ) Total $ (165 ) $ (258 ) The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax law and regulations in a multitude of jurisdictions. Although the guidance on the accounting for uncertainty in income taxes prescribes the use of a recognition and measurement model, the determination of whether an uncertain tax position has met those thresholds will continue to require significant judgment by management. In accordance with the guidance on the accounting for uncertainty in income taxes, for all U.S. and other tax jurisdictions, we recognize potential liabilities for anticipated tax audit issues based on our estimate of whether, and the extent to which, additional taxes and interest will be due. The ultimate resolution of tax uncertainties may differ from what is currently estimated, which could result in a material impact on income tax expense. If our estimate of income tax liabilities proves to be less than the ultimate assessment, a further charge to expense would be required. If events occur and the payment of these amounts ultimately proves to be unnecessary, the reversal of the liabilities would result in tax benefits being recognized in the period when we determine the liabilities are no longer necessary. The aggregate changes in the balances of our unrecognized tax benefits including all federal, state and foreign tax jurisdictions are as follows: 2015 2014 2013 (in millions) Balance, beginning of year $ 417 $ 512 $ 457 Additions for tax positions related to the current year 33 45 52 Additions for tax positions from prior years 3 11 15 Reductions for tax positions from prior years (156 ) (141 ) (6 ) Settlements with taxing authorities (4 ) (2 ) (3 ) Statute of limitations expirations (4 ) (8 ) (3 ) Balance, end of year $ 289 $ 417 $ 512 As of October 31, 2015 , we had $289 million of unrecognized tax benefits of which $269 million , if recognized, would affect our effective tax rate. We recognized a tax benefit of $2 million , a tax benefit of $10 million and a tax benefit $5 million of interest and penalties related to unrecognized tax benefits in 2015 , 2014 and 2013 , respectively. Interest and penalties accrued as of October 31, 2015 and 2014 were $24 million and $29 million , respectively. On November 1, 2014, Agilent transferred deferred tax assets of $237 million , deferred tax liabilities of $37 million , current income tax payable of $40 million , and other long-term liabilities related to uncertain tax positions totaling $8 million to Keysight as part of its separation from Agilent. A current prepaid income tax asset of $19 million and long-term prepaid income tax asset of $3 million related to sales of intercompany assets was also transferred to Keysight upon separation from Agilent. In the U.S., tax years remain open back to the year 2012 for federal income tax purposes and the year 2000 for significant states. On September 22, 2015, we reached an agreement with the IRS for the tax years 2008 through 2011. We expect to make a payment of approximately $9 million as part of closing the exam. As a result, in 2015 we reclassified a portion of other long-term liabilities to other accrued liabilities related to uncertain tax positions of continuing operations that we expect to pay within the next twelve months. This amount is partially offset by a prepaid tax account of approximately $3 million that the IRS is allowing as an offset to the $12 million in incremental taxes. The settlement resulted in the recognition, within the continuing operations, of previously unrecognized tax benefits of $119 million , offset by a tax liability on foreign distributions of approximately $99 million principally related to the repatriation of foreign earnings. On January 29, 2014 we reached an agreement with the IRS for the tax years 2006 through 2007. The settlement resulted in the recognition, within the continuing operations, of previously unrecognized tax benefits of $111 million , offset by a tax liability on foreign distributions of approximately $75 million principally related to the repatriation of foreign earnings. In other major jurisdictions where the company conducts business, the tax years generally remain open back to the year 2003. With these jurisdictions and the U.S., it is reasonably possible that there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitation or a tax audit settlement which will be partially offset by an anticipated tax liability related to unremitted foreign earnings, where applicable. Given the number of years and numerous matters that remain subject to examination in various tax jurisdictions, management is unable to estimate the range of possible changes to the balance of our unrecognized tax benefits. On July 27, 2015, the U.S. Tax Court issued an opinion in Altera Corp. v. Commissioner related to the treatment of stock-based compensation expense in an intercompany cost-sharing arrangement. A final decision was entered by the U.S. Tax Court on December 1, 2015. At this time, the U.S. Department of the Treasury has not withdrawn the requirement from its regulations to include stock-based compensation. The I.R.S. has the right to appeal the U.S. Tax Court decision. We concluded that no adjustment to our consolidated financial statements is appropriate at this time due to the uncertainties with respect to the ultimate resolution of this case.

NET INCOME (LOSS) PER SHARE

NET INCOME (LOSS) PER SHARE	12 Months Ended
	Oct. 31, 2015
Earnings Per Share [Abstract]
NET INCOME (LOSS) PER SHARE	7. NET INCOME PER SHARE The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented below. Years Ended October 31, 2015 2014 2013 (in millions) Numerator: Income from continuing operations $ 438 $ 232 $ 225 Income (loss) from discontinued operations $ (37 ) $ 317 $ 509 Net income 401 549 734 Denominators: Basic weighted average shares 333 333 341 Potential common shares — stock options and other employee stock plans 2 5 4 Diluted weighted average shares 335 338 345 In connection with the separation of Keysight on November 1, 2014 and in accordance with the Employee Matters Agreement we made certain adjustments to the exercise price and number of our share-based compensation awards. These adjustments to our share-based awards did not have a material impact on our dilutive weighted average shares. The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense, the tax benefits or shortfalls charged to additional paid-in capital and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense and tax benefits or shortfalls collectively are assumed proceeds to be used to repurchase hypothetical shares. An increase in the fair market value of the company's common stock can result in a greater dilutive effect from potentially dilutive awards. The total number of share-based awards issued in 2015 , 2014 and 2013 were 3 million , 6 million and 6 million , respectively. We exclude stock options with exercise prices greater than the average market price of our common stock from the calculation of diluted earnings per share because their effect would be anti-dilutive. For 2015, 2014 and 2013, options to purchase 1.2 million , 1,500 and 4,200 shares respectively were excluded from the calculation of diluted earnings per share. In addition, we also exclude from the calculation of diluted earnings per share, stock options, ESPP, LTPP and restricted stock awards whose combined exercise price, unamortized fair value and excess tax benefits or shortfalls collectively were greater than the average market price of our common stock because their effect would also be anti-dilutive. For the year ended 2015, 2014 and 2013, options to purchase 368,900 , 383,200 and 18,300 shares respectively were excluded from the calculation of diluted earnings per share.

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	12 Months Ended
	Oct. 31, 2015
Supplemental Cash Flow Information [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	8. SUPPLEMENTAL CASH FLOW INFORMATION Net cash paid for income taxes was $129 million in 2015 , $131 million in 2014 , and $110 million in 2013 . Cash paid for interest was $71 million in 2015 , $142 million in 2014 and $112 million in 2013 .

INVENTORY

INVENTORY	12 Months Ended
	Oct. 31, 2015
Inventory Disclosure [Abstract]
INVENTORY	9. INVENTORY October 31, 2015 2014 (in millions) Finished goods $ 362 $ 366 Purchased parts and fabricated assemblies 179 208 Inventory $ 541 $ 574 Inventory-related excess and obsolescence charges, included in continuing operations, of $30 million were recorded in total cost of products in 2015 , $46 million in 2014 and $27 million in 2013 , respectively. We record excess and obsolete inventory charges for both inventory on our site as well as inventory at our contract manufacturers and suppliers where we have non-cancellable purchase commitments.

PROPERTY, PLANT AND EQUIPMENT,

PROPERTY, PLANT AND EQUIPMENT, NET	12 Months Ended
	Oct. 31, 2015
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	10. PROPERTY, PLANT AND EQUIPMENT, NET October 31, 2015 2014 (in millions) Land $ 53 $ 58 Buildings and leasehold improvements 705 714 Machinery and equipment 401 443 Software 168 154 Total property, plant and equipment 1,327 1,369 Accumulated depreciation and amortization (723 ) (738 ) Property, plant and equipment, net $ 604 $ 631 Asset impairments other than related to our exit of the NMR business were zero in 2015 , zero in 2014 and $3 million in 2013 . Asset impairments in connection with the exit of the NMR business were $7 million in 2014. Depreciation expenses were $98 million in 2015 , $120 million in 2014 and $116 million in 2013 .

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	12 Months Ended
	Oct. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	11. GOODWILL AND OTHER INTANGIBLE ASSETS The goodwill balances at October 31, 2015 , 2014 and 2013 and the movements in 2015 and 2014 for each of our reportable segments are shown in the table below: Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Goodwill as of October 31, 2013 $ 626 $ 1,546 $ 456 $ 2,628 Foreign currency translation impact 42 (201 ) 38 (121 ) Goodwill as of October 31, 2014 $ 668 $ 1,345 $ 494 $ 2,507 Foreign currency translation impact (18 ) (166 ) (12 ) (196 ) Goodwill arising from acquisitions — 55 — 55 Goodwill as of October 31, 2015 $ 650 $ 1,234 $ 482 $ 2,366 As of September 30, 2015, we assessed goodwill impairment for our reporting units and no impairment of goodwill was indicated. The component parts of other intangible assets at October 31, 2015 and 2014 are shown in the table below: Other Intangible Assets Gross Carrying Amount Accumulated Amortization and Impairments Net Book Value (in millions) As of October 31, 2014: Purchased technology $ 880 $ 475 $ 405 Trademark/Tradename 167 52 115 Customer relationships 368 257 111 Total amortizable intangible assets $ 1,415 $ 784 $ 631 In-Process R&D 18 — 18 Total $ 1,433 $ 784 $ 649 As of October 31, 2015: Purchased technology $ 746 $ 476 $ 270 Trademark/Tradename 141 50 91 Customer relationships 230 168 62 Total amortizable intangible assets $ 1,117 $ 694 $ 423 In-Process R&D 22 — 22 Total $ 1,139 $ 694 $ 445 In 2015, we recorded additions to goodwill of $55 million and to other intangible assets of $13 million related to the single acquisition of the company, Cartagenia. During the year other intangible assets decreased $58 million , due to the impact of foreign exchange translation. During 2015, we also removed the gross carrying amount of $246 million and the related accumulated amortization of fully amortized intangible assets which were no longer being used. In 2014, there were no additions to goodwill and intangible assets. In 2014, we recorded $12 million of impairment of other intangibles due to the exit of the NMR business. In addition, we recorded $3 million , $4 million and zero of impairments of other intangibles related to the cancellation of in-process research and development projects during 2015, 2014 and 2013, respectively. Amortization of intangible assets was $156 million in 2015 , $189 million in 2014 , and $190 million in 2013 . Future amortization expense related to existing finite-lived purchased intangible assets for the next five fiscal years and thereafter is estimated below: Estimated future amortization expense: (in millions) 2016 $ 131 2017 $ 92 2018 $ 61 2019 $ 47 2020 $ 36 Thereafter $ 56

INVESTMENTS

INVESTMENTS	12 Months Ended
	Oct. 31, 2015
Schedule of Investments [Abstract]
INVESTMENTS	12. INVESTMENTS The following table summarizes the company's equity investments as of October 31, 2015 and 2014 (net book value): October 31, 2015 2014 (in millions) Long-Term Cost method investments $ 23 $ 25 Trading securities 35 35 Equity method investments 28 36 Total $ 86 $ 96 Cost method investments consist of non-marketable equity securities and two funds and are accounted for at historical cost. Trading securities are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in earnings. Equity method investments are reported at the amount of the company’s initial investment and adjusted each period for the company’s share of the investee’s income or loss and dividend paid. All of our investments, excluding trading securities, are subject to periodic impairment review. The impairment analysis requires significant judgment to identify events or circumstances that would likely have significant adverse effect on the future value of the investment. We consider various factors in determining whether an impairment is other-than-temporary, including the severity and duration of the impairment, forecasted recovery, the financial condition and near-term prospects of the investee, and our ability and intent to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. Amounts included in other income (expense), net for the appropriate share of loss on equity method investments were as follows: Years Ended October 31, 2015 2014 2013 (in millions) Equity method investments - share of losses (9 ) $ (7 ) (2 ) Net unrealized gains on our trading securities portfolio were $2 million in 2015 , $2 million in 2014 and $6 million in 2013 .

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Oct. 31, 2015
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	13. FAIR VALUE MEASUREMENTS The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability. Fair Value Hierarchy The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into three levels. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value: Level 1 — applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 — applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data. Level 3 — applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2015 were as follows: Fair Value Measurement at October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 1,411 $ 1,411 $ — $ — Derivative instruments (foreign exchange contracts) 4 — 4 — Long-term Trading securities 35 35 — — Total assets measured at fair value $ 1,450 $ 1,446 $ 4 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 5 $ — $ 5 $ — Long-term Deferred compensation liability 35 — 35 — Total liabilities measured at fair value $ 40 $ — $ 40 $ — Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2014 were as follows: Fair Value Measurement at October 31, 2014 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 1,117 $ 1,117 $ — $ — Derivative instruments (foreign exchange contracts) 10 — 10 — Long-term Trading securities 35 35 — — Total assets measured at fair value $ 1,162 $ 1,152 $ 10 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 4 $ — $ 4 $ — Long-term Deferred compensation liability 35 — 35 — Total liabilities measured at fair value $ 39 $ — $ 39 $ — Our money market funds and trading securities are generally valued using quoted market prices and therefore are classified within level 1 of the fair value hierarchy. Our derivative financial instruments are classified within level 2, as there is not an active market for each hedge contract, but the inputs used to calculate the value of the instruments are tied to active markets. Our deferred compensation liability is classified as level 2 because although the values are not directly based on quoted market prices, the inputs used in the calculations are observable. Trading securities and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Certain derivative instruments are reported at fair value, with unrealized gains and losses, net of tax, included in stockholders' equity. Realized gains and losses from the sale of these instruments are recorded in net income. Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis Long-Lived Assets For assets measured at fair value on a non-recurring basis, the following table summarizes the impairments included in net income for the years ended October 31, 2015 , 2014 and 2013: Years Ended October 31, 2015 2014 2013 (in millions) Long-lived assets held and used $ 3 $ 23 $ 1 Long-lived assets held for sale $ — $ — $ 1 Long-lived assets held and used with a carrying amount of $3 million were written down to their fair value of zero , resulting in an impairment charge of $3 million , which was included in net income for 2015 . Long-lived assets held and used with a carrying amount of $23 million were written down to their fair value of zero , resulting in an impairment charge of $23 million , which was included in net income for 2014 . The impairment charge for 2014 includes $19 million relating to the exit of a business and $4 million related to various IPR&D projects that were written down to their fair value of zero. Long-lived assets held and used with a carrying amount of $1 million were written down to their fair value of zero , resulting in an impairment charge of $1 million , which was included in net income for 2013 . There were no impairments of long-lived assets held for sale in 2015 and 2014. Long-lived assets held for sale with a carrying amount of $3 million were written down to their fair value of $2 million , resulting in an impairment charge of $1 million which was included in net income for 2013. Fair values for the impaired long-lived assets were measured using level 2 inputs.

DERIVATIVES

DERIVATIVES	12 Months Ended
	Oct. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVES	14. DERIVATIVES We are exposed to foreign currency exchange rate fluctuations and interest rate changes in the normal course of our business. As part of risk management strategy, we use derivative instruments, primarily forward contracts, purchased options, and interest rate swaps, to hedge economic and/or accounting exposures resulting from changes in foreign currency exchange rates and interest rates. Fair Value Hedges We are exposed to interest rate risk due to the mismatch between the interest expense we pay on our loans at fixed rates and the variable rates of interest we receive from cash, cash equivalents and other short-term investments. We have issued long-term debt in U.S. dollars at fixed interest rates based on the market conditions at the time of financing. The fair value of our fixed rate debt changes when the underlying market rates of interest change, and, in the past, we have used interest rate swaps to change our fixed interest rate payments to U.S. dollar LIBOR-based variable interest expense to match the floating interest income from our cash, cash equivalents and other short term investments. As of October 31, 2015 , all interest rate swap contracts had either been terminated or had expired. On November 25, 2008, we terminated two interest rate swap contracts associated with our 2017 senior notes that represented the notional amount of $400 million . On October 20, 2014 we prepaid $500 million out of $600 million principal of our 2017 senior notes and fully amortized the associated proportionate deferred gain to other income (expense). The remaining gain to be amortized related to the $100 million of 2017 senior notes at October 31, 2015 was $2 million . On August 9, 2011, we terminated five interest rate swap contracts related to our 2020 senior notes that represented the notional amount of $500 million . The gain to be amortized at October 31, 2015 was $19 million . All deferred gains from terminated interest rate swaps are being amortized over the remaining life of the respective senior notes. Cash Flow Hedges We enter into foreign exchange contracts to hedge our forecasted operational cash flow exposures resulting from changes in foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities between one and twelve months. These derivative instruments are designated and qualify as cash flow hedges under the criteria prescribed in the authoritative guidance. The changes in the fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income. Amounts associated with cash flow hedges are reclassified to cost of sales in the consolidated statement of operations when the forecasted transaction occurs. If it becomes probable that the forecasted transaction will not occur, the hedge relationship will be de-designated and amounts accumulated in other comprehensive income will be reclassified to other income (expense) in the current period. Changes in the fair value of the ineffective portion of derivative instruments are recognized in other income (expense) in the consolidated statement of operations in the current period. We record the premium paid (time value) of an option on the date of purchase as an asset. For options designated as cash flow hedges, changes in the time value are excluded from the assessment of hedge effectiveness and are recognized in other income (expense) over the life of the option contract. Ineffectiveness in 2015, 2014 and 2013 was not significant. For the years ended October 31, 2015, 2014 and 2013 gains and losses recognized in earnings due to de-designation of cash flow hedge contracts were not significant. In July 2012, Agilent executed treasury lock agreements for $400 million in connection with future interest payments to be made on our 2022 senior notes issued on September 10, 2012. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 10, 2012 and we recognized a deferred gain in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2022 senior notes. The remaining gain to be amortized related to the treasury lock agreements at October 31, 2015 was $2 million . Other Hedges Additionally, we enter into foreign exchange contracts to hedge monetary assets and liabilities that are denominated in currencies other than the functional currency of our subsidiaries. These foreign exchange contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as hedging instruments. Changes in value of the derivative are recognized in other income (expense) in the consolidated statement of operations, in the current period, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities. Our use of derivative instruments exposes us to credit risk to the extent that the counterparties may be unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting our counterparties to major financial institutions which are selected based on their credit ratings and other factors. We have established policies and procedures for mitigating credit risk that include establishing counterparty credit limits, monitoring credit exposures, and continually assessing the creditworthiness of counterparties. A number of our derivative agreements contain threshold limits to the net liability position with counterparties and are dependent on our corporate credit rating determined by the major credit rating agencies. The counterparties to the derivative instruments may request collateralization, in accordance with derivative agreements, on derivative instruments in net liability positions. The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position as of October 31, 2015 , was $2 million . The credit-risk-related contingent features underlying these agreements had not been triggered as of October 31, 2015 . There were 53 foreign exchange forward contracts open as of October 31, 2015 and designated as cash flow hedges. There were 170 foreign exchange forward contracts open as of October 31, 2015 not designated as hedging instruments. The aggregated notional amounts by currency and designation as of October 31, 2015 were as follows: Derivatives Designated as Derivatives Not Designated as Hedging Instruments Forward Forward Forward Contracts DKK Currency Buy/(Sell) Buy/(Sell) Buy/(Sell) (in millions) Euro $ (19 ) $ 186 $ (60 ) British Pound (15 ) (10 ) (4 ) Canadian Dollar (23 ) — (2 ) Australian Dollars 10 13 (3 ) Malaysian Ringgit — (4 ) — Japanese Yen (67 ) (5 ) (1 ) American Dollar — — 33 Other (2 ) 21 (9 ) $ (116 ) $ 201 $ (46 ) Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of October 31, 2015 and 2014 were as follows: Fair Values of Derivative Instruments Asset Derivatives Liability Derivatives Fair Value Fair Value Balance Sheet Location October 31, October 31, Balance Sheet Location October 31, October 31, (in millions) Derivatives designated as hedging instruments: Cash flow hedges Foreign exchange contracts Other current assets $ 2 $ 9 Other accrued liabilities $ 1 $ 1 $ 2 $ 9 $ 1 $ 1 Derivatives not designated as hedging instruments: Foreign exchange contracts Other current assets $ 2 $ 1 Other accrued liabilities $ 4 $ 3 Total derivatives $ 4 $ 10 $ 5 $ 4 The effect of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows: 2015 2014 2013 (in millions) Derivatives designated as hedging instruments: Cash Flow Hedges Gain recognized in accumulated other comprehensive income $ 11 $ 13 $ 10 Gain (loss) reclassified from accumulated other comprehensive income into cost of sales $ 18 $ (1 ) $ 13 Derivatives not designated as hedging instruments: Gain (loss) recognized in other income (expense), net within continuing operations $ (21 ) $ (20 ) $ 10 The estimated net amount of existing gain at October 31, 2015 that is expected to be reclassified from other comprehensive income to the cost of sales within the next twelve months is $1 million .

RESTRUCTURING AND EXIT OF NMR B

RESTRUCTURING AND EXIT OF NMR BUSINESS	12 Months Ended
	Oct. 31, 2015
Restructuring and Related Activities [Abstract]
RESTRUCTURING	15. EXIT OF NMR BUSINESS During the fourth quarter of fiscal year 2014, we made the decision to cease the manufacture and sale of our nuclear magnetic resonance (“NMR”) product line within our life sciences and applied markets segment. The exit of the NMR business was primarily due to the lack of growth and profitability of the product line. These actions involved severance and other personnel costs related to the workforce reduction of approximately 300 employees primarily located in the United Kingdom and California and non-cash charges related to intangible asset impairments and other asset write-downs including inventory. After including employee reductions due to attrition and the application to open positions and acceptance of employment within the company of some employees previously affected, we have approximately 30 employees that are pending termination under the above actions as of October 31, 2015. We expect to complete these restructuring activities by early fiscal 2016. A summary of total “NMR” restructuring activity and other special charges is shown in the table below: Workforce Reduction Impairments of Building and Other Assets Special Charges Related to Inventory and Others Total (in millions) Balance as of October 31, 2013 $ — $ — $ — $ — Income statement expense 16 19 33 68 Asset impairments/inventory charges — (19 ) (30 ) (49 ) Cash payments (2 ) — — (2 ) Balance as of October 31, 2014 $ 14 $ — $ 3 $ 17 Income statement expense/(reversal) (2 ) — 8 6 Asset impairments/inventory charges — — (2 ) (2 ) Cash payments (10 ) — (3 ) (13 ) Balance as of October 31, 2015 $ 2 $ — $ 6 $ 8 The restructuring and other special accruals related to the NMR closure, which totaled $8 million at October 31, 2015, are recorded in other accrued liabilities on the consolidated balance sheet. These balances reflect estimated future cash outlays. A summary of the charges in the consolidated statement of operations resulting from the NMR closure is shown below: Year Ended Year Ended October 31, October 31, 2015 2014 (in millions) Cost of products and services $ (2 ) $ 48 Research and development 4 5 Selling, general and administrative 4 15 Total restructuring, asset impairments and other special charges $ 6 $ 68

RETIREMENT PLANS AND POST RETIR

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS	12 Months Ended
	Oct. 31, 2015
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS	16. RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS General. Substantially all of our employees are covered under various defined benefit and/or defined contribution retirement plans. Additionally, we sponsor post-retirement health care benefits for our eligible U.S. employees. Agilent provides U.S. employees, who meet eligibility criteria under the Agilent Technologies, Inc. Retirement Plan (the "RP"), defined benefits which are based on an employee's base or target pay during the years of employment and on length of service. For eligible service through October 31, 1993, the benefit payable under the Agilent Retirement Plans is reduced by any amounts due to the eligible employee under the Agilent defined contribution Deferred Profit-Sharing Plan (the "DPSP"), which was closed to new participants as of November 1993. Effective November 1, 2014, Agilent’s U.S. defined benefit retirement plan is closed to new entrants including new employees, new transfers to the U.S. payroll and rehires. These employees will instead be eligible for an enhanced 6 percent employer match in the Agilent 401(k) plan. Current eligible employees will continue to participate in the U.S. defined benefit retirement plan and will remain eligible for the 401(k) plan with the current 4 percent employer match. Retirees maintain the retirement benefits they are eligible for as of November 1, 2014. As of October 31, 2015 and 2014 , the fair value of plan assets of the DPSP was $169 million and $520 million , respectively. Note that the projected benefit obligation for the DPSP equals the fair value of plan assets. In addition to the DPSP, in the U.S., Agilent maintains a Supplemental Benefits Retirement Plan ("SBRP"), supplemental unfunded non-qualified defined benefit plan to provide benefits that would be provided under the RP but for limitations imposed by the Internal Revenue Code. The RP and the SBRP comprise the "U.S. Plans" in the tables below. Eligible employees outside the U.S. generally receive retirement benefits under various retirement plans based upon factors such as years of service and/or employee compensation levels. Eligibility is generally determined in accordance with local statutory requirements. 401(k) defined contribution plan . Eligible Agilent U.S. employees may participate in the Agilent Technologies, Inc. 401(k) Plan. Under the 401(k) Plan, we provide matching contributions to employees up to a maximum of 4 percent of an employee's annual eligible compensation. Effective November 1, 2014, new employees and new transfers to the U.S. payroll and rehires are eligible for an enhanced 6 percent employer match in the Agilent 401(k) Plan. The maximum contribution to the 401(k) Plan is 50 percent of an employee's annual eligible compensation, subject to regulatory limitations. The 401(k) Plan employer expense included in income from continuing operations was $14 million in 2015 , $15 million in 2014 and $13 million in 2013 . Post-retirement medical benefit plans. In addition to receiving retirement benefits, Agilent U.S. employees who meet eligibility requirements as of their termination date may participate in the Agilent Technologies, Inc. Health Plan for Retirees. Eligible retirees who were less than age 50 as of January 1, 2005 and who retire after age 55 with 15 or more years of service are eligible for a fixed amount which can be utilized to pay for either sponsored plans and/or individual medicare plans. Eligible retirees who were at least age 50 as of January 1, 2005 and who retire after age 55 with 15 or more years of service currently choose from managed-care, indemnity options or individual medicare plans, with the company subsidization level or stipend dependent on a number of factors including eligibility and length of service. On April 1, 2011, changes to the Agilent Technologies, Inc. Health Plan for Retirees were approved. Effective January 1, 2012, employees who were at least age 50 as of January 1, 2005 and who retire after age 55 with 15 or more years of service are eligible for fixed dollar subsidies and stipends. Grandfathered retirees receive a fixed monthly subsidy toward pre-65 premium costs (subsidy capped at 2011 levels) and a fixed monthly stipend post-65. The subsidy amounts will not increase. In addition, any new employee hired on or after November 1, 2014, will not be eligible to participate in the retiree medical plans upon retiring. Current eligible employees will continue to participate in the retiree medical program in place as of November 1, 2014. Retirees will maintain the retiree medical benefits they are eligible for as of November 1, 2014. Components of net periodic cost. The company uses alternate methods of amortization as allowed by the authoritative guidance which amortizes the actuarial gains and losses on a consistent basis for the years presented. For U.S. Plans, gains and losses are amortized over the average future working lifetime. For most Non-U.S. Plans and U.S. Post-Retirement Benefit Plans, gains and losses are amortized using a separate layer for each year's gains and losses. For the years ended October 31, 2015 , 2014 and 2013 , components of net periodic benefit cost and other amounts recognized in other comprehensive income were comprised of: Pensions U.S. Post-Retirement Benefit Plans U.S. Plans Non-U.S. Plans 2015 2014 2013 2015 2014 2013 2015 2014 2013 (in millions) Net periodic benefit cost (benefit) Service cost — benefits earned during the period $ 25 $ 46 $ 44 $ 18 $ 36 $ 36 $ 2 $ 3 $ 4 Interest cost on benefit obligation 14 34 24 23 74 68 4 12 12 Expected return on plan assets (27 ) (64 ) (51 ) (42 ) (118 ) (97 ) (8 ) (22 ) (20 ) Amortization of net actuarial loss 3 1 13 25 48 55 6 14 18 Amortization of prior service benefit (5 ) (12 ) (12 ) — (1 ) (1 ) (12 ) (35 ) (35 ) Total periodic benefit cost (benefit) $ 10 $ 5 $ 18 $ 24 $ 39 $ 61 $ (8 ) $ (28 ) $ (21 ) Summary of total periodic benefit cost (benefit): Continuing operations $ 10 $ 2 $ 9 $ 24 $ 27 $ 38 $ (8 ) $ (14 ) $ (11 ) Discontinued operations — 3 9 — 12 23 — (14 ) (10 ) Total periodic benefit cost (benefit) $ 10 $ 5 $ 18 $ 24 $ 39 $ 61 $ (8 ) $ (28 ) $ (21 ) Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss Net actuarial (gain) loss $ 44 $ 86 $ (122 ) $ 32 $ 173 $ (85 ) $ 16 $ 12 $ (57 ) Amortization of net actuarial loss (3 ) (1 ) (13 ) (25 ) (48 ) (55 ) (6 ) (14 ) (18 ) Prior service cost (benefit) — — — — (2 ) — — — — Amortization of prior service benefit 5 12 12 — 1 1 12 35 35 Foreign currency — — — 10 (28 ) 2 — — — Total recognized in other comprehensive (income) loss $ 46 $ 97 $ (123 ) $ 17 $ 96 $ (137 ) $ 22 $ 33 $ (40 ) Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss $ 56 $ 102 $ (105 ) $ 41 $ 135 $ (76 ) $ 14 $ 5 $ (61 ) Funded status. As of October 31, 2015 and 2014 , the funded status of the defined benefit and post-retirement benefit plans was: U.S. Defined Benefit Plans Non-U.S. Defined Benefit Plans U.S. Post-Retirement Benefit Plans 2015 2014 2015 2014 2015 2014 (in millions) Change in fair value of plan assets: Fair value — beginning of year $ 837 $ 782 $ 2,108 $ 2,045 $ 284 $ 288 Actual return on plan assets 6 64 53 180 2 18 Employer contributions 15 30 25 72 — 1 Participants' contributions — — 1 3 — — Benefits paid (21 ) (39 ) (20 ) (62 ) (8 ) (23 ) Transfer due to Keysight separation (490 ) — (1,327 ) — (187 ) — Currency impact — — (62 ) (130 ) — — Fair value — end of year $ 347 $ 837 $ 778 $ 2,108 $ 91 $ 284 Change in benefit obligation: Benefit obligation — beginning of year $ 889 $ 763 $ 2,344 $ 2,199 $ 309 $ 307 Service cost 25 46 18 36 2 3 Interest cost 14 34 23 74 4 12 Participants' contributions — — 1 3 — — Plan amendment — — — (2 ) — — Actuarial (gain) loss 23 85 40 236 11 10 Benefits paid (22 ) (39 ) (20 ) (62 ) (8 ) (23 ) Transfer due to Keysight separation (514 ) — (1,429 ) — (206 ) — Currency impact — — (77 ) (140 ) — — Benefit obligation — end of year $ 415 $ 889 $ 900 $ 2,344 $ 112 $ 309 Overfunded (underfunded) status of PBO $ (68 ) $ (52 ) $ (122 ) $ (236 ) $ (21 ) $ (25 ) Amounts recognized in the consolidated balance sheet consist of: Continuing operations: Other assets $ — $ — $ 26 $ 22 $ — $ — Employee compensation and benefits (2 ) (1 ) — — — — Retirement and post-retirement benefits (66 ) (28 ) (148 ) (147 ) (21 ) (6 ) Net asset (liability) - continuing operations $ (68 ) $ (29 ) $ (122 ) $ (125 ) $ (21 ) $ (6 ) Discontinued operations: Other assets $ — $ — $ — $ — $ — $ — Employee compensation and benefits — (1 ) — 48 — — Retirement and post-retirement benefits — (22 ) — (159 ) — (19 ) Net asset (liability) - discontinued operations $ — $ (23 ) $ — $ (111 ) $ — $ (19 ) Total net asset (liability) $ (68 ) $ (52 ) $ (122 ) $ (236 ) $ (21 ) $ (25 ) Amounts Recognized in Accumulated Other Comprehensive Income (loss): Actuarial (gains) losses $ 73 $ 77 $ 256 $ 621 $ 49 $ 118 Prior service costs (benefits) (18 ) (55 ) — (4 ) (40 ) (149 ) Total $ 55 $ 22 $ 256 $ 617 $ 9 $ (31 ) In connection with the separation of Keysight Technologies on November 1, 2014, Agilent transferred certain liabilities and assets of the U.S. and Non-U.S. defined benefit pension plans, and U.S. Post-Retirement Benefit Plans to similar plans created for Keysight Technologies employees. Total transfers are as follows: U.S. Defined Benefit Plans Non-U.S. Defined Benefit Plans U.S. Post-Retirement Benefit Plans (in millions) Fair value of plan assets transferred to Keysight $ 490 $ 1,327 $ 187 Benefit obligation transferred to Keysight $ 514 $ 1,429 $ 206 The amounts in accumulated other comprehensive income expected to be recognized by Agilent as components of net expense during 2016 are as follows: U.S. Defined Benefit Plans Non-U.S. Defined Benefit Plans U.S. Post-Retirement Benefit Plans (in millions) Amortization of net prior service cost (benefit) $ (5 ) $ — $ (10 ) Amortization of actuarial net loss (gain) $ 8 $ 26 $ 10 Investment policies and strategies as of October 31, 2015 and 2014 . In the U.S., target asset allocations for our retirement and post-retirement benefit plans are approximately 80 percent to equities and approximately 20 percent to fixed income investments. Our DPSP target asset allocation is approximately 60 percent to equities and approximately 40 percent to fixed income investments. Approximately, 5 percent of our U.S. equity portfolio consists of limited partnerships. The general investment objective for all our plan assets is to obtain the optimum rate of investment return on the total investment portfolio consistent with the assumption of a reasonable level of risk. Specific investment objectives for the plans' portfolios are to: maintain and enhance the purchasing power of the plans' assets; achieve investment returns consistent with the level of risk being taken; and earn performance rates of return in accordance with the benchmarks adopted for each asset class. Outside the U.S., our target asset allocation is from 37 to 60 percent to equities, from 40 to 60 percent to fixed income investments, and from zero to 6 percent to real estate investments and from zero to 7 percent to cash, depending on the plan. All plans' assets are broadly diversified. Due to fluctuations in equity markets, our actual allocations of plan assets at October 31, 2015 and 2014 differ from the target allocation. Our policy is to bring the actual allocation in line with the target allocation. Equity securities include exchange-traded common stock and preferred stock of companies from broadly diversified industries. Fixed income securities include a global portfolio of corporate bonds of companies from diversified industries, government securities, mortgage-backed securities, asset-backed securities, derivative instruments and other. Other investments include a group trust consisting primarily of private equity partnerships as well as other investments. Portions of the cash and cash equivalent, equity, and fixed income investments are held in commingled funds. Fair Value. The measurement of the fair value of pension and post-retirement plan assets uses the valuation methodologies and the inputs as described in Note 13, "Fair Value Measurements". Cash and Cash Equivalents - Cash and cash equivalents consist of short-term investment funds. The funds also invest in short-term domestic fixed income securities and other securities with debt-like characteristics emphasizing short-term maturities and quality. Cash and cash equivalents are classified as Level 1 investments except when the cash and cash equivalents are held in commingled funds, which have a daily net value derived from quoted prices for the underlying securities in active markets; these are classified as Level 2 investments. Equity - Some equity securities consisting of common and preferred stock are held in commingled funds, which have daily net asset values derived from quoted prices for the underlying securities in active markets; these are classified as Level 2 investments. Commingled funds which have quoted prices in active markets are classified as Level 1 investments. Fixed Income - Some of the fixed income securities are held in commingled funds, which have daily net asset values derived from the underlying securities; these are classified as Level 2 investments. Commingled funds which have quoted prices in active markets are classified as Level 1 investments. Other Investments - Other investments includes property based pooled vehicles which invest in real estate. Market net asset values are regularly published in the financial press or on corporate websites and so these investments are classified as Level 2. Other investments also includes partnership investments where, due to their private nature, pricing inputs are not readily observable. Asset valuations are developed by the general partners that manage the partnerships. These valuations are based on proprietary appraisals, application of public market multiples to private company cash flows, utilization of market transactions that provide valuation information for comparable companies and other methods. Holdings of limited partnerships are classified as Level 3. The following tables present the fair value of U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2015 and 2014 . Fair Value Measurement October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Cash and Cash Equivalents $ 3 $ 1 $ 2 $ — Equity 258 61 197 — Fixed Income 76 22 54 — Other Investments 10 — 1 9 Total assets measured at fair value $ 347 $ 84 $ 254 $ 9 Fair Value Measurement October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Cash and Cash Equivalents $ 9 $ 2 $ 7 $ — Equity 668 156 512 — Fixed Income 145 40 105 — Other Investments 15 1 — 14 Total assets measured at fair value $ 837 $ 199 $ 624 $ 14 Assets measured at fair value - continuing operations $ 347 $ 73 $ 260 $ 14 Assets measured at fair value - discontinued operations 490 126 364 — Total assets measured at fair value $ 837 $ 199 $ 624 $ 14 For U.S. Defined Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2015 and 2014 for continuing operations: Years Ended October 31. 2015 2014 Balance, beginning of year $ 14 $ 17 Realized gains/(losses) (1 ) (1 ) Unrealized gains/(losses) (2 ) 2 Purchases, sales, issuances, and settlements (2 ) (4 ) Transfers in (out) — — Balance, end of year $ 9 $ 14 The following tables present the fair value of U.S. Post-Retirement Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2015 and 2014 . Fair Value Measurement at October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Cash and Cash Equivalents $ 3 $ 2 $ 1 $ — Equity 62 15 47 — Fixed Income 20 6 14 — Other Investments 6 — — 6 Total assets measured at fair value $ 91 $ 23 $ 62 $ 6 Fair Value Measurement at October 31, 2014 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Cash and Cash Equivalents $ 6 $ 3 $ 3 $ — Equity 217 51 166 — Fixed Income 53 14 39 — Other Investments 8 — — 8 Total assets measured at fair value $ 284 $ 68 $ 208 $ 8 Assets measured at fair value - continuing operations $ 97 $ 19 $ 70 $ 8 Assets measured at fair value - discontinued operations 187 49 138 — Total assets measured at fair value $ 284 $ 68 $ 208 $ 8 For U.S. Post-Retirement Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2015 and 2014 for continuing operations: Years Ended October 31, 2015 2014 Balance, beginning of year $ 8 $ 10 Realized gains/(losses) (1 ) (1 ) Unrealized gains/(losses) — 1 Purchases, sales, issuances, and settlements (1 ) (2 ) Transfers in (out) — — Balance, end of year $ 6 $ 8 The following tables present the fair value of non-U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2015 and 2014: Fair Value Measurement at October 31, 2015 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Cash and Cash Equivalents $ 3 $ 1 $ 2 $ — Equity 396 172 224 — Fixed Income 379 13 366 — Other Investments — — — — Total assets measured at fair value $ 778 $ 186 $ 592 $ — Fair Value Measurement October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Cash and Cash Equivalents $ 10 $ 3 $ 7 $ — Equity 1,078 335 743 — Fixed Income 974 37 937 — Other Investments 46 — 25 21 Total assets measured at fair value $ 2,108 $ 375 $ 1,712 $ 21 Assets measured at fair value - continuing operations $ 790 $ 200 $ 586 $ 4 Assets measured at fair value - discontinued operations 1,318 175 1,126 17 Total assets measured at fair value $ 2,108 $ 375 $ 1,712 $ 21 For non-U.S. Defined Benefit Plans, assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the changes in balances during 2015 and 2014 for continuing operations: Years Ended October 31, 2015 2014 Balance, beginning of year $ 4 $ — Realized gains/(losses) 1 — Unrealized gains/(losses) — — Purchases, sales, issuances, and settlements (5 ) — Transfers in (out) — 4 Balance, end of year $ — $ 4 The table below presents the combined projected benefit obligation ("PBO"), accumulated benefit obligation ("ABO") and fair value of plan assets, grouping plans using comparisons of the PBO and ABO relative to the plan assets as of October 31, 2015 or 2014 . 2015 2014 Benefit Obligation Benefit Obligation Fair Value of Plan Assets Fair Value of Plan Assets PBO PBO (in millions) U.S. defined benefit plans where PBO exceeds the fair value of plan assets - continuing operations $ 415 $ 347 $ 375 $ 347 U.S. defined benefit plans where PBO exceeds the fair value of plan assets - discontinued operations — — 514 490 Total $ 415 $ 347 $ 889 $ 837 Non-U.S. defined benefit plans where PBO exceeds or is equal to the fair value of plan assets - continuing operations $ 771 $ 623 $ 754 $ 607 Non-U.S. defined benefit plans where PBO exceeds or is equal to the fair value of plan assets - discontinued operations — — 1,111 952 Non-U.S. defined benefit plans where fair value of plan assets exceeds PBO - continuing operations 129 155 161 183 Non-U.S. defined benefit plans where fair value of plan assets exceeds PBO - discontinued operations — — 318 366 Total $ 900 $ 778 $ 2,344 $ 2,108 ABO ABO U.S. defined benefit plans where ABO exceeds the fair value of plan assets - continuing operations $ 389 $ 347 $ 9 $ — U.S. defined benefit plans where ABO exceeds the fair value of plan assets - discontinued operations — — 5 — U.S. defined benefit plans where the fair value of plan assets exceeds ABO - continuing operations — — 340 347 U.S. defined benefit plans where the fair value of plan assets exceeds ABO - discontinued operations — — 472 490 Total $ 389 $ 347 $ 826 $ 837 Non-U.S. defined benefit plans where ABO exceeds or is equal to the fair value of plan assets - continuing operations $ 732 $ 623 $ 714 $ 607 Non-U.S. defined benefit plans where ABO exceeds or is equal to the fair value of plan assets - discontinued operations — — 1,081 952 Non-U.S. defined benefit plans where fair value of plan assets exceeds ABO - continuing operations 127 155 158 183 Non-U.S. defined benefit plans where fair value of plan assets exceeds ABO - discontinued operations — — 310 366 Total $ 859 $ 778 $ 2,263 $ 2,108 Contributions and estimated future benefit payments. During fiscal year 2016 , we expect to contribute $0 million to the U.S. defined benefit plans, $25 million to plans outside the U.S., and $1 million to the Post-retirement Medical Plans. The following table presents expected future benefit payments for the next 10 years: U.S. Defined Benefit Plans Non-U.S. Defined Benefit Plans U.S. Post-Retirement Benefit Plans (in millions) 2016 $ 25 $ 21 $ 8 2017 $ 26 $ 22 $ 9 2018 $ 28 $ 24 $ 8 2019 $ 30 $ 26 $ 8 2020 $ 33 $ 27 $ 8 2021 - 2025 $ 177 $ 166 $ 40 Assumptions. The assumptions used to determine the benefit obligations and expense for our defined benefit and post-retirement benefit plans are presented in the tables below. The expected long-term return on assets below represents an estimate of long-term returns on investment portfolios consisting of a mixture of equities, fixed income and alternative investments in proportion to the asset allocations of each of our plans. We consider long-term rates of return, which are weighted based on the asset classes (both historical and forecasted) in which we expect our pension and post-retirement funds to be invested. Discount rates reflect the current rate at which pension and post-retirement obligations could be settled based on the measurement dates of the plans - October 31. The U.S. discount rates at October 31, 2014 and 2015, were determined based on the results of matching expected plan benefit payments with cash flows from a hypothetically constructed bond portfolio. The non-U.S. rates were generally based on published rates for high-quality corporate bonds. The range of assumptions that were used for the non-U.S. defined benefit plans reflects the different economic environments within various countries. Assumptions used to calculate the net periodic cost in each year were as follows: For years ended October 31, 2015 2014 2013 U.S. defined benefit plans: Discount rate 4.00% 4.00-4.50% 3.25% Average increase in compensation levels 3.50% 3.50% 3.50% Expected long-term return on assets 8.00% 8.00% 8.00% Non-U.S. defined benefit plans: Discount rate 1.50-4.00% 1.50-4.50% 1.50-4.50% Average increase in compensation levels 2.5-3.25% 2.50-3.25% 2.50-3.00% Expected long-term return on assets 4.00-6.50% 4.00-6.50% 4.00-6.50% U.S. post-retirement benefits plans: Discount rate 4.00% 4.00-4.25% 3.50% Expected long-term return on assets 8.00% 8.00% 8.00% Current medical cost trend rate 8.00% 8.00% 9.00% Ultimate medical cost trend rate 3.50% 3.50% 3.50% Medical cost trend rate decreases to ultimate rate in year 2028 2028 2027 Assumptions used to calculate the benefit obligation were as follows: As of the Years Ending October 31, 2015 2014 U.S. defined benefit plans: Discount rate 4.20% 4.00% Average increase in compensation levels 3.50% 3.50% Non-U.S. defined benefit plans: Discount rate 0.77-3.76% 1.50-4.00% Average increase in compensation levels 2.25-4.00% 2.50-3.25% U.S. post-retirement benefits plans: Discount rate 4.00% 3.75-4.00% Current medical cost trend rate 7.00% 8.00% Ultimate medical cost trend rate 3.50% 3.50% Medical cost trend rate decreases to ultimate rate in year 2029 2028 Health care trend rates do not have a significant effect on the total service and interest cost components or on the post-retirement benefit obligation amounts reported for the U.S. Post-Retirement Benefit Plan for the year ended October 31, 2015 .

GUARANTEES

GUARANTEES	12 Months Ended
	Oct. 31, 2015
Guarantees [Abstract]
GUARANTEES	17. GUARANTEES Standard Warranty We accrue for standard warranty costs based on historical trends in warranty charges as a percentage of net product shipments. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost estimates. Estimated warranty charges are recorded within cost of products at the time products are sold. The standard warranty accrual balances are held in other accrued and other long-term liabilities on our consolidated balance sheet. Our standard warranty terms typically extend between one and three years from the date of delivery, depending on the product. A summary of the standard warranty accrual activity is shown in the table below. The standard warranty accrual balances are held in other accrued and other long-term liabilities. October 31, 2015 2014 (in millions) Balance as of October 31, 2014 and 2013 $ 30 $ 31 Accruals for warranties including change in estimates 53 44 Settlements made during the period (52 ) (45 ) Balance as of October 31, 2015 and 2014 $ 31 $ 30 Accruals for warranties due within one year 29 26 Accruals for warranties due after one year 2 4 Balance as of October 31, 2015 and 2014 $ 31 $ 30 Indemnifications to Keysight In connection with the separation of Keysight from Agilent on November 1, 2014 we agreed to indemnify Keysight and its affiliates against certain damages and expenses that might occur in the future. These indemnifications cover a variety of liabilities, including, but not limited to, employee, tax and environmental matters. The agreements containing these indemnifications have been previously disclosed as exhibits to our current report on Form 8-K filed on August 1, 2014. In our opinion, the fair value of these indemnification obligations was not material as of October 31, 2015 . Indemnifications to Avago In connection with the sale of our semiconductor products business in December 2005, we agreed to indemnify Avago, its affiliates and other related parties against certain damages and expenses that it might incur in the future. The continuing indemnifications primarily cover damages and expenses relating to liabilities of the businesses that Agilent retained and did not transfer to Avago, as well as pre-closing taxes and other specified items. In connection with the separation of Keysight from Agilent, Keysight assumed the indemnification obligations to Avago. In our opinion, the fair value of these indemnification obligations was not material as of October 31, 2015 . Indemnifications to Verigy In connection with the spin-off of Verigy, we agreed to indemnify Verigy and its affiliates against certain damages which it might incur in the future. These indemnifications primarily cover damages relating to liabilities of the businesses that Agilent did not transfer to Verigy, liabilities that might arise under limited portions of Verigy's IPO materials that relate to Agilent, and costs and expenses incurred by Agilent or Verigy to effect the IPO, arising out of the distribution of Agilent's remaining holding in Verigy ordinary shares to Agilent's stockholders, or incurred to effect the separation of the semiconductor test solutions business from Agilent to the extent incurred prior to the separation on June 1, 2006. On July 4, 2011, Verigy announced the completion by Advantest Corporation of its acquisition of Verigy. Verigy will operate as a wholly-owned subsidiary of Advantest and our indemnification obligations to Verigy should be unaffected. In connection with the separation of Keysight from Agilent, Keysight assumed the indemnification obligations to Verigy. In our opinion, the fair value of these indemnification obligations was not material as of October 31, 2015 . Indemnifications to HP Inc. and Hewlett-Packard Enterprise (formerly Hewlett-Packard Company) We have given multiple indemnities to HP Inc. and Hewlett-Packard Enterprise (formerly Hewlett-Packard Company) (together "HP") in connection with our activities prior to our spin-off from HP for the businesses that constituted Agilent prior to the spin-off. These indemnifications cover a variety of aspects of our business, including, but not limited to, employee, tax, intellectual property and environmental matters. The agreements containing these indemnifications have been previously disclosed as exhibits to our registration statement on Form S-1 filed on August 16, 1999. In our opinion, the fair value of these indemnification obligations was not material as of October 31, 2015 . Indemnifications to Varian Medical Systems and Varian Semiconductor Equipment Associates In connection with our acquisition of Varian, we are subject to certain indemnification obligations to Varian Medical Systems (formerly Varian Associates, Inc. ("VAI")) and Varian Semiconductor Equipment Associates ("VSEA") in connection with the Instruments business as conducted by VAI prior to the Distribution (as described in Note 1 of Varian's Annual Report on Form 10-K filed on November 25, 2009). These indemnification obligations cover a variety of aspects of our business, including, but not limited to, employee, tax, intellectual property, litigation and environmental matters. Certain of the agreements containing these indemnification obligations are disclosed as exhibits to Varian's Annual Report on Form 10-K filed on November 25, 2009. On November 10, 2011, Applied Materials announced that it had completed the acquisition of VSEA, which is now a wholly-owned subsidiary of Applied Materials; our indemnification obligations to VSEA should be unaffected. In our opinion, the fair value of these indemnification obligations was not material as of October 31, 2015 . Indemnifications to Officers and Directors Our corporate by-laws require that we indemnify our officers and directors, as well as those who act as directors and officers of other entities at our request, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to Agilent and such other entities, including service with respect to employee benefit plans. In addition, we have entered into separate indemnification agreements with each director and each board-appointed officer of Agilent which provide for indemnification of these directors and officers under similar circumstances and under additional circumstances. The indemnification obligations are more fully described in the by-laws and the indemnification agreements. We purchase standard insurance to cover claims or a portion of the claims made against our directors and officers. Since a maximum obligation is not explicitly stated in our by-laws or in our indemnification agreements and will depend on the facts and circumstances that arise out of any future claims, the overall maximum amount of the obligations cannot be reasonably estimated. Historically, we have not made payments related to these obligations, and the fair value for these indemnification obligations was not material as of October 31, 2015 . Other Indemnifications As is customary in our industry and as provided for in local law in the U.S. and other jurisdictions, many of our standard contracts provide remedies to our customers and others with whom we enter into contracts, such as defense, settlement, or payment of judgment for intellectual property claims related to the use of our products. From time to time, we indemnify customers, as well as our suppliers, contractors, lessors, lessees, companies that purchase our businesses or assets and others with whom we enter into contracts, against combinations of loss, expense, or liability arising from various triggering events related to the sale and the use of our products and services, the use of their goods and services, the use of facilities and state of our owned facilities, the state of the assets and businesses that we sell and other matters covered by such contracts, usually up to a specified maximum amount. In addition, from time to time we also provide protection to these parties against claims related to undiscovered liabilities, additional product liability or environmental obligations. In our experience, claims made under such indemnifications are rare and the associated estimated fair value of the liability was not material as of October 31, 2015 . In connection with the sale of several of our businesses, we have agreed to indemnify the buyers of such business, their respective affiliates and other related parties against certain damages that they might incur in the future. The continuing indemnifications primarily cover damages relating to liabilities of the businesses that Agilent retained and did not transfer to the buyers, as well as other specified items. In our opinion, the fair value of these indemnification obligations was not material as of October 31, 2015 .

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Oct. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	18. COMMITMENTS AND CONTINGENCIES Operating Lease Commitments: We lease certain real and personal property from unrelated third parties under non-cancelable operating leases. Future minimum lease payments under operating leases at October 31, 2015 were $35 million for 2016 , $31 million for 2017 , $23 million for 2018 , $15 million for 2019 , $11 million for 2020 and $34 million thereafter. Future minimum lease income under leases at October 31, 2015 was $9 million for 2016 , $9 million for 2017 , $7 million for 2018 , and $23 million thereafter. Certain leases require us to pay property taxes, insurance and routine maintenance, and include escalation clauses. Total rent expense was $65 million in 2015 , $55 million in 2014 and $53 million in 2013 . Contingencies: We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, patent, commercial and environmental matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are reasonably possible of having a material impact to our business, consolidated financial condition, results of operations or cash flows.

SHORT-TERM DEBT

SHORT-TERM DEBT	12 Months Ended
	Oct. 31, 2015
Short-term Debt [Abstract]
SHORT-TERM DEBT	19. SHORT-TERM DEBT Credit Facilities On September 15, 2014 , Agilent entered into a credit agreement with a financial institution which provides for a $400 million five -year unsecured credit facility that will expire on September 15, 2019 . On June 9, 2015, the commitments under the existing credit facility were increased by $300 million so that the aggregate commitments under the facility now total $700 million . As of October 31, 2015, the company had no borrowings outstanding under the facility. We were in compliance with the covenants for the credit facility during the years ended October 31, 2015 and 2014.

LONG-TERM DEBT

LONG-TERM DEBT	12 Months Ended
	Oct. 31, 2015
Debt Disclosure [Abstract]
LONG-TERM DEBT	20. LONG-TERM DEBT Senior Notes The following table summarizes the company's long-term senior notes and the related interest rate swaps: October 31, 2015 October 31, 2014 Amortized Principal Swap Total Amortized Principal Swap Total (in millions) 2017 Senior Notes 100 2 102 100 3 103 2020 Senior Notes 499 19 518 499 22 521 2022 Senior Notes 399 — 399 399 — 399 2023 Senior Notes 598 — 598 598 — 598 Total $ 1,596 $ 21 $ 1,617 $ 1,596 $ 25 $ 1,621 2017 Senior Notes In October 2007 , the company issued an aggregate principal amount of $600 million in senior notes ("2017 senior notes"). The 2017 senior notes were issued at 99.60% of their principal amount. The notes will mature on November 1, 2017 , and bear interest at a fixed rate of 6.50% per annum. The interest is payable semi-annually on May 1st and November 1st of each year and payments commenced on May 1, 2008 . On November 25, 2008 , we terminated two interest rate swap contracts associated with our 2017 senior notes that represented the notional amount of $400 million . The asset value, including interest receivable, upon termination was approximately $43 million and the amount to be amortized at October 31, 2015 was $2 million . The gain is being deferred and amortized to interest expense over the remaining life of the 2017 senior notes. On October 20, 2014, we settled the redemption of $500 million of the $600 million outstanding aggregate principal amount of our 2017 senior notes due November 1, 2017 that had been called for redemption on September 19, 2014. The redemption price of approximately $580 million included a $80 million prepayment penalty computed in accordance with the terms of the 2017 senior notes as the present value of the remaining scheduled payments of principal and unpaid interest related to $500 million partial redemption. The prepayment penalty less partial amortization of previously deferred interest rate swap gain of approximately $14 million together with $2 million of amortization of debt issuance costs and discount was disclosed in other income (expense), net in the condensed consolidated statement of operations. We also paid accrued and unpaid interest of $15 million on the 2017 senior notes up to but not including the redemption date. 2020 Senior Notes In July 2010 , the company issued an aggregate principal amount of $500 million in senior notes ("2020 senior notes"). The 2020 senior notes were issued at 99.54% of their principal amount. The notes will mature on July 15, 2020 , and bear interest at a fixed rate of 5.00% per annum. The interest is payable semi-annually on January 15th and July 15th of each year, payments commenced on January 15, 2011 . On August 9, 2011 , we terminated our interest rate swap contracts related to our 2020 senior notes that represented the notional amount of $500 million . The asset value, including interest receivable, upon termination for these contracts was approximately $34 million and the amount to be amortized at October 31, 2015 was $19 million . The gain is being deferred and amortized to interest expense over the remaining life of the 2020 senior notes. 2022 Senior Notes In September 2012 , the company issued an aggregate principal amount of $400 million in senior notes ("2022 senior notes"). The 2022 senior notes were issued at 99.80% of their principal amount. The notes will mature on October 1, 2022 , and bear interest at a fixed rate of 3.20% per annum. The interest is payable semi-annually on April 1st and October 1st of each year, payments commenced on April 1, 2013 . 2023 Senior Notes In June 2013 , the company issued aggregate principal amount of $600 million in senior notes ("2023 senior notes"). The 2023 senior notes were issued at 99.544% of their principal amount. The notes will mature on July 15, 2023 and bear interest at a fixed rate of 3.875% per annum. The interest is payable semi annually on January 15th and July 15th of each year and payments will commence January 15, 2014 . All notes issued are unsecured and rank equally in right of payment with all of Agilent's other senior unsecured indebtedness. Other debt As of October 31, 2015 , and as a result of the Dako acquisition, we have mortgage debts, secured on buildings in Denmark, in Danish Krone equivalent of $38 million aggregate principal outstanding with a Danish financial institution. The loans have a variable interest rate based on 3 months Copenhagen Interbank Rate ("Cibor") and will mature on September 30, 2027 . Interest payments are made in March, June, September and December of each year .

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Oct. 31, 2015
Stockholders' Equity Note [Abstract]
STOCKHOLDERS EQUITY	21. STOCKHOLDERS' EQUITY Stock Repurchase Program On November 22, 2013 we announced that our board of directors had authorized a share repurchase program. The existing program is designed to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs to target maintaining a weighted average share count of approximately 335 million diluted shares. For the year ended October 31, 2015 , we repurchased 6 million shares for $267 million . For the year ended October 31, 2014 we repurchased approximately 4 million shares for $200 million . For the year ended October 31, 2013 we repurchased 20 million shares for $900 million . All such shares and related costs are held as treasury stock and accounted for using the cost method. On May 28, 2015 we announced that our board of directors had approved a new share repurchase program (the "2015 repurchase program"). The 2015 share repurchase program authorizes the purchase of up to $1.14 billion of our common stock through and including November 1, 2018. The 2015 share repurchase program will commence, at the option of the company, on either November 1, 2015, or the date on which we complete the purchase of the remaining $98 million for a total of $365 million of common stock in fiscal 2015 under the existing stock repurchase program. Upon commencement, the 2015 share repurchase program replaces our existing stock repurchase program, which authorized the repurchase of shares to reduce or eliminate share dilution from equity programs. The 2015 repurchase program does not require the company to acquire a specific number of shares and may be suspended or discontinued at any time. Cash Dividends on Shares of Common Stock During the year ended October 31, 2015 , cash dividends of $0.40 per share, or $133 million were declared and paid on the company's outstanding common stock. During the year ended October 31, 2014 , cash dividends of $0.53 per share, or $176 million were declared and paid on the company's outstanding common stock. During the year ended October 31, 2013 , cash dividends of $0.46 per share, or $156 million were declared and paid on the company's outstanding common stock. On November 19, 2015, we declared a quarterly dividend of $0.115 per share of common stock, or approximately $38 million which will be paid on January 27, 2016 to shareholders of record as of the close of business on January 5, 2016 . The timing and amounts of any future dividends are subject to determination and approval by our board of directors. Accumulated other comprehensive income (loss) The following table summarizes the components of our accumulated other comprehensive income (loss) as of October 31, 2015 and 2014, net of tax effect: October 31, 2015 2014 (in millions) Unrealized gain on equity securities, net of $(0) and $(3) of tax expense for 2015 and 2014, respectively $ — $ 17 Foreign currency translation, net of $(2) and $(86) of tax expense for 2015 and 2014, respectively (189 ) 156 Unrealized losses on defined benefit plans, net of tax benefit of $126 and $145 for 2015 and 2014, respectively (204 ) (516 ) Unrealized gains (losses) on derivative instruments, net of tax expense of $(2) and $(7) for 2015 and 2014, respectively 2 9 Total accumulated other comprehensive loss $ (391 ) $ (334 ) Changes in accumulated other comprehensive income (loss) by component and related tax effects for the years ended October 31, 2015 and 2014 were as follows (in millions): Net defined benefit pension cost and post retirement plan costs Unrealized gain on investments Foreign currency translation Prior service credits Actuarial Losses Unrealized gains (losses) on derivatives Total (in millions) As of October 31, 2013 $ 7 $ 425 $ 287 $ (628 ) $ — $ 91 Other comprehensive income (loss) before reclassifications 12 (277 ) — (273 ) 13 (525 ) Amounts reclassified out of accumulated other comprehensive income (1 ) — (48 ) 65 1 17 Tax (expense) benefit (1 ) 8 16 65 (5 ) 83 Other comprehensive income (loss) 10 (269 ) (32 ) (143 ) 9 (425 ) As of October 31, 2014 $ 17 $ 156 $ 255 $ (771 ) $ 9 $ (334 ) Transfer to Keysight $ (17 ) $ (9 ) $ (83 ) $ 444 $ (3 ) $ 332 Balance after transfer to Keysight — 147 172 (327 ) 6 (2 ) Other comprehensive income (loss) before reclassifications — (360 ) — (90 ) 11 (439 ) Amounts reclassified out of accumulated other comprehensive income — — (17 ) 35 (18 ) — Tax benefit — 24 6 17 3 50 Other comprehensive loss — (336 ) (11 ) (38 ) (4 ) (389 ) As of October 31, 2015 $ — $ (189 ) $ 161 $ (365 ) $ 2 $ (391 ) Reclassifications out of accumulated other comprehensive income (loss) for the years ended October 31, 2015 and 2014 were as follows (in millions): Details about accumulated other Amounts Reclassified Affected line item in comprehensive income components from other comprehensive income statement of operations 2015 2014 Unrealized gain on equity securities $ — $ 1 Other income (expense), net — 1 Total before income tax — — Provision for income tax — 1 Total net of income tax Unrealized gains and (losses) on derivatives 18 (1 ) Cost of products 18 (1 ) Total before income tax (6 ) — (Provision)/benefit for income tax 12 (1 ) Total net of income tax Net defined benefit pension cost and post retirement plan costs: Actuarial net loss (35 ) (65 ) Prior service benefit 17 48 (18 ) (17 ) Total before income tax 5 (2 ) (Provision)/benefit for income tax (13 ) (19 ) Total net of income tax Total reclassifications for the period $ (1 ) $ (19 ) Amounts in parentheses indicate reductions to income and increases to other comprehensive income. Reclassifications of prior service benefit and actuarial net loss in respect of retirement plans and post retirement pension plans are included in the computation of net periodic cost (see Note 16 "Retirement Plans and Post Retirement Pension Plans").

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Oct. 31, 2015
Segment Reporting [Abstract]
SEGMENT INFORMATION	22. SEGMENT INFORMATION Description of segments. We are a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. In the first fiscal quarter of 2015, we completed the separation of our electronic measurement business. See Note 4, "Discontinued Operations" for further information. In November 2014, we announced a change in organizational structure designed to better serve our customers. Our new structure reflects our strategy to focus our expertise on the market segments we serve and utilize our resources to offer product solutions to address our customer needs. The new operating structure ensures that we are able to respond to market demand while reducing costs through increased efficiencies. As a result, our life sciences business, excluding the nucleic acid solutions division, together with the chemical analysis business merged to form a new segment called life sciences and applied markets business. Our diagnostics and genomics businesses combined and includes the nucleic acid solutions division of our life sciences business and became the diagnostics and genomics segment. Finally, the Agilent CrossLab segment was formed from the services and consumables businesses. The historical financial segment information has been recast to conform to this new presentation. Following this reorganization, Agilent has three business segments comprised of the life sciences and applied markets business, diagnostics and genomics business and the Agilent CrossLab business each of which comprises a reportable segment. The three operating segments were determined based primarily on how the chief operating decision maker views and evaluates our operations. Operating results are regularly reviewed by the chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance. Other factors, including market separation and customer specific applications, go-to-market channels, products and services and manufacturing are considered in determining the formation of these operating segments. A description of our three reportable segments is as follows: Our life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Key product categories include: liquid chromatography ("LC") systems and components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography ("GC") systems and components; gas chromatography mass spectrometry ("GCMS") systems; inductively coupled plasma mass spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave plasma-atomic emission spectrometry (“MP-AES”) instruments; inductively coupled plasma optical emission spectrometry ("ICP-OES") instruments; laboratory software and informatics systems; laboratory automation and robotic systems; dissolution testing; vacuum pumps and measurement technologies. Our diagnostics and genomics business is comprised of three areas of activity providing solutions that include pathology, reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our Pathology solutions business is focused on product offerings to cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes immunohistochemistry (“IHC”), In Situ Hybridization (“ISH”), Hematoxylin and Eosin (“H&E”) staining and special staining. We also collaborate with a number of major pharmaceutical companies to develop new potential pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Second, our genomics business includes arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as Next Generation Sequencing ("NGS") target enrichment. Finally, our nucleic acid solutions business provides equipment and expertise focused on production of synthesized oligonucleotides under pharmaceutical Good Manufacturing Practices ("GMP") conditions for use as Active Pharmaceutical Ingredients ("API") in an emerging class of drugs that utilize nucleic acid molecules for disease therapy. The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which is designed to improve customer outcomes. The majority of the portfolio is vendor neutral, meaning Agilent can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries and supplies to services and software helping to connect the entire lab. Key product categories in consumables include GC and LC columns, sample preparation products, custom chemistries, and a large selection of laboratory instrument supplies. Services include startup, operational, training and compliance support, as well as asset management and consultative services that help increase customer productivity. Custom service and consumable bundles are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements. A significant portion of the segments' expenses arise from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges, include legal, accounting, real estate, insurance services, information technology services, treasury, other corporate infrastructure expenses and costs of centralized research and development. Charges are allocated to the segments, and the allocations have been determined on a basis that we consider to be a reasonable reflection of the utilization of services provided to or benefits received by the segments. Corporate charges previously allocated to our electronic measurement business, but not classified within discontinued operations, were not reallocated to our other segments. These charges are presented below as a component of the reconciliation between segments' income from operations and Agilent's income from continuing operations and are classified as unallocated corporate charges. In addition, we do not allocate amortization and impairment of acquisition-related intangible assets, restructuring and transformational expenses, acquisition and integration costs and certain other charges to the operating margin for each segment because management does not include this information in its measurement of the performance of the operating segments. The following tables reflect the results of our reportable segments under our management reporting system. The performance of each segment is measured based on several metrics, including segment income from operations. These results are used, in part, by the chief operating decision maker in evaluating the performance of, and in allocating resources to, each of the segments. The profitability of each of the segments is measured after excluding restructuring and asset impairment charges, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization and other items as noted in the reconciliations below. Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total Segments (in millions) Year ended October 31, 2015: Total net revenue $ 2,046 $ 662 $ 1,330 $ 4,038 Income from operations $ 380 $ 88 $ 299 $ 767 Depreciation expense $ 27 $ 37 $ 34 $ 98 Share-based compensation expense $ 27 $ 9 $ 18 $ 54 Year ended October 31, 2014: Total net revenue $ 2,078 $ 663 $ 1,307 $ 4,048 Income from operations $ 369 $ 93 $ 301 $ 763 Depreciation expense $ 29 $ 43 $ 33 $ 105 Share-based compensation expense $ 29 $ 9 $ 18 $ 56 Year ended October 31, 2013: Total net revenue $ 2,035 $ 635 $ 1,224 $ 3,894 Income from operations $ 338 $ 95 $ 299 $ 732 Depreciation expense $ 28 $ 43 $ 27 $ 98 Share-based compensation expense $ 27 $ 4 $ 16 $ 47 For the years ended October 31, 2014 and 2013, depreciation expense and share-based compensation expense exclude unallocated corporate charges. The following table reconciles reportable segments' income from operations to Agilent's total enterprise income before taxes: Years Ended October 31, 2015 2014 2013 (in millions) Total reportable segments' income from operations $ 767 $ 763 $ 732 Restructuring and business exit related costs (12 ) (66 ) (34 ) Acceleration of depreciation for held and used assets — — — Asset Impairments (3 ) (4 ) (2 ) Transformational programs (56 ) (29 ) (19 ) Amortization of intangibles (156 ) (189 ) (190 ) Acquisition and integration costs (13 ) (11 ) (22 ) Acceleration of share-based compensation expense related to workforce reduction (2 ) (1 ) (2 ) One-time and pre-separation costs — (14 ) — Other (3 ) 10 (13 ) Interest Income 7 9 7 Interest Expense (66 ) (110 ) (107 ) Other income (expense), net 17 (89 ) 7 Unallocated corporate charges — (40 ) (64 ) Income before taxes, as reported $ 480 $ 229 $ 293 Major customers. No customer represented 10 percent or more of our total net revenue in 2015 , 2014 or 2013 . The following table presents assets and capital expenditures directly managed by each segment. Unallocated assets primarily consist of cash, cash equivalents, accumulated amortization of other intangibles and other assets. Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total Segments (in millions) As of October 31, 2015: Assets $ 1,539 $ 2,027 $ 1,008 $ 4,574 Capital expenditures $ 28 $ 33 $ 37 $ 98 As of October 31, 2014: Assets $ 1,663 $ 2,302 $ 1,001 $ 4,966 Capital expenditures $ 33 $ 40 $ 37 $ 110 The following table reconciles segment assets to Agilent's total assets: October 31, 2015 2014 (in millions) Total reportable segments' assets $ 4,574 $ 4,966 Cash, cash equivalents and short-term investments 2,003 2,218 Short-term restricted cash and cash equivalents 242 — Prepaid expenses 105 85 Investments 86 96 Long-term and other receivables 104 90 Other 365 377 Current and non-current assets of discontinued operations $ — $ 2,983 Total assets $ 7,479 $ 10,815 The other category primarily represents the difference between how segments report deferred taxes. The following table represents total revenue by product category: Years Ended October 31, 2015 2014 2013 (in millions) Instrumentation $ 1,827 $ 1,839 $ 1,802 Analytical lab services 843 831 768 Analytical lab consumables 489 476 456 Diagnostics and genomics solutions 662 663 635 Informatics and other 217 239 233 Total $ 4,038 $ 4,048 $ 3,894 The following table presents summarized information for net revenue and long-lived assets by geographic region. Revenues from external customers are generally attributed to countries based upon the location of the Agilent sales representative. Long lived assets consist of property, plant, and equipment, long-term receivables and other long-term assets excluding intangible assets. The rest of the world primarily consists of rest of Asia and Europe. United States China Rest of the World Total (in millions) Net revenue: Year ended October 31, 2015 $ 1,206 $ 633 $ 2,199 $ 4,038 Year ended October 31, 2014 $ 1,019 $ 543 $ 2,486 $ 4,048 Year ended October 31, 2013 $ 1,077 $ 619 $ 2,198 $ 3,894 United States Rest of the World Total (in millions) Long-lived assets: October 31, 2015 $ 391 $ 379 $ 770 October 31, 2014 $ 379 $ 451 $ 830

SUBSEQUENT EVENTS (Notes)

SUBSEQUENT EVENTS (Notes)	12 Months Ended
	Oct. 31, 2015
Subsequent Event [Line Items]
Subsequent Events [Text Block]	23. SUBSEQUENT EVENT On November 2, 2015 we completed the acquisition of Seahorse Bioscience ("Seahorse"), a leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics for $242 million in cash. Seahorse's technology enables researchers to better understand cell health, function and signaling, and how the cell may be impacted by the introduction of a specific drug, by providing real-time kinetics to unlock essential cellular bioenergetics data. As of October 31, 2015 $242 million of cash and cash equivalents was held in escrow relating to the Seahorse acquisition and was classified as short-term restricted cash and cash equivalents in the consolidated balance sheet. We have not yet finished allocating the purchase price to the net assets acquired. The financial results of Seahorse will be included within Agilent's from the beginning of the first quarter of 2016.

Schedule II Valuation and Quali

Schedule II Valuation and Qualifying Accounts	12 Months Ended
	Oct. 31, 2015
Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS Column A Column B Column C Column D Column E Description Balance at Additions Charged to Deductions Credited to Expenses or Other Accounts** Balance at (in millions) 2015 Tax valuation allowance $ 134 $ 6 $ (9 ) $ 131 2014 Tax valuation allowance $ 131 $ 3 $ — $ 134 2013 Tax valuation allowance $ 139 $ — $ (8 ) $ 131 * Additions include current year additions charged to expenses and current year build due to increases in net deferred tax assets, return to provision true-ups, other adjustments and OCI impact to deferred taxes. ** Deductions include current year releases credited to expenses and current year reductions due to decreases in net deferred tax assets, return to provision true-ups, other adjustments and OCI impact to deferred taxes.

OVERVIEW AND SUMMARY OF SIGNI35

OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Oct. 31, 2015
Accounting Policies [Abstract]
Business Description and Basis of Presentation [Text Block]	Overview. Agilent Technologies Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that includes instruments, software, services and consumables for the entire laboratory workflow. Keysight Separation. On November 1, 2014, we completed the distribution of 100% of the outstanding common shares of Keysight Technologies, Inc. ("Keysight") to Agilent stockholders who received one share of Keysight common stock for every two shares of Agilent held as of the close of business on the record date, October 22, 2014. The historical results of operations and the financial position of Keysight are included in the consolidated financial statements of Agilent and are reported as discontinued operations within this Form 10-K. Exit of Nuclear Magnetic Resonance Business. During the fourth quarter of fiscal year 2014, we made the decision to cease the manufacture and sale of our nuclear magnetic resonance (“NMR”) product line within our life sciences and applied markets segment. In connection with the exit from this business, we recorded approximately $6 million and $68 million in restructuring and other related costs in 2015 and 2014, respectively. For additional details related to the exit of the NMR business see Note 15, "Exit of NMR Business". We will continue to provide service support to the NMR installed base. New Segment Structure. In November 2014, we announced a change in organizational structure designed to better serve our customers. Our life sciences business, excluding the nucleic acid solutions division, together with the chemical analysis business combined to form a new segment called life sciences and applied markets business. Our diagnostics and genomics businesses combined with the nucleic acid solutions division from our life sciences business and became the diagnostics and genomics segment. Finally, the Agilent CrossLab segment was formed from the services and consumables businesses previously part of the life sciences and chemicals analysis businesses. Financial reporting under this new structure is included within this report on Form 10-K and historical financial segment information has been recast to conform to this new presentation within our financial statements. Basis of presentation. The accompanying financial data has been prepared by us pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") and is in conformity with U.S. generally accepted accounting principles ("GAAP"). Our fiscal year end is October 31. Unless otherwise stated, all years and dates refer to our fiscal year.
Principles of consolidation	Principles of consolidation. The consolidated financial statements include the accounts of the company and our wholly- and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Reclassification, Policy [Policy Text Block]	Revision of Services and other and Product Net Revenues and related Cost of Sales. In 2015 we revised amounts shown in our consolidated statement of operations to more accurately reflect the character of items delivered to customers. Our diagnostic and genomics segment identified a stream of service revenues that had been presented as product revenue in previous years. We have now revised those years’ presentation to show the revenue within services and other. The cost of sales associated with these newly identified service revenues has also been revised to align with the new presentation. For the year ended October 31, 2014 service and other revenue increased $21 million and service and other cost of sales increased $19 million with corresponding reductions in product revenue and cost of sales. For the year ended October 31, 2013 service and other revenue increased $17 million and service and other cost of sales increased $12 million with corresponding reductions in product revenue and cost of sales.These corrections to the classifications are not considered to be material to current or prior periods and had no impact to our consolidated statement of operations.
Use of estimates	Use of estimates. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, share-based compensation, retirement and post-retirement plan assumptions, restructuring and accounting for income taxes.
Revenue recognition	Revenue recognition. We enter into agreements to sell products (hardware and/or software), services and other arrangements (multiple element arrangements) that include combinations of products and services. We recognize revenue, net of trade discounts and allowances, provided that (1) persuasive evidence of an arrangement exists, (2) delivery has occurred, (3) the price is fixed or determinable and (4) collectability is reasonably assured. Delivery is considered to have occurred when title and risk of loss have transferred to the customer for products, or when the service has been provided. We consider the price to be fixed or determinable when the price is not subject to refund or adjustments. We consider arrangements with extended payment terms not to be fixed or determinable, and accordingly we defer revenue for these sales arrangements for which the payment is not yet due. At the time of the transaction, we evaluate the creditworthiness of our customers to determine the appropriate timing of revenue recognition. Product revenue. Our product revenue is generated predominantly from the sales of various types of analytical instrumentation. Product revenue, including sales to resellers and distributors, is reduced for estimated returns when appropriate. For sales or arrangements that include customer-specified acceptance criteria, including those where acceptance is required upon achievement of performance milestones, revenue is recognized after the acceptance criteria have been met. For products that include installation, if the installation meets the criteria to be considered a separate element, product revenue is recognized upon delivery, and recognition of installation revenue is delayed until the installation is complete. Otherwise, neither the product nor the installation revenue is recognized until the installation is complete. Where software is licensed separately, revenue is recognized when the software is delivered and has been transferred to the customer or, in the case of electronic delivery of software, when the customer is given access to the licensed software programs. We also evaluate whether collection of the receivable is probable, the fee is fixed or determinable and whether any other undelivered elements of the arrangement exist on which a portion of the total fee would be allocated based on vendor-specific objective evidence. Service revenue. Revenue from services includes extended warranty, customer and software support, consulting including companion diagnostics and training and education. Service revenue is deferred and recognized over the contractual period or as services are rendered and accepted by the customer. For example, customer support contracts are recognized ratably over the contractual period, while training revenue is recognized as the training is provided to the customer. In addition the four revenue recognition criteria described above must be met before service revenue is recognized. Revenue Recognition for Arrangements with Multiple Deliverables. Our multiple-element arrangements are generally comprised of a combination of measurement instruments, installation or other start-up services, and/or software and/or support or services. Hardware and software elements are typically delivered at the same time and revenue is recognized upon delivery once title and risk of loss pass to the customer. Delivery of installation, start-up services and other services varies based on the complexity of the equipment, staffing levels in a geographic location and customer preferences, and can range from a few days to a few months. Service revenue is deferred and recognized over the contractual period or as services are rendered and accepted by the customer. Revenue from the sale of software products that are not required to deliver the tangible product's essential functionality are accounted for under software revenue recognition rules which require vendor specific objective evidence (VSOE) of fair value to allocate revenue in a multiple element arrangement. Our arrangements generally do not include any provisions for cancellation, termination, or refunds that would significantly impact recognized revenue. We have evaluated the deliverables in our multiple-element arrangements and concluded that they are separate units of accounting if the delivered item or items have value to the customer on a standalone basis and for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in our control. We allocate revenue to each element in our multiple-element arrangements based upon their relative selling prices. We determine the selling price for each deliverable based on a selling price hierarchy. The selling price for a deliverable is based on VSOE if available, third-party evidence (TPE) if VSOE is not available, or estimated selling price (ESP) if neither VSOE nor TPE is available. Revenue allocated to each element is then recognized when the basic revenue recognition criteria for that element have been met. We use VSOE of selling price in the selling price allocation in all instances where it exists. VSOE of selling price for products and services is determined when a substantial majority of the selling prices fall within a reasonable range when sold separately. TPE of selling price can be established by evaluating largely interchangeable competitor products or services in standalone sales to similarly situated customers. As our products contain a significant element of proprietary technology and the solution offered differs substantially from that of competitors, it is difficult to obtain the reliable standalone competitive pricing necessary to establish TPE. ESP represents the best estimate of the price at which we would transact a sale if the product or service were sold on a standalone basis. We determine ESP for a product or service by using historical selling prices which reflect multiple factors including, but not limited to customer type, geography, market conditions, competitive landscape, gross margin objectives and pricing practices. The determination of ESP is made through consultation with and approval by management. We may modify or develop new pricing practices and strategies in the future. As these pricing strategies evolve changes may occur in ESP. The aforementioned factors may result in a different allocation of revenue to the deliverables in multiple element arrangements, which may change the pattern and timing of revenue recognition for these elements but will not change the total revenue recognized for the arrangement. Deferred revenue. Deferred revenue represents the amount that is allocated to undelivered elements in multiple element arrangements. We limit the revenue recognized to the amount that is not contingent on the future delivery of products or services or meeting other specified performance conditions.
Accounts receivable, net	Accounts receivable, net. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Such accounts receivable has been reduced by an allowance for doubtful accounts, which is our best estimate of the amount of probable credit losses in our existing accounts receivable. We determine the allowance based on customer specific experience and the aging of such receivables, among other factors. The allowance for doubtful accounts as of October 31, 2015 and 2014 was not material. We do not have any off-balance-sheet credit exposure related to our customers. Accounts receivable are also recorded net of product returns.
Share-based compensation	Share-based compensation. For the years ended 2015 , 2014 and 2013 , we accounted for share-based awards made to our employees and directors including employee stock option awards, restricted stock units, employee stock purchases made under our Employee Stock Purchase Plan ("ESPP") and performance share awards under Agilent Technologies, Inc. Long-Term Performance Program ("LTPP") using the estimated grant date fair value method of accounting. Under the fair value method, we recorded compensation expense, in continuing operations, for all share-based awards of $55 million in 2015 , $59 million in 2014 and $51 million in 2013 . For the stock option and long term performance plan grants in 2015 we are now using a volatility measure derived from a selection of our peer companies. In prior periods, we used Agilent stock historical volatility. We currently consider this method to not be reflective of our future volatility due to the separation of Keysight. See Note 5, "Share-based compensation" for additional information.
Inventory	Inventory. Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with manufacturing to maximize recovery of excess inventory.
Warranty	Warranty. Our standard warranty terms typically extend for one year from the date of delivery. We accrue for standard warranty costs based on historical trends in warranty charges as a percentage of net product revenue. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost estimates. Estimated warranty charges are recorded within cost of products at the time products are sold. See Note 17, "Guarantees".
Taxes on income	Taxes on income. Income tax expense or benefit is based on income or loss before taxes. Deferred tax assets and liabilities are recognized principally for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. See Note 6, "Income Taxes" for more information
Shipping and handling costs	Shipping and handling costs. Our shipping and handling costs charged to customers are included in net revenue, and the associated expense is recorded in cost of products for all periods presented.
Goodwill and Purchased Intangible Assets	Goodwill and Purchased Intangible Assets. Under the authoritative guidance we have the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The accounting standard gives an entity the option to first assess qualitative factors to determine whether performing the two-step test is necessary. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e. greater than 50% chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test will be required. Otherwise, no further testing will be required. The guidance includes examples of events and circumstances that might indicate that a reporting unit's fair value is less than its carrying amount. These include macro-economic conditions such as deterioration in the entity's operating environment or industry or market considerations; entity-specific events such as increasing costs, declining financial performance, or loss of key personnel; or other events such as an expectation that a reporting unit will be sold or a sustained decrease in the stock price on either an absolute basis or relative to peers. If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, the provisions of authoritative guidance require that we perform a two-step impairment test on goodwill. In the first step, we compare the fair value of each reporting unit to its carrying value. The second step (if necessary) measures the amount of impairment by applying fair-value-based tests to the individual assets and liabilities within each reporting unit. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. We aggregate components of an operating segment that have similar economic characteristics into our reporting units. In fiscal year 2015, we assessed goodwill impairment for our three reporting units which consisted of three segments: life sciences and applied markets, diagnostics and genomics and Agilent CrossLab. Due to the new segment structure in November 2014 we performed a quantitative test for goodwill impairment of the three reporting units, as of September 30, 2015. Based on the results of our testing, the fair value of these reporting units are greater than their respective carrying values. Each quarter we review the events and circumstances to determine if goodwill impairment is indicated. There was no impairment of goodwill during the years ended October 31, 2015, 2014 and 2013. Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how, trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that reflect the pattern in which the economic benefits are consumed or used up or a straight-line method ranging from 6 months to 15 years. In-process research and development ("IPR&D") is initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When the IPR&D project is complete, it is reclassified as an amortizable purchased intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, Agilent will record a charge for the value of the related intangible asset to Agilent's condensed consolidated statement of operations in the period it is abandoned. Agilent's indefinite-lived intangible assets are IPR&D intangible assets. The accounting guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to determine whether it is more-likely-than-not (i.e. greater than 50% chance) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. We performed a qualitative test for impairment of indefinite-lived intangible assets as of September 30, 2015. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of these indefinite-lived intangible assets is greater than their respective carrying values. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible asset is indicated. In the years ended October 31, 2015, 2014 and 2013, we recorded an impairment of $3 million , $4 million and zero , respectively due to the cancellation of certain IPR&D projects. In addition, in the year ended October 31, 2014, we also recorded $12 million of impairment of other intangibles due to the exit of our NMR business.
Advertising	Advertising. Advertising costs are generally expensed as incurred and amounted to $25 million in 2015 , $31 million in 2014 and $28 million in 2013 .
Research and development	Research and development. Costs related to research, design and development of our products are charged to research and development expense as they are incurred.
Sales Taxes	Sales Taxes. Sales taxes collected from customers and remitted to governmental authorities are not included in our revenue.
Net income (loss) per share	Net income per share. Basic net income per share is computed by dividing net income - the numerator - by the weighted average number of common shares outstanding - the denominator - during the period excluding the dilutive effect of stock options and other employee stock plans. Diluted net income per share gives effect to all potential common shares outstanding during the period unless the effect is anti-dilutive. The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense, the tax benefits and shortfalls charged to additional paid-in capital and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options, unamortized share-based compensation expense and tax benefits or shortfalls are assumed proceeds to be used to repurchase hypothetical shares. See Note 7, "Net Income Per Share".
Cash, cash equivalents and short term investments	Cash, cash equivalents and short term investments. We classify investments as cash equivalents if their original or remaining maturity is three months or less at the date of purchase. Cash equivalents are stated at cost, which approximates fair value. As of October 31, 2015 , approximately $1,780 million of our cash and cash equivalents is held outside of the U.S. in our foreign subsidiaries. Under current tax laws, the cash could be repatriated to the U.S. but most of it would be subject to U.S. federal and state income taxes, less applicable foreign tax credits. Our cash and cash equivalents mainly consist of short term deposits held at major global financial institutions, institutional money market funds, and similar short duration instruments with original maturities of 90 days or less. We continuously monitor the creditworthiness of the financial institutions and institutional money market funds in which we invest our funds. We classify investments as short-term investments if their original maturities are greater than three months and their remaining maturities are one year or less. Currently, we have no short-term investments.
Fair Value of Financial Instruments	Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments is determined using quoted market prices for those securities when available. For those long-term equity investments accounted for under the cost or equity method, their carrying value approximates their estimated fair value. Equity method investments are reported at the amount of the company’s initial investment and adjusted each period for the company’s share of the investee’s income or loss and dividend paid. The fair value of our long-term debt, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy, exceeds the carrying value by approximately $30 million and $53 million as of October 31, 2015 and 2014, respectively. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 13, "Fair Value Measurements" for additional information on the fair value of financial instruments.
Concentration of credit risk	Concentration of credit risk. Financial instruments that potentially subject Agilent to significant concentration of credit risk include money market fund investments, time deposits and demand deposit balances. These investments are categorized as cash and cash equivalents. In addition, Agilent has credit risk from derivative financial instruments used in hedging activities and accounts receivable. We invest in a variety of financial instruments and limit the amount of credit exposure with any one financial institution. We have a comprehensive credit policy in place and credit exposure is monitored on an ongoing basis. Credit risk with respect to our accounts receivable is diversified due to the large number of entities comprising our customer base and their dispersion across many different industries and geographies. Credit evaluations are performed on customers requiring credit over a certain amount and we sell the majority of our products through our direct sales force. Credit risk is mitigated through collateral such as letter of credit, bank guarantees or payment terms like cash in advance. No single customer accounted for more than 10 percent of combined accounts receivable as of October 31, 2015 , or 2014 .
Derivative instruments	Derivative instruments. Agilent is exposed to global foreign currency exchange rate and interest rate risks in the normal course of business. We enter into foreign exchange hedging contracts, primarily forward contracts and purchased options and, in the past, interest rate swaps to manage financial exposures resulting from changes in foreign currency exchange rates and interest rates. In the vast majority of cases, these contracts are designated at inception as hedges of the related foreign currency or interest exposures. Foreign currency exposures include committed and anticipated revenue and expense transactions and assets and liabilities that are denominated in currencies other than the functional currency of the subsidiary. Interest rate exposures are associated with the company's fixed-rate debt. For option contracts, we exclude time value from the measurement of effectiveness. To qualify for hedge accounting, contracts must reduce the foreign currency exchange rate and interest rate risk otherwise inherent in the amount and duration of the hedged exposures and comply with established risk management policies; foreign exchange hedging contracts generally mature within twelve months and interest rate swaps, if any, mature at the same time as the maturity of the debt. In order to manage foreign currency exposures in a few limited jurisdictions we may enter into foreign exchange contracts that do not qualify for hedge accounting. In such circumstances, the local foreign currency exposure is offset by contracts owned by the parent company. We do not use derivative financial instruments for speculative trading purposes. All derivatives are recognized on the balance sheet at their fair values. For derivative instruments that are designated and qualify as a fair value hedge, changes in value of the derivative are recognized in the consolidated statement of operations in the current period, along with the offsetting gain or loss on the hedged item attributable to the hedged risk. For derivative instruments that are designated and qualify as a cash flow hedges, changes in the value of the effective portion of the derivative instrument is recognized in comprehensive income (loss), a component of stockholders' equity. Amounts associated with cash flow hedges are reclassified and recognized in income when either the forecasted transaction occurs or it becomes probable the forecasted transaction will not occur. Derivatives not designated as hedging instruments are recorded on the balance sheet at their fair value and changes in the fair values are recorded in the income statement in the current period. Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet. Changes in the fair value of the ineffective portion of derivative instruments are recognized in earnings in the current period. Ineffectiveness in 2015 , 2014 and 2013 was not material. Cash flows from derivative instruments are classified in the statement of cash flows in the same category as the cash flows from the hedged or economically hedged item, primarily in operating activities.
Property, plant and equipment	Property, plant and equipment. Property, plant and equipment are stated at cost less accumulated depreciation. Additions, improvements and major renewals are capitalized; maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation and amortization are removed from our general ledger, and the resulting gain or loss is reflected in the consolidated statement of operations. Buildings and improvements are depreciated over the lesser of their useful lives or the remaining term of the lease and machinery and equipment over three to ten years. We use the straight-line method to depreciate assets.
Leases	Leases. We lease buildings, machinery and equipment under operating leases for original terms ranging generally from one year to twenty years. Certain leases contain renewal options for periods up to six years. In addition, we lease equipment to customers in connection with our diagnostics business using both capital and operating leases. As of October 31, 2015 and 2014 our diagnostics and genomics segment has approximately $11 million and $8 million , respectively, of lease receivables related to capital leases and approximately $31 million and $33 million , respectively, of net assets for operating leases. We depreciate the assets related to the operating leases over their estimated useful lives.
Capitalized software	Capitalized software. We capitalize certain internal and external costs incurred to acquire or create internal use software. Capitalized software is included in property, plant and equipment and is depreciated over three to five years once development is complete.
Impairment of long-lived assets	Impairment of long-lived assets. We continually monitor events and changes in circumstances that could indicate carrying amounts of long-lived assets, including intangible assets, may not be recoverable. When such events or changes in circumstances occur, we assess the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the undiscounted future cash flows is less than the carrying amount of those assets, we recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets.
Restructuring and asset impairments	Restructuring and exit of NMR business. The main components of expenses are related to workforce reductions, assets impairments and write-downs and special charges to inventory, which mainly relates to exiting of one of our businesses. Workforce reduction charges are accrued when payment of benefits that the employees are entitled to becomes probable and the amounts can be estimated. We have also assessed the recoverability of our long-lived assets, by determining whether the carrying value of such assets will be recovered through undiscounted future cash flows. Asset impairments primarily consist of property, plant and equipment and are based on an estimate of the amounts and timing of future cash flows related to the expected future remaining use and ultimate sale or disposal of buildings and equipment net of costs to sell. The charges related to inventory include estimated future inventory disposal payments that we are contractually obliged to make to our suppliers and inventory written-down to net realizable value. If the amounts and timing of cash flows from restructuring activities are significantly different from what we have estimated, the actual amount of restructuring and asset impairment charges could be materially different, either higher or lower, than those we have recorded.
Employee compensation and benefits	Employee compensation and benefits. Amounts owed to employees, such as accrued salary, bonuses and vacation benefits are accounted for within employee compensation and benefits. The total amount of accrued vacation benefit was $86 million and $100 million as of October 31, 2015 , and 2014 , respectively.
Foreign currency translation	Foreign currency translation. We translate and remeasure balance sheet and income statement items into U.S. dollars. For those subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using monthly exchange rates which approximate to average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) in stockholders' equity. For those subsidiaries that operate in a U.S. dollar functional environment, foreign currency assets and liabilities are remeasured into U.S. dollars at current exchange rates except for non-monetary assets and capital accounts which are remeasured at historical exchange rates. Revenue and expenses are generally remeasured at monthly exchange rates which approximate average exchange rates in effect during each period. Gains or losses from foreign currency remeasurement are included in consolidated net income. Net gains or losses resulting from foreign currency transactions, including hedging gains and losses, are reported in other income (expense), net and was $9 million loss for fiscal year 2015 , $4 million loss for 2014 and $2 million loss for 2013 , respectively.

REVISION OF PRIOR PERIOD FINA36

REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS (Tables)	12 Months Ended
	Oct. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	The errors discussed above resulted in an understatement of net income of $45 million and $10 million relating to the provision for income taxes for the years ended October 31, 2014 and 2013, respectively. Year Ended October 31, 2014 As Reported Adjustments Revised Reclassified for Discontinued Operations (in millions, except per share data) Income before taxes $ 646 $ 646 Provision (benefit) for income taxes 142 (45 ) 97 Income from continuing operations before taxes 229 Provision for income taxes on continuing operations (3 ) Income from continuing operations 232 Income from discontinued operations, net of tax expense of $100 317 Net income $ 504 $ 45 $ 549 $ 549 Net income per share: Basic $ 1.51 $ 0.14 $ 1.65 Diluted $ 1.49 $ 0.13 $ 1.62 Net income per share - basic Income from continuing operations $ 0.70 Income from discontinued operations $ 0.95 Net income per share - basic $ 1.65 Net income per share - diluted Income from continuing operations $ 0.69 Income from discontinued operations $ 0.93 Net income per share - diluted $ 1.62 Total comprehensive income $ 79 $ 45 $ 124 Year Ended October 31, 2013 As Reported Adjustments Revised Reclassified for Discontinued Operations (in millions, except per share data) Income before taxes $ 859 $ 859 Provision (benefit) for income taxes 135 (10 ) 125 Income from continuing operations before taxes 293 Provision for income taxes on continuing operations 68 Income from continuing operations 225 Income from discontinued operations, net of tax expense of $57 509 Net income $ 724 $ 10 $ 734 $ 734 Net income per share: Basic $ 2.12 $ 0.03 $ 2.15 Diluted $ 2.10 $ 0.03 $ 2.13 Net income per share - basic Income from continuing operations $ 0.66 Income form discontinued operations $ 1.49 Net income per share - basic $ 2.15 Net income per share - diluted Income from continuing operations $ 0.65 Income form discontinued operations $ 1.48 Net income per share - diluted $ 2.13 Total comprehensive income $ 926 $ 10 $ 936 These adjustments also cumulatively impacted the following balance sheet line items as of October 31, 2014: October 31, 2014 As Reported Adjustments As Revised (in millions) Other current assets $ 261 $ 2 $ 263 Current assets of discontinued operations $ 1,821 7 $ 1,828 Total current assets $ 5,500 9 $ 5,509 Other assets $ 283 (15 ) $ 268 Non-current assets of discontinued operations $ 1,165 (10 ) $ 1,155 Total assets $ 10,831 $ (16 ) $ 10,815 Other accrued liabilities $ 289 $ (10 ) $ 279 Total current liabilities $ 1,702 $ (10 ) $ 1,692 Other long-term liabilities $ 522 $ (9 ) $ 513 Total liabilities $ 5,530 $ (19 ) $ 5,511 Retained earnings $ 6,466 $ 3 $ 6,469 Total stockholders equity $ 5,298 $ 3 $ 5,301 The adjustments resulted in the following revisions to our consolidated cash flow statements. Year Ended October 31, 2014 As Reported Adjustments As Revised (in millions) Net income $ 504 $ 45 $ 549 Deferred taxes $ (132 ) $ (60 ) $ (192 ) Changes in assets and liabilities: Other assets and liabilities $ (60 ) $ 15 $ (45 ) Year Ended October 31, 2013 As Reported Adjustments As Revised (in millions) Net income $ 724 $ 10 $ 734 Deferred taxes $ 31 (35 ) $ (4 ) Changes in assets and liabilities: Other assets and liabilities $ (17 ) 25 $ 8

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	12 Months Ended
	Oct. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Schedule of income (loss) from discontinued operations	The following table summarizes results from discontinued operations of Keysight included in the consolidated statement of operations: Years Ended October 31, 2015 2014 2013 (in millions) Net revenue $ — $ 2,933 $ 2,888 Costs and expenses 39 2,521 2,323 Operating income (loss) (39 ) 412 565 Other income (expense), net — 5 1 Income (loss) from discontinued operations before tax (39 ) 417 566 Provision (benefit) for income taxes (2 ) 100 57 Net income (loss) from discontinued operations $ (37 ) $ 317 $ 509
Schedule of assets and liabilities attributable to discontinued operations [Table Text Block]	The following table presents Agilent's electronic measurement business assets and liabilities removed from the consolidated balance sheet as of November 1, 2014 and presented as discontinued operations as of October 31, 2014: October 31, 2014 (in millions) Assets: Cash and cash equivalents $ 810 Accounts receivable, net 357 Inventory 498 Other current assets 163 Current assets of discontinued operations 1,828 Property, plant and equipment, net 470 Goodwill 392 Other intangible assets, net 18 Long-term investments 63 Other assets 212 Non-current assets of discontinued operations 1,155 Total assets of discontinued operations $ 2,983 Liabilities: Accounts payable $ 173 Employee compensation and benefits 167 Deferred revenue 175 Other accrued liabilities 108 Current liabilities of discontinued operations 623 Long-term debt 1,099 Retirement and post-retirement benefits 213 Other long-term liabilities 122 Long-term liabilities of discontinued operations 1,434 Total liabilities of discontinued operations $ 2,057 The following table presents Agilent's electronic measurement business assets and liabilities removed from the consolidated balance sheet as of November 1, 2014 and presented as discontinued operations as of October 31, 2014: October 31, 2014 (in millions) Assets: Cash and cash equivalents $ 810 Accounts receivable, net 357 Inventory 498 Other current assets 163 Current assets of discontinued operations 1,828 Property, plant and equipment, net 470 Goodwill 392 Other intangible assets, net 18 Long-term investments 63 Other assets 212 Non-current assets of discontinued operations 1,155 Total assets of discontinued operations $ 2,983 Liabilities: Accounts payable $ 173 Employee compensation and benefits 167 Deferred revenue 175 Other accrued liabilities 108 Current liabilities of discontinued operations 623 Long-term debt 1,099 Retirement and post-retirement benefits 213 Other long-term liabilities 122 Long-term liabilities of discontinued operations 1,434 Total liabilities of discontinued operations $ 2,057

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	12 Months Ended
	Oct. 31, 2015
Share-based Compensation [Abstract]
Allocated Share-based compensation expense disclosure	The impact on our results for share-based compensation was as follows: Years Ended October 31, 2015 2014 2013 (in millions) Cost of products and services $ 11 $ 13 $ 12 Research and development 5 7 5 Selling, general and administrative 39 39 34 Share-based compensation expense in continuing operations 55 59 51 Share-based compensation expense in discontinued operations — 39 37 Total share-based compensation expense $ 55 $ 98 $ 88
Share-based compensation arrangement by share-based payment award fair value assumptions and methodology schedule	The following assumptions were used to estimate the fair value of employee stock options and LTPP grants. Years Ended October 31, 2015 2014 2013 Stock Option Plans: Weighted average risk-free interest rate 1.75% 1.69% 0.86% Dividend yield 1% 1% 1% Weighted average volatility 28% 39% 39% Expected life 5.5 years 5.8 years 5.8 years LTPP: Volatility of Agilent shares 25% 36% 37% Volatility of selected peer-company shares 12%-57% 13%-57% 6%-64% Price-wise correlation with selected peers 37% 47% 49%
Summary of stock option award activity	The following table summarizes employee stock option award activity made to our employees and directors for 2015 . The amount of options outstanding and the weighted average exercise price at October 31, 2014, have been revised to reflect the impact of the Keysight separation. Options Outstanding Weighted Average Exercise Price (in thousands) Outstanding at October 31, 2014 6,584 $ 27 Granted 1,347 $ 41 Exercised (1,925 ) $ 24 Cancelled/Forfeited/Expired (294 ) $ 35 Outstanding at October 31, 2015 5,712 $ 31 Forfeited and expired options from total cancellations in 2015 were as follows: Options Cancelled Weighted Average Exercise Price (in thousands) Forfeited 277 $ 36 Expired 17 $ 20 Total Options Cancelled during 2015 294 $ 35
Schedule of share-based compensation, shares authorized under stock option plans, by exercise price range	The options outstanding and exercisable for equity share-based payment awards at October 31, 2015 were as follows: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life Weighted Average Exercise Price Aggregate Intrinsic Value Number Exercisable Weighted Average Remaining Contractual Life Weighted Average Exercise Price Aggregate Intrinsic Value (in thousands) (in years) (in thousands) (in thousands) (in years) (in thousands) $0 - 25 1,120 1.9 $ 21 $ 18,873 1,120 1.9 $ 21 $ 18,873 $25.01 - 30 2,425 6.1 $ 26 27,504 1,539 5.7 $ 26 17,545 $30.01 - 40 921 8.1 $ 39 — 224 8.1 $ 39 — $40.01 - over 1,246 9.1 $ 41 — 13 8.6 $ 41 — 5,712 6.2 $ 31 $ 46,377 2,896 4.4 $ 25 $ 36,418
Schedule of intrinsic value of options exercised and the fair value of options granted	The following table summarizes the aggregate intrinsic value of options exercised and the fair value of options granted in 2015 , 2014 and 2013 : Aggregate Intrinsic Value Weighted Average Exercise Price Per Share Value Using Black-Scholes Model (in thousands) Options exercised in fiscal 2013 $ 71,499 $ 28 Black-Scholes per share value of options granted during fiscal 2013 $ 12 Options exercised in fiscal 2014 $ 98,075 $ 30 Black-Scholes per share value of options granted during fiscal 2014 $ 19 Options exercised in fiscal 2015 $ 33,258 $ 24 Black-Scholes per share value of options granted during fiscal 2015 $ 11
Non-vested award activity disclosure	The following table summarizes non-vested award activity in 2015 primarily for our LTPP and restricted stock unit awards. The amount of non-vested awards and the weighted average grant price at October 31, 2014, have been revised to reflect the impact of the Keysight separation. Shares Weighted Average Grant Price (in thousands) Non-vested at October 31, 2014 2,750 $ 32 Granted 955 $ 42 Vested (1,016 ) $ 30 Forfeited (159 ) $ 36 Change in LTPP shares vested in the year due to performance conditions (113 ) $ — Non-vested at October 31, 2015 2,417 $ 36

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Oct. 31, 2015
Income Tax Disclosure [Abstract]
Income before income taxes domestic and foreign	The domestic and foreign components of income from continuing operations before taxes are: Years Ended October 31, 2015 2014 2013 (in millions) U.S. operations $ 77 $ (72 ) $ 5 Non-U.S. operations 403 301 288 Total income from continuing operations before taxes $ 480 $ 229 $ 293
Provision for income taxes from operations	The provision (benefit) for income taxes is comprised of: Years Ended October 31, 2015 2014 2013 (in millions) U.S. federal taxes: Current $ (91 ) $ 17 $ 13 Deferred 97 (80 ) 3 Non-U.S. taxes: Current 62 176 88 Deferred (27 ) (111 ) (43 ) State taxes, net of federal benefit: Current 1 — 2 Deferred — (5 ) 5 Total provision (benefit) $ 42 $ (3 ) $ 68
Significant components of deferred tax assets and deferred tax liabilities	The significant components of deferred tax assets and deferred tax liabilities included on the consolidated balance sheet are: October 31, 2015 2014 Deferred Tax Assets Deferred Tax Liabilities Deferred Tax Assets Deferred Tax Liabilities (in millions) Inventory $ 13 $ — $ 18 $ — Intangibles — 95 — 142 Property, plant and equipment 17 — 18 — Warranty reserves 11 — 9 — Pension benefits and retiree medical benefits 93 — 85 — Employee benefits, other than retirement 26 — 27 — Net operating loss, capital loss, and credit carryforwards 173 — 176 — Unremitted earnings of foreign subsidiaries — 33 — 44 Share-based compensation 39 — 41 — Deferred revenue 41 — 41 — Other 4 — 9 3 Subtotal 417 128 424 189 Tax valuation allowance (131 ) — (134 ) — Total deferred tax assets or deferred tax liabilities $ 286 $ 128 $ 290 $ 189
Current and long-term deferred tax assets and deferred tax liabilities	The breakdown between current and long-term deferred tax assets and deferred tax liabilities was as follows for the years 2015 and 2014 : October 31, 2015 2014 (in millions) Current deferred tax assets (included within other current assets) $ 84 $ 88 Long-term deferred tax assets (included within other assets) 180 145 Current deferred tax liabilities (included within other accrued liabilities) (10 ) (7 ) Long-term deferred tax liabilities (included within other long-term liabilities) (96 ) (125 ) Total $ 158 $ 101
Tax rate reconciliation, U.S. federal statutory rate to effective tax rate from operations	Years Ended October 31, 2015 2014 2013 (in millions) Profit before tax times statutory rate $ 167 $ 80 $ 103 State income taxes, net of federal benefit (8 ) (7 ) 5 Non-U.S. income taxed at different rates (72 ) (39 ) (34 ) Change in unrecognized U.S. tax benefits (116 ) (111 ) — Repatriation of foreign earnings 68 75 — Valuation allowances (2 ) 2 (8 ) Transfer pricing adjustments for prior years — — 8 Adjustment to income taxes payable — (6 ) — Other, net 5 3 (6 ) Provision (benefit) for income taxes $ 42 $ (3 ) $ 68 Effective tax rate 8.7 % (1.3 )% 23.4 %
Current and Long Term Tax Assets and Liabilities [Table Text Block]	The breakdown between current and long-term income tax assets and liabilities, excluding deferred tax assets and liabilities, was as follows for the years 2015 and 2014 : October 31, 2015 2014 (in millions) Current income tax assets (included within other current assets) $ 104 $ 82 Long-term income tax assets (included within other assets) 20 45 Current income tax liabilities (included within other accrued liabilities) (62 ) (100 ) Long-term income tax liabilities (included within other long-term liabilities) (227 ) (285 ) Total $ (165 ) $ (258 )
Income tax contingencies rollforward	tax benefits including all federal, state and foreign tax jurisdictions are as follows: 2015 2014 2013 (in millions) Balance, beginning of year $ 417 $ 512 $ 457 Additions for tax positions related to the current year 33 45 52 Additions for tax positions from prior years 3 11 15 Reductions for tax positions from prior years (156 ) (141 ) (6 ) Settlements with taxing authorities (4 ) (2 ) (3 ) Statute of limitations expirations (4 ) (8 ) (3 ) Balance, end of year $ 289 $ 417 $ 512

NET INCOME (LOSS) PER SHARE (Ta

NET INCOME (LOSS) PER SHARE (Tables)	12 Months Ended
	Oct. 31, 2015
Earnings Per Share [Abstract]
Reconciliation of the numerators and denominators of the basic and diluted net income per share	The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented below. Years Ended October 31, 2015 2014 2013 (in millions) Numerator: Income from continuing operations $ 438 $ 232 $ 225 Income (loss) from discontinued operations $ (37 ) $ 317 $ 509 Net income 401 549 734 Denominators: Basic weighted average shares 333 333 341 Potential common shares — stock options and other employee stock plans 2 5 4 Diluted weighted average shares 335 338 345

INVENTORY (Tables)

INVENTORY (Tables)	12 Months Ended
	Oct. 31, 2015
Inventory Disclosure [Abstract]
Inventory	October 31, 2015 2014 (in millions) Finished goods $ 362 $ 366 Purchased parts and fabricated assemblies 179 208 Inventory $ 541 $ 574

PROPERTY, PLANT AND EQUIPMENT42

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	12 Months Ended
	Oct. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	October 31, 2015 2014 (in millions) Land $ 53 $ 58 Buildings and leasehold improvements 705 714 Machinery and equipment 401 443 Software 168 154 Total property, plant and equipment 1,327 1,369 Accumulated depreciation and amortization (723 ) (738 ) Property, plant and equipment, net $ 604 $ 631

GOODWILL AND OTHER INTANGIBLE43

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	12 Months Ended
	Oct. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Future amortization expense related to existing finite-lived purchased intangible assets for the next five fiscal years and thereafter is estimated below: Estimated future amortization expense: (in millions) 2016 $ 131 2017 $ 92 2018 $ 61 2019 $ 47 2020 $ 36 Thereafter $ 56
Goodwill balances and movements for each reportable segments during the period	The goodwill balances at October 31, 2015 , 2014 and 2013 and the movements in 2015 and 2014 for each of our reportable segments are shown in the table below: Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Goodwill as of October 31, 2013 $ 626 $ 1,546 $ 456 $ 2,628 Foreign currency translation impact 42 (201 ) 38 (121 ) Goodwill as of October 31, 2014 $ 668 $ 1,345 $ 494 $ 2,507 Foreign currency translation impact (18 ) (166 ) (12 ) (196 ) Goodwill arising from acquisitions — 55 — 55 Goodwill as of October 31, 2015 $ 650 $ 1,234 $ 482 $ 2,366
Components of other intangibles during the period	The component parts of other intangible assets at October 31, 2015 and 2014 are shown in the table below: Other Intangible Assets Gross Carrying Amount Accumulated Amortization and Impairments Net Book Value (in millions) As of October 31, 2014: Purchased technology $ 880 $ 475 $ 405 Trademark/Tradename 167 52 115 Customer relationships 368 257 111 Total amortizable intangible assets $ 1,415 $ 784 $ 631 In-Process R&D 18 — 18 Total $ 1,433 $ 784 $ 649 As of October 31, 2015: Purchased technology $ 746 $ 476 $ 270 Trademark/Tradename 141 50 91 Customer relationships 230 168 62 Total amortizable intangible assets $ 1,117 $ 694 $ 423 In-Process R&D 22 — 22 Total $ 1,139 $ 694 $ 445

INVESTMENTS (Tables)

INVESTMENTS (Tables)	12 Months Ended
	Oct. 31, 2015
Schedule of Investments [Abstract]
Equity Investments	The following table summarizes the company's equity investments as of October 31, 2015 and 2014 (net book value): October 31, 2015 2014 (in millions) Long-Term Cost method investments $ 23 $ 25 Trading securities 35 35 Equity method investments 28 36 Total $ 86 $ 96
Realized gains and losses on sale of available-for-sale securities and other than temporary impairments Included in Other income (expense)	Amounts included in other income (expense), net for the appropriate share of loss on equity method investments were as follows: Years Ended October 31, 2015 2014 2013 (in millions) Equity method investments - share of losses (9 ) $ (7 ) (2 )

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Oct. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Assets And Liabilities Measured On Recurring Basis	Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2015 were as follows: Fair Value Measurement at October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 1,411 $ 1,411 $ — $ — Derivative instruments (foreign exchange contracts) 4 — 4 — Long-term Trading securities 35 35 — — Total assets measured at fair value $ 1,450 $ 1,446 $ 4 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 5 $ — $ 5 $ — Long-term Deferred compensation liability 35 — 35 — Total liabilities measured at fair value $ 40 $ — $ 40 $ — Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2014 were as follows: Fair Value Measurement at October 31, 2014 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 1,117 $ 1,117 $ — $ — Derivative instruments (foreign exchange contracts) 10 — 10 — Long-term Trading securities 35 35 — — Total assets measured at fair value $ 1,162 $ 1,152 $ 10 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 4 $ — $ 4 $ — Long-term Deferred compensation liability 35 — 35 — Total liabilities measured at fair value $ 39 $ — $ 39 $ —
Impairment of Long-lived assets included in net income	For assets measured at fair value on a non-recurring basis, the following table summarizes the impairments included in net income for the years ended October 31, 2015 , 2014 and 2013: Years Ended October 31, 2015 2014 2013 (in millions) Long-lived assets held and used $ 3 $ 23 $ 1 Long-lived assets held for sale $ — $ — $ 1

DERIVATIVES (Tables)

DERIVATIVES (Tables)	12 Months Ended
	Oct. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Aggregated notional amounts by currency and designation	The aggregated notional amounts by currency and designation as of October 31, 2015 were as follows: Derivatives Designated as Derivatives Not Designated as Hedging Instruments Forward Forward Forward Contracts DKK Currency Buy/(Sell) Buy/(Sell) Buy/(Sell) (in millions) Euro $ (19 ) $ 186 $ (60 ) British Pound (15 ) (10 ) (4 ) Canadian Dollar (23 ) — (2 ) Australian Dollars 10 13 (3 ) Malaysian Ringgit — (4 ) — Japanese Yen (67 ) (5 ) (1 ) American Dollar — — 33 Other (2 ) 21 (9 ) $ (116 ) $ 201 $ (46 )
Gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet	The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of October 31, 2015 and 2014 were as follows: Fair Values of Derivative Instruments Asset Derivatives Liability Derivatives Fair Value Fair Value Balance Sheet Location October 31, October 31, Balance Sheet Location October 31, October 31, (in millions) Derivatives designated as hedging instruments: Cash flow hedges Foreign exchange contracts Other current assets $ 2 $ 9 Other accrued liabilities $ 1 $ 1 $ 2 $ 9 $ 1 $ 1 Derivatives not designated as hedging instruments: Foreign exchange contracts Other current assets $ 2 $ 1 Other accrued liabilities $ 4 $ 3 Total derivatives $ 4 $ 10 $ 5 $ 4
Effect of derivative instruments for foreign exchange contracts in the consolidated statement of operations	The effect of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows: 2015 2014 2013 (in millions) Derivatives designated as hedging instruments: Cash Flow Hedges Gain recognized in accumulated other comprehensive income $ 11 $ 13 $ 10 Gain (loss) reclassified from accumulated other comprehensive income into cost of sales $ 18 $ (1 ) $ 13 Derivatives not designated as hedging instruments: Gain (loss) recognized in other income (expense), net within continuing operations $ (21 ) $ (20 ) $ 10

RESTRUCTURING AND EXIT OF NMR47

RESTRUCTURING AND EXIT OF NMR BUSINESS (Tables)	12 Months Ended
	Oct. 31, 2015
Restructuring Cost and Reserve
Schedule of Restructuring Reserve by Type of Cost	A summary of total “NMR” restructuring activity and other special charges is shown in the table below: Workforce Reduction Impairments of Building and Other Assets Special Charges Related to Inventory and Others Total (in millions) Balance as of October 31, 2013 $ — $ — $ — $ — Income statement expense 16 19 33 68 Asset impairments/inventory charges — (19 ) (30 ) (49 ) Cash payments (2 ) — — (2 ) Balance as of October 31, 2014 $ 14 $ — $ 3 $ 17 Income statement expense/(reversal) (2 ) — 8 6 Asset impairments/inventory charges — — (2 ) (2 ) Cash payments (10 ) — (3 ) (13 ) Balance as of October 31, 2015 $ 2 $ — $ 6 $ 8
Restructuring And Related Charges By Statement Of Operations Caption [Text Block]	A summary of the charges in the consolidated statement of operations resulting from the NMR closure is shown below: Year Ended Year Ended October 31, October 31, 2015 2014 (in millions) Cost of products and services $ (2 ) $ 48 Research and development 4 5 Selling, general and administrative 4 15 Total restructuring, asset impairments and other special charges $ 6 $ 68

RETIREMENT PLANS AND POST RET48

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables)	12 Months Ended
	Oct. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Schedule of net pension and post-retirement benefit costs	For the years ended October 31, 2015 , 2014 and 2013 , components of net periodic benefit cost and other amounts recognized in other comprehensive income were comprised of: Pensions U.S. Post-Retirement Benefit Plans U.S. Plans Non-U.S. Plans 2015 2014 2013 2015 2014 2013 2015 2014 2013 (in millions) Net periodic benefit cost (benefit) Service cost — benefits earned during the period $ 25 $ 46 $ 44 $ 18 $ 36 $ 36 $ 2 $ 3 $ 4 Interest cost on benefit obligation 14 34 24 23 74 68 4 12 12 Expected return on plan assets (27 ) (64 ) (51 ) (42 ) (118 ) (97 ) (8 ) (22 ) (20 ) Amortization of net actuarial loss 3 1 13 25 48 55 6 14 18 Amortization of prior service benefit (5 ) (12 ) (12 ) — (1 ) (1 ) (12 ) (35 ) (35 ) Total periodic benefit cost (benefit) $ 10 $ 5 $ 18 $ 24 $ 39 $ 61 $ (8 ) $ (28 ) $ (21 ) Summary of total periodic benefit cost (benefit): Continuing operations $ 10 $ 2 $ 9 $ 24 $ 27 $ 38 $ (8 ) $ (14 ) $ (11 ) Discontinued operations — 3 9 — 12 23 — (14 ) (10 ) Total periodic benefit cost (benefit) $ 10 $ 5 $ 18 $ 24 $ 39 $ 61 $ (8 ) $ (28 ) $ (21 ) Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss Net actuarial (gain) loss $ 44 $ 86 $ (122 ) $ 32 $ 173 $ (85 ) $ 16 $ 12 $ (57 ) Amortization of net actuarial loss (3 ) (1 ) (13 ) (25 ) (48 ) (55 ) (6 ) (14 ) (18 ) Prior service cost (benefit) — — — — (2 ) — — — — Amortization of prior service benefit 5 12 12 — 1 1 12 35 35 Foreign currency — — — 10 (28 ) 2 — — — Total recognized in other comprehensive (income) loss $ 46 $ 97 $ (123 ) $ 17 $ 96 $ (137 ) $ 22 $ 33 $ (40 ) Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss $ 56 $ 102 $ (105 ) $ 41 $ 135 $ (76 ) $ 14 $ 5 $ (61 )
Change in fair value of plan assets	Funded status. As of October 31, 2015 and 2014 , the funded status of the defined benefit and post-retirement benefit plans was: U.S. Defined Benefit Plans Non-U.S. Defined Benefit Plans U.S. Post-Retirement Benefit Plans 2015 2014 2015 2014 2015 2014 (in millions) Change in fair value of plan assets: Fair value — beginning of year $ 837 $ 782 $ 2,108 $ 2,045 $ 284 $ 288 Actual return on plan assets 6 64 53 180 2 18 Employer contributions 15 30 25 72 — 1 Participants' contributions — — 1 3 — — Benefits paid (21 ) (39 ) (20 ) (62 ) (8 ) (23 ) Transfer due to Keysight separation (490 ) — (1,327 ) — (187 ) — Currency impact — — (62 ) (130 ) — — Fair value — end of year $ 347 $ 837 $ 778 $ 2,108 $ 91 $ 284
Change in benefit obligation	U.S. Defined Benefit Plans Non-U.S. Defined Benefit Plans U.S. Post-Retirement Benefit Plans 2015 2014 2015 2014 2015 2014 (in millions) Change in benefit obligation: Benefit obligation — beginning of year $ 889 $ 763 $ 2,344 $ 2,199 $ 309 $ 307 Service cost 25 46 18 36 2 3 Interest cost 14 34 23 74 4 12 Participants' contributions — — 1 3 — — Plan amendment — — — (2 ) — — Actuarial (gain) loss 23 85 40 236 11 10 Benefits paid (22 ) (39 ) (20 ) (62 ) (8 ) (23 ) Transfer due to Keysight separation (514 ) — (1,429 ) — (206 ) — Currency impact — — (77 ) (140 ) — — Benefit obligation — end of year $ 415 $ 889 $ 900 $ 2,344 $ 112 $ 309 Overfunded (underfunded) status of PBO $ (68 ) $ (52 ) $ (122 ) $ (236 ) $ (21 ) $ (25 )
Amounts recognized in the consolidated balance sheet	U.S. Defined Benefit Plans Non-U.S. Defined Benefit Plans U.S. Post-Retirement Benefit Plans 2015 2014 2015 2014 2015 2014 (in millions) Amounts recognized in the consolidated balance sheet consist of: Other assets $ — $ — $ 26 $ 22 $ — $ — Employee compensation and benefits (2 ) (1 ) — — — — Retirement and post-retirement benefits (66 ) (28 ) (148 ) (147 ) (21 ) (6 ) Net asset (liability) $ (68 ) $ (29 ) $ (122 ) $ (125 ) $ (21 ) $ (6 ) Discontinued operations: Other assets $ — $ — $ — $ — $ — $ — Employee compensation and benefits — (1 ) — 48 — — Retirement and post-retirement benefits — (22 ) — (159 ) — (19 ) Net asset (liability) - discontinued operations $ — $ (23 ) $ — $ (111 ) $ — $ (19 ) Total net asset (liability) $ (68 ) $ (52 ) $ (122 ) $ (236 ) $ (21 ) $ (25 )
Amounts recognized in accumulated other comprehensive income (loss)	U.S. Defined Benefit Plans Non-U.S. Defined Benefit Plans U.S. Post-Retirement Benefit Plans 2015 2014 2015 2014 2015 2014 Amounts Recognized in Accumulated Other Comprehensive Income (loss): Actuarial (gains) losses $ 73 $ 77 $ 256 $ 621 $ 49 $ 118 Prior service costs (benefits) (18 ) (55 ) — (4 ) (40 ) (149 ) Total $ 55 $ 22 $ 256 $ 617 $ 9 $ (31 )
Fair value of plan assets and Benefit obligation transferred to Keysight [Table Text Block]	In connection with the separation of Keysight Technologies on November 1, 2014, Agilent transferred certain liabilities and assets of the U.S. and Non-U.S. defined benefit pension plans, and U.S. Post-Retirement Benefit Plans to similar plans created for Keysight Technologies employees. Total transfers are as follows: U.S. Defined Benefit Plans Non-U.S. Defined Benefit Plans U.S. Post-Retirement Benefit Plans (in millions) Fair value of plan assets transferred to Keysight $ 490 $ 1,327 $ 187 Benefit obligation transferred to Keysight $ 514 $ 1,429 $ 206
Amounts in accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year	The amounts in accumulated other comprehensive income expected to be recognized by Agilent as components of net expense during 2016 are as follows: U.S. Defined Benefit Plans Non-U.S. Defined Benefit Plans U.S. Post-Retirement Benefit Plans (in millions) Amortization of net prior service cost (benefit) $ (5 ) $ — $ (10 ) Amortization of actuarial net loss (gain) $ 8 $ 26 $ 10
Defined benefit plan assets by fair value hierarchy	The following tables present the fair value of U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2015 and 2014 . Fair Value Measurement October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Cash and Cash Equivalents $ 3 $ 1 $ 2 $ — Equity 258 61 197 — Fixed Income 76 22 54 — Other Investments 10 — 1 9 Total assets measured at fair value $ 347 $ 84 $ 254 $ 9 Fair Value Measurement October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Cash and Cash Equivalents $ 9 $ 2 $ 7 $ — Equity 668 156 512 — Fixed Income 145 40 105 — Other Investments 15 1 — 14 Total assets measured at fair value $ 837 $ 199 $ 624 $ 14 Assets measured at fair value - continuing operations $ 347 $ 73 $ 260 $ 14 Assets measured at fair value - discontinued operations 490 126 364 — Total assets measured at fair value $ 837 $ 199 $ 624 $ 14 The following tables present the fair value of U.S. Post-Retirement Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2015 and 2014 . . Fair Value Measurement at October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Cash and Cash Equivalents $ 3 $ 2 $ 1 $ — Equity 62 15 47 — Fixed Income 20 6 14 — Other Investments 6 — — 6 Total assets measured at fair value $ 91 $ 23 $ 62 $ 6 Fair Value Measurement October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Cash and Cash Equivalents $ 6 $ 3 $ 3 $ — Equity 217 51 166 — Fixed Income 53 14 39 — Other Investments 8 — — 8 Total assets measured at fair value $ 284 $ 68 $ 208 $ 8 Assets measured at fair value - continuing operations $ 97 $ 19 $ 70 $ 8 Assets measured at fair value - discontinued operations 187 49 138 — Total assets measured at fair value $ 284 $ 68 $ 208 $ 8 The following tables present the fair value of non-U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2015 and 2014 : Fair Value Measurement October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Cash and Cash Equivalents $ 3 $ 1 $ 2 $ — Equity 396 172 224 — Fixed Income 379 13 366 — Other Investments — — — — Total assets measured at fair value $ 778 $ 186 $ 592 $ — Fair Value Measurement October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Cash and Cash Equivalents $ 10 $ 3 $ 7 $ — Equity 1,078 335 743 — Fixed Income 974 37 937 — Other Investments 46 — 25 21 Total assets measured at fair value $ 2,108 $ 375 $ 1,712 $ 21 Assets measured at fair value - continuing operations $ 790 $ 200 $ 586 $ 4 Assets measured at fair value - discontinued operations 1,318 175 1,126 17 Total assets measured at fair value $ 2,108 $ 375 $ 1,712 $ 21
Defined benefit plans assets measured at fair value using significant unobservable inputs (level 3)	For U.S. Defined Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2015 and 2014 for continuing operations: Years Ended October 31. 2015 2014 Balance, beginning of year $ 14 $ 17 Realized gains (1 ) (1 ) Unrealized gains/(losses) (2 ) 2 Purchases, sales, issuances, and settlements (2 ) (4 ) Transfers in (out) — — Balance, end of year $ 9 $ 14 For U.S. Post-Retirement Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2015 and 2014 for continuing operations: Years Ended October 31, 2015 2014 Balance, beginning of year $ 8 $ 10 Realized gains (1 ) (1 ) Unrealized gains/(losses) — 1 Purchases, sales, issuances, and settlements (1 ) (2 ) Transfers in (out) — — Balance, end of year $ 6 $ 8 For non-U.S. Defined Benefit Plans, assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the changes in balances during 2015 and 2014 for continuing operations: Years Ended October 31, 2015 2014 Balance, beginning of year $ 4 $ — Realized gains/(losses) 1 — Unrealized gains/(losses) — — Purchases, sales, issuances, and settlements (5 ) — Transfers in (out) — 4 Balance, end of year $ — $ 4
Combined projected benefit obligation, accumulated benefit obligations and fair value of plan assets	The table below presents the combined projected benefit obligation ("PBO"), accumulated benefit obligation ("ABO") and fair value of plan assets, grouping plans using comparisons of the PBO and ABO relative to the plan assets as of October 31, 2015 or 2014 . 2015 2014 Benefit Obligation Benefit Obligation Fair Value of Plan Assets Fair Value of Plan Assets PBO PBO (in millions) U.S. defined benefit plans where PBO exceeds the fair value of plan assets - continuing operations $ 415 $ 347 $ 375 $ 347 U.S. defined benefit plans where PBO exceeds the fair value of plan assets - discontinued operations — — 514 490 Total $ 415 $ 347 $ 889 $ 837 Non-U.S. defined benefit plans where PBO exceeds or is equal to the fair value of plan assets - continuing operations $ 771 $ 623 $ 754 $ 607 Non-U.S. defined benefit plans where PBO exceeds or is equal to the fair value of plan assets - discontinued operations — — 1,111 952 Non-U.S. defined benefit plans where fair value of plan assets exceeds PBO - continuing operations 129 155 161 183 Non-U.S. defined benefit plans where fair value of plan assets exceeds PBO - discontinued operations — — 318 366 Total $ 900 $ 778 $ 2,344 $ 2,108 ABO ABO U.S. defined benefit plans where ABO exceeds the fair value of plan assets - continuing operations $ 389 $ 347 $ 9 $ — U.S. defined benefit plans where ABO exceeds the fair value of plan assets - discontinued operations — — 5 — U.S. defined benefit plans where the fair value of plan assets exceeds ABO - continuing operations — — 340 347 U.S. defined benefit plans where the fair value of plan assets exceeds ABO - discontinued operations — — 472 490 Total $ 389 $ 347 $ 826 $ 837 Non-U.S. defined benefit plans where ABO exceeds or is equal to the fair value of plan assets - continuing operations $ 732 $ 623 $ 714 $ 607 Non-U.S. defined benefit plans where ABO exceeds or is equal to the fair value of plan assets - discontinued operations — — 1,081 952 Non-U.S. defined benefit plans where fair value of plan assets exceeds ABO - continuing operations 127 155 158 183 Non-U.S. defined benefit plans where fair value of plan assets exceeds ABO - discontinued operations — — 310 366 Total $ 859 $ 778 $ 2,263 $ 2,108
Schedule of expected benefit payments	The following table presents expected future benefit payments for the next 10 years: U.S. Defined Benefit Plans Non-U.S. Defined Benefit Plans U.S. Post-Retirement Benefit Plans (in millions) 2016 $ 25 $ 21 $ 8 2017 $ 26 $ 22 $ 9 2018 $ 28 $ 24 $ 8 2019 $ 30 $ 26 $ 8 2020 $ 33 $ 27 $ 8 2021 - 2025 $ 177 $ 166 $ 40
Assumptions used to calculate the net periodic cost and benefit obligation	Assumptions used to calculate the net periodic cost in each year were as follows: For years ended October 31, 2015 2014 2013 U.S. defined benefit plans: Discount rate 4.00% 4.00-4.50% 3.25% Average increase in compensation levels 3.50% 3.50% 3.50% Expected long-term return on assets 8.00% 8.00% 8.00% Non-U.S. defined benefit plans: Discount rate 1.50-4.00% 1.50-4.50% 1.50-4.50% Average increase in compensation levels 2.5-3.25% 2.50-3.25% 2.50-3.00% Expected long-term return on assets 4.00-6.50% 4.00-6.50% 4.00-6.50% U.S. post-retirement benefits plans: Discount rate 4.00% 4.00-4.25% 3.50% Expected long-term return on assets 8.00% 8.00% 8.00% Current medical cost trend rate 8.00% 8.00% 9.00% Ultimate medical cost trend rate 3.50% 3.50% 3.50% Medical cost trend rate decreases to ultimate rate in year 2028 2028 2027 Assumptions used to calculate the benefit obligation were as follows: As of the Years Ending October 31, 2015 2014 U.S. defined benefit plans: Discount rate 4.20% 4.00% Average increase in compensation levels 3.50% 3.50% Non-U.S. defined benefit plans: Discount rate 0.77-3.76% 1.50-4.00% Average increase in compensation levels 2.25-4.00% 2.50-3.25% U.S. post-retirement benefits plans: Discount rate 4.00% 3.75-4.00% Current medical cost trend rate 7.00% 8.00% Ultimate medical cost trend rate 3.50% 3.50% Medical cost trend rate decreases to ultimate rate in year 2029 2028

GUARANTEES (Tables)

GUARANTEES (Tables)	12 Months Ended
	Oct. 31, 2015
Guarantees [Abstract]
Standard Warranty	A summary of the standard warranty accrual activity is shown in the table below. The standard warranty accrual balances are held in other accrued and other long-term liabilities. October 31, 2015 2014 (in millions) Balance as of October 31, 2014 and 2013 $ 30 $ 31 Accruals for warranties including change in estimates 53 44 Settlements made during the period (52 ) (45 ) Balance as of October 31, 2015 and 2014 $ 31 $ 30
Schedule of Product Warranty Liability classification [Table Text Block]	Accruals for warranties due within one year 29 26 Accruals for warranties due after one year 2 4 Balance as of October 31, 2015 and 2014 $ 31 $ 30

LONG-TERM DEBT (Tables)

LONG-TERM DEBT (Tables)	12 Months Ended
	Oct. 31, 2015
Debt Disclosure [Abstract]
Schedule of Interest Rate Swaps pertaining to Senior Notes offered	The following table summarizes the company's long-term senior notes and the related interest rate swaps: October 31, 2015 October 31, 2014 Amortized Principal Swap Total Amortized Principal Swap Total (in millions) 2017 Senior Notes 100 2 102 100 3 103 2020 Senior Notes 499 19 518 499 22 521 2022 Senior Notes 399 — 399 399 — 399 2023 Senior Notes 598 — 598 598 — 598 Total $ 1,596 $ 21 $ 1,617 $ 1,596 $ 25 $ 1,621

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
	Oct. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income	The following table summarizes the components of our accumulated other comprehensive income (loss) as of October 31, 2015 and 2014, net of tax effect: October 31, 2015 2014 (in millions) Unrealized gain on equity securities, net of $(0) and $(3) of tax expense for 2015 and 2014, respectively $ — $ 17 Foreign currency translation, net of $(2) and $(86) of tax expense for 2015 and 2014, respectively (189 ) 156 Unrealized losses on defined benefit plans, net of tax benefit of $126 and $145 for 2015 and 2014, respectively (204 ) (516 ) Unrealized gains (losses) on derivative instruments, net of tax expense of $(2) and $(7) for 2015 and 2014, respectively 2 9 Total accumulated other comprehensive loss $ (391 ) $ (334 ) Changes in accumulated other comprehensive income (loss) by component and related tax effects for the years ended October 31, 2015 and 2014 were as follows (in millions): Net defined benefit pension cost and post retirement plan costs Unrealized gain on investments Foreign currency translation Prior service credits Actuarial Losses Unrealized gains (losses) on derivatives Total (in millions) As of October 31, 2013 $ 7 $ 425 $ 287 $ (628 ) $ — $ 91 Other comprehensive income (loss) before reclassifications 12 (277 ) — (273 ) 13 (525 ) Amounts reclassified out of accumulated other comprehensive income (1 ) — (48 ) 65 1 17 Tax (expense) benefit (1 ) 8 16 65 (5 ) 83 Other comprehensive income (loss) 10 (269 ) (32 ) (143 ) 9 (425 ) As of October 31, 2014 $ 17 $ 156 $ 255 $ (771 ) $ 9 $ (334 ) Transfer to Keysight $ (17 ) $ (9 ) $ (83 ) $ 444 $ (3 ) $ 332 Balance after transfer to Keysight — 147 172 (327 ) 6 (2 ) Other comprehensive income (loss) before reclassifications — (360 ) — (90 ) 11 (439 ) Amounts reclassified out of accumulated other comprehensive income — — (17 ) 35 (18 ) — Tax benefit — 24 6 17 3 50 Other comprehensive loss — (336 ) (11 ) (38 ) (4 ) (389 ) As of October 31, 2015 $ — $ (189 ) $ 161 $ (365 ) $ 2 $ (391 )
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	Reclassifications out of accumulated other comprehensive income (loss) for the years ended October 31, 2015 and 2014 were as follows (in millions): Details about accumulated other Amounts Reclassified Affected line item in comprehensive income components from other comprehensive income statement of operations 2015 2014 Unrealized gain on equity securities $ — $ 1 Other income (expense), net — 1 Total before income tax — — Provision for income tax — 1 Total net of income tax Unrealized gains and (losses) on derivatives 18 (1 ) Cost of products 18 (1 ) Total before income tax (6 ) — (Provision)/benefit for income tax 12 (1 ) Total net of income tax Net defined benefit pension cost and post retirement plan costs: Actuarial net loss (35 ) (65 ) Prior service benefit 17 48 (18 ) (17 ) Total before income tax 5 (2 ) (Provision)/benefit for income tax (13 ) (19 ) Total net of income tax Total reclassifications for the period $ (1 ) $ (19 )

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Oct. 31, 2015
Revenue from External Customer [Line Items]
Segment profitability	Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total Segments (in millions) Year ended October 31, 2015: Total net revenue $ 2,046 $ 662 $ 1,330 $ 4,038 Income from operations $ 380 $ 88 $ 299 $ 767 Depreciation expense $ 27 $ 37 $ 34 $ 98 Share-based compensation expense $ 27 $ 9 $ 18 $ 54 Year ended October 31, 2014: Total net revenue $ 2,078 $ 663 $ 1,307 $ 4,048 Income from operations $ 369 $ 93 $ 301 $ 763 Depreciation expense $ 29 $ 43 $ 33 $ 105 Share-based compensation expense $ 29 $ 9 $ 18 $ 56 Year ended October 31, 2013: Total net revenue $ 2,035 $ 635 $ 1,224 $ 3,894 Income from operations $ 338 $ 95 $ 299 $ 732 Depreciation expense $ 28 $ 43 $ 27 $ 98 Share-based compensation expense $ 27 $ 4 $ 16 $ 47
Reconciliation of segment results to total enterprise results	The following table reconciles reportable segments' income from operations to Agilent's total enterprise income before taxes: Years Ended October 31, 2015 2014 2013 (in millions) Total reportable segments' income from operations $ 767 $ 763 $ 732 Restructuring and business exit related costs (12 ) (66 ) (34 ) Acceleration of depreciation for held and used assets — — — Asset Impairments (3 ) (4 ) (2 ) Transformational programs (56 ) (29 ) (19 ) Amortization of intangibles (156 ) (189 ) (190 ) Acquisition and integration costs (13 ) (11 ) (22 ) Acceleration of share-based compensation expense related to workforce reduction (2 ) (1 ) (2 ) One-time and pre-separation costs — (14 ) — Other (3 ) 10 (13 ) Interest Income 7 9 7 Interest Expense (66 ) (110 ) (107 ) Other income (expense), net 17 (89 ) 7 Unallocated corporate charges — (40 ) (64 ) Income before taxes, as reported $ 480 $ 229 $ 293
Assets and capital expenditures directly managed by each segment	The following table presents assets and capital expenditures directly managed by each segment. Unallocated assets primarily consist of cash, cash equivalents, accumulated amortization of other intangibles and other assets. Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total Segments (in millions) As of October 31, 2015: Assets $ 1,539 $ 2,027 $ 1,008 $ 4,574 Capital expenditures $ 28 $ 33 $ 37 $ 98 As of October 31, 2014: Assets $ 1,663 $ 2,302 $ 1,001 $ 4,966 Capital expenditures $ 33 $ 40 $ 37 $ 110 The following table reconciles segment assets to Agilent's total assets: October 31, 2015 2014 (in millions) Total reportable segments' assets $ 4,574 $ 4,966 Cash, cash equivalents and short-term investments 2,003 2,218 Short-term restricted cash and cash equivalents 242 — Prepaid expenses 105 85 Investments 86 96 Long-term and other receivables 104 90 Other 365 377 Current and non-current assets of discontinued operations $ — $ 2,983 Total assets $ 7,479 $ 10,815
Revenue by product category	The following table represents total revenue by product category: Years Ended October 31, 2015 2014 2013 (in millions) Instrumentation $ 1,827 $ 1,839 $ 1,802 Analytical lab services 843 831 768 Analytical lab consumables 489 476 456 Diagnostics and genomics solutions 662 663 635 Informatics and other 217 239 233 Total $ 4,038 $ 4,048 $ 3,894
Revenue and assets by geographic areas	The following table presents summarized information for net revenue and long-lived assets by geographic region. Revenues from external customers are generally attributed to countries based upon the location of the Agilent sales representative. Long lived assets consist of property, plant, and equipment, long-term receivables and other long-term assets excluding intangible assets. The rest of the world primarily consists of rest of Asia and Europe. United States China Rest of the World Total (in millions) Net revenue: Year ended October 31, 2015 $ 1,206 $ 633 $ 2,199 $ 4,038 Year ended October 31, 2014 $ 1,019 $ 543 $ 2,486 $ 4,048 Year ended October 31, 2013 $ 1,077 $ 619 $ 2,198 $ 3,894 United States Rest of the World Total (in millions) Long-lived assets: October 31, 2015 $ 391 $ 379 $ 770 October 31, 2014 $ 379 $ 451 $ 830

OVERVIEW AND SUMMARY OF SIGNI53

OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) $ in Millions	12 Months Ended
	Oct. 31, 2015USD ($)yrsegment	Oct. 31, 2014USD ($)	Oct. 31, 2013USD ($)
Accounting Policies [Abstract]
Share-based compensation	$ 55	$ 98	$ 88
Advertising costs expensed as incurred	25	$ 31	28
Cash and cash equivalents held outside the U.S.	$ 1,780
Maximum percentage of accounts receivable a single customer accounts for	less than 10 percent	less than 10 percent
Employee compensation and benefits accrued	$ 86	$ 100
Hedging contracts general maturity	12 months
Business Acquisition [Line Items]
Revenue reclassification		21	17
Cost of Sales reclassification		19	12
Foreign currency translation net gain (Ioss)	$ (9)	(4)	(2)
Long -Lived Assets [Abstract]
Operating Lease Term Range Minimum | yr	1
Operating Lease Term Range Maximum | yr	20
Lease renewal options | yr	6
Financing Receivable, Net	$ 11	8
operating lease net assets	31	33
Restructuring Costs and Asset Impairment Charges	6	68
Goodwill and Intangible Assets Disclosure [Abstract]
Impairment of other intangibles related to cancellation of IPRD project	$ 3	4	0
Number of operating segments | segment	3
Goodwill, Impairment Loss	$ 0	0	0
Fair Value Disclosures [Abstract]
Fair value of long term debt in excess of carrying value	$ 30	53
Minimum [Member]
Goodwill and Intangible Assets Disclosure [Abstract]
Finite Lived Intangible Assets Useful Life	6 months
Minimum [Member] | Machinery and Equipment [Member]
Long -Lived Assets [Abstract]
Property, Plant and Equipment, Useful Life	3 years
Minimum [Member] | Software Development [Member]
Long -Lived Assets [Abstract]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
Goodwill and Intangible Assets Disclosure [Abstract]
Finite Lived Intangible Assets Useful Life	15 years
Maximum [Member] | Machinery and Equipment [Member]
Long -Lived Assets [Abstract]
Property, Plant and Equipment, Useful Life	10 years
Maximum [Member] | Software Development [Member]
Long -Lived Assets [Abstract]
Property, Plant and Equipment, Useful Life	5 years
NMR Asset impairment
Goodwill and Intangible Assets Disclosure [Abstract]
Impairment of Intangible Assets, Finite-lived		12
NMR [Member]
Long -Lived Assets [Abstract]
Restructuring Costs and Asset Impairment Charges	$ 6	68
Continuing Operations [Member]
Accounting Policies [Abstract]
Share-based compensation	$ 55	$ 59	$ 51

REVISION OF PRIOR PERIOD FINA54

REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Textuals (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Operating Loss Carryforwards [Line Items]
Other Tax Expense (Benefit)	$ 23	$ 13
Tax Adjustments, Settlements, and Unusual Provisions		45	$ 10
Adjustments to Additional Paid in Capital, Other			12
Overstatement of taxes payable [Member]
Operating Loss Carryforwards [Line Items]
Other Tax Expense (Benefit)	(10)
Foreign deferred tax assets [Member]
Operating Loss Carryforwards [Line Items]
Other Tax Expense (Benefit)	4
Understatement of prepaid taxes[Member] [Member]
Operating Loss Carryforwards [Line Items]
Other Tax Expense (Benefit)	(7)
Deferred Tax Liabilities for Unremitted Foreign Earnings [Member]
Operating Loss Carryforwards [Line Items]
Other Tax Expense (Benefit)	(17)
Due to Error in prior year tax return [Member]
Operating Loss Carryforwards [Line Items]
Other Tax Expense (Benefit)	4
Due to Error in prior year tax return [Member] [Member]
Operating Loss Carryforwards [Line Items]
Other Tax Expense (Benefit)	2
Transfer Pricing correction [Member]
Operating Loss Carryforwards [Line Items]
Other Tax Expense (Benefit)		12
Foreign tax basis correction [Member]
Operating Loss Carryforwards [Line Items]
Other Tax Expense (Benefit)		(9)
Tax related Balance Sheet accounts correction [Member]
Operating Loss Carryforwards [Line Items]
Other Tax Expense (Benefit)		3
Foreign tax rate change [Member]
Operating Loss Carryforwards [Line Items]
Other Tax Expense (Benefit)	$ (13)
Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards [Line Items]
Income Tax Effects Allocated Directly to Equity, Prior Period Adjustment		$ 65	$ 13

REVISION OF PRIOR PERIOD FINA55

REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Balance Sheet (Details) - USD ($) $ in Millions	Oct. 31, 2015	Oct. 31, 2014
Other current assets	$ 294	$ 263
Current assets of discontinued operations	0	1,828
Total current assets	3,686	5,509
Other assets	292	268
Non-current assets of discontinued operations	0	1,155
Total assets	7,479	10,815
Impact of prior period tax adjustment on assets		(16)
Other accrued liabilities	218	279
Total current liabilities	976	1,692
Other long-term liabilities	414	513
Total liabilities	3,309	5,511
Retained earnings	5,581	6,469
Stockholders' Equity Attributable to Parent	$ 4,167	5,301
Retained earnings
Impact of prior period tax adjustments to liabilities and equity		3
Other Current Assets
Impact of prior period tax adjustment on assets		2
Total Current Assets
Impact of prior period tax adjustment on assets		9
Other Non-current Assets
Impact of prior period tax adjustment on assets		(15)
Other Accrued Liabilities
Impact of prior period tax adjustments to liabilities and equity		(10)
Total Current Liabilities
Impact of prior period tax adjustments to liabilities and equity		(10)
Other Long-Term Liabilities
Impact of prior period tax adjustments to liabilities and equity		(9)
Total Liabilities
Impact of prior period tax adjustments to liabilities and equity		(19)
Total Stockholders' Equity
Impact of prior period tax adjustments to liabilities and equity		3
Discontinued Operations [Member] | Other Current Assets
Impact of prior period tax adjustment on assets		7
Discontinued Operations [Member] | Other Non-current Assets
Impact of prior period tax adjustment on assets		(10)
As Previously Reported
Other current assets		261
Current assets of discontinued operations		1,821
Total current assets		5,500
Other assets		283
Non-current assets of discontinued operations		1,165
Total assets		10,831
Other accrued liabilities		289
Total current liabilities		1,702
Other long-term liabilities		522
Total liabilities		5,530
Retained earnings		6,466
Stockholders' Equity Attributable to Parent		$ 5,298

REVISION OF PRIOR PERIOD FINA56

REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Statement of Operations (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Income tax expense (benefit) from discontinued operations	$ (2)	$ 100	$ 57
Income before tax, including income from discontinued operations		646	859
Provision (Benefit) for income tax, continuing operations and discontinued operations		97	125
Tax Adjustments, Settlements, and Unusual Provisions		(45)	(10)
Income from continuing operations before taxes	480	229	293
Provision (benefit) for income taxes	42	(3)	68
Income from continuing operations	438	232	225
Income (loss) from discontinued operations	(37)	317	509
Net income	$ 401	$ 549	$ 734
Impact of prior period tax adjustment on basic earnings per share		$ 0.14	$ 0.03
Impact of prior period tax adjustment on diluted earnings per share		0.13	0.03
Income from continuing operations, Basic	$ 1.32	0.70	0.66
Income from discontinued operations, Basic	(0.12)	0.95	1.49
Net income per share - basic	1.20	1.65	2.15
Income from continuing operations, Diluted	1.31	0.69	0.65
Income from discontinued operations, Diluted	(0.11)	0.93	1.48
Net income per share - diluted	$ 1.20	$ 1.62	$ 2.13
Total comprehensive income	$ 12	$ 124	$ 936
As Previously Reported
Provision (Benefit) for income tax, continuing operations and discontinued operations		142	135
Net income		$ 504	$ 724
Net income per share - basic		$ 1.51	$ 2.12
Net income per share - diluted		$ 1.49	$ 2.10
Total comprehensive income		$ 79	$ 926

REVISION OF PRIOR PERIOD FINA57

REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Statement of Cash Flows (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Net income	$ 401	$ 549	$ 734
Tax Adjustments, Settlements, and Unusual Provisions		45	10
Deferred taxes	70	(192)	(4)
Impact of tax adjustment on deferred taxes		(60)	(35)
Other assets and liabilities	$ (262)	(45)	8
Impact of prior period tax adjustment on other assets and liabilities		15	25
As Previously Reported
Net income		504	724
Deferred taxes		(132)	31
Other assets and liabilities		$ (60)	$ (17)

DISCONTINUED OPERATIONS DISCONT

DISCONTINUED OPERATIONS DISCONTINUED OPERATIONS-Textual (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013	Nov. 01, 2014
Discontinued Operations and Disposal Groups [Abstract]
Accumulated other comprehensive loss transferred to discontinued operations				$ 332
Separation transaction costs	$ 39	$ 178
Cash per separation agreement				700
Net Transfer To Subsidiaries	734	$ 0	$ 0
Additional paid in capital transferred to discontinued operations				$ 28
Future transition service income	12
Future yearly lease income	13
Transition service and lease income	$ 25

DISCONTINUED OPERATIONS - State

DISCONTINUED OPERATIONS - Statement of Operations (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Discontinued Operations and Disposal Groups [Abstract]
Net revenue	$ 0	$ 2,933	$ 2,888
Cost and expenses	39	2,521	2,323
Operating income (loss)	(39)	412	565
Other income (expense), net	0	5	1
Income (loss) from discontinued operations before tax	(39)	417	566
Provision (benefit) for income taxes	(2)	100	57
Net Income (loss) from discontinued operations	$ (37)	$ 317	$ 509

DISCONTINUED OPERATIONS DISCO60

DISCONTINUED OPERATIONS DISCONTINUED OPERATIONS - Assets and Liabilities (Details) - USD ($) $ in Millions	Oct. 31, 2015	Oct. 31, 2014
Assets [Abstract]
Cash and cash equivalents		$ 810
Accounts receivable, net		357
Inventory		498
Other current assets		163
Current assets of discontinued operations	$ 0	1,828
Property, plant and equipment		470
Goodwill		392
Other intangible assets, net		18
Long term investments		63
Other assets		212
Non-current assets of discontinued operations	0	1,155
Total assets of discontinued operation		2,983
Liabilities [Abstract]
Accounts payable		173
Employee compensation and benefit		167
Deferred revenue		175
Other accrued liabilities		108
Current liabilities of discontinued operations	0	623
Long term debt		1,099
Retirement and post retirement benefits		213
Other long term liabilities		122
Long-term liabilities of discontinued operations	$ 0	1,434
Total liabilities of discontinued operations		$ 2,057

SHARE-BASED COMPENSATION Genera

SHARE-BASED COMPENSATION General Disclosures (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Employee stock purchase plan [Abstract]
Compensation percentage maximum eligible contribution to purchase shares of common stock	10.00%
ESPP eligible employee common stock purchase price ratio	85.00%
Automatic annual increase in shares authorized for issuance in ESPP, without the Board of Directors determined amount, percentage (in hundredths)	1.00%
Maximum number of shares issued under the ESPP (in shares)	75,000,000
ESPP Employee purchased shares (in shares)	346,472	1,604,406	1,454,724
ESPP employee purchases	$ 12	$ 73	$ 48
Common stock shares authorized and available for issuance under our ESPP (in shares)	42,605,407
Incentive compensation plans [Abstract]
Common stock issuable under the 2009 Plan (in shares)	25,000,000
Term of the 2009 Stock Plan (in years)	ten years
Common stock available for future awards under the 2009 Stock Plan (in shares)	13,524,407
Percentage which rate options generally vest per year (in hundredths)	25.00%
Number of years from the date of grant generally vest (in years)	4 years
Maximum contractual term (in years)	10 years
Percentage market value of the common stock option exercise price is generally not less than (in hundredths)	100.00%
Minimum final share award percentage of the target award based on performance metrics (in hundredths)	0.00%
Maximum final share award percentage of the target award based on performance metrics (in hundredths)	200.00%
Time period after which participants of the performance stock award plan are entitled to receive unrestricted share of the company's stock, if specified performance targets are met	3 years
Percentage rate restricted stock units generally vest per year (in hundredths)	25.00%
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vesting Period By Year	4 years

SHARE-BASED COMPENSATION Alloca

SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	12 Months Ended
	Jan. 31, 2014	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Share-based compensation expense		$ 55	$ 98	$ 88
Share-based compensation disclosures
Windfall tax benefit reversal due to IRS settlement	$ 11		(11)
Windfall income tax benefit realized from excercised from stock options and similar awards		8	1	2
Incremental expense for the acceleration of share-based compensation related to the announced workforce reduction plan		$ 2	$ 1	$ 2
Time period which employees have to exercise options related to the workforce reduction before such options are cancelled (in months)		3 months
Weighted per share average grant date fair value of options granted (per share)		$ 10.58	$ 18.73	$ 12.18
Cost of Products and Services [Member]
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Share-based compensation expense		$ 11	$ 13	$ 12
Research and Development
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Share-based compensation expense		5	7	5
Selling, General and Administrative
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Share-based compensation expense		39	39	34
Continuing Operations [Member]
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Share-based compensation expense		55	59	51
Discontinued Operations [Member]
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Share-based compensation expense		$ 0	$ 39	$ 37

SHARE-BASED COMPENSATION-Fair V

SHARE-BASED COMPENSATION-Fair Value Assumptions (Details)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average risk-free interest rate (in hundredths)	1.75%	1.69%	0.86%
Dividend yield (in hundredths)	1.00%	1.00%	1.00%
Weighted average volatility (in hundredths)	28.00%	39.00%	39.00%
Expected life (in years)	5 years 6 months	5 years 9 months 19 days	5 years 9 months 19 days
LTPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility of Agilent shares (in hundredths)	25.00%	36.00%	37.00%
Volatility of selected peer-company shares minimum (in hundredths)	12.00%	13.00%	6.00%
Volatility of selected peer-company shares maximum (in hundredths)	57.00%	57.00%	64.00%
Price-wise correlation with selected peers (in hundredths)	37.00%	47.00%	49.00%

SHARE-BASED COMPENSATION Stock

SHARE-BASED COMPENSATION Stock Option Activity (Details) - $ / shares shares in Thousands	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding, beginning balance (in shares)	6,584
Granted (in shares)	1,347
Exercised (in shares)	(1,925)
Options Cancelled/Forfeited/Expired (in shares)	(294)
Outstanding, ending balance (in shares)	5,712	6,584
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted-average exercise price per share, beginning of period (in dollars per share)	$ 27
Weighted-average exercise price per share, granted (in dollars per share)	41
Weighted-average exercise price per share, exercised (in dollars per share)	24	$ 30	$ 28
Weighted-average exercise price per share, cancelled, expired and forfeited (in dollars per shares)	35
Weighted-average exercise price per share, end of period (in dollars per share)	$ 31
Forfeited and expired options from total cancellations [Abstract]
Forfeited (in shares)	277
Expired (in shares)	17
Options Cancelled/Forfeited/Expired (in shares)	294
Share-based Compensation Arrangement by Share-based Payment Award, Options forfeited and expired, Additional Disclosures [Abstract]
Weighted-average exercise price per share, forfeited (in dollars per share)	$ 36
Weighted-average exercise price per share, expired (in dollars per share)	20
Weighted-average exercise price per share, total options cancelled (in dollars per share)	$ 35

SHARE-BASED COMPENSATION Shares

SHARE-BASED COMPENSATION Shares Authorized by Exercise Price Range (Details) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Oct. 31, 2015USD ($)yr$ / sharesshares	Oct. 31, 2014USD ($)$ / shares	Oct. 31, 2013USD ($)$ / shares
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]
Number Outstanding (in shares) | shares	5,712
Weighted Average Remaining Contractual Life (in years)	6 years 2 months
Weighted Average Exercise Price (in dollars per share)	$ 31
Aggregate Intrinsic Value | $	$ 46,377
Number Exercisable (in shares) | shares	2,896
Weighted Average Remaining Contractual Life (in years)	4 years 4 months
Weighted Average Exercise Price (in dollars per share)	$ 25
Aggregate Intrinsic Value | $	$ 36,418
Closing stock price basis for aggregate intrinsic value (in dollars per share)	$ 37.76
In-the-money awards exercisable (in shares) | shares	2,700
Aggregate instrinsic value of options [Abstract]
Options exercised in period aggregate intrinsic value | $	$ 33,258	$ 98,075	$ 71,499
Options exercised in period aggregate weighted average exercise price (in dollars per share)	$ 24	$ 30	$ 28
Black-Scholes valuation of options granted in the period (in dollars per share)	$ 10.58	$ 18.73	$ 12.18
Unrecognized share-based compensation costs for outstanding stock option awards, net of expected foreitures | $	$ 5,000
Weighted-average period unrecognized share-based compensation costs for outstanding stock option awards, expected amortization period (in years) | yr	2
Amount of cash received from the exercise of share-based awards granted | $	$ 58,000	$ 188,000	$ 161,000
Range of Exercise Prices - $0 - $25 [Member]
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]
Minimum price of options outstanding, end of the period (in dollars per share)	$ 0
Maximum price of options outstanding, end of the period (in dollars per share)	$ 25
Number Outstanding (in shares) | shares	1,120
Weighted Average Remaining Contractual Life (in years)	1 year 11 months
Weighted Average Exercise Price (in dollars per share)	$ 21
Aggregate Intrinsic Value | $	$ 18,873
Number Exercisable (in shares) | shares	1,120
Weighted Average Remaining Contractual Life (in years)	1 year 11 months
Weighted Average Exercise Price (in dollars per share)	$ 21
Aggregate Intrinsic Value | $	$ 18,873
Range of Exercise Prices - $25.01 - $30 [Member]
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]
Minimum price of options outstanding, end of the period (in dollars per share)	$ 25.01
Maximum price of options outstanding, end of the period (in dollars per share)	$ 30
Number Outstanding (in shares) | shares	2,425
Weighted Average Remaining Contractual Life (in years)	6 years 1 month
Weighted Average Exercise Price (in dollars per share)	$ 26
Aggregate Intrinsic Value | $	$ 27,504
Number Exercisable (in shares) | shares	1,539
Weighted Average Remaining Contractual Life (in years)	5 years 8 months
Weighted Average Exercise Price (in dollars per share)	$ 26
Aggregate Intrinsic Value | $	$ 17,545
Range of Exercise Prices - $30.01 - $40 [Member]
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]
Minimum price of options outstanding, end of the period (in dollars per share)	$ 30.01
Maximum price of options outstanding, end of the period (in dollars per share)	$ 40
Number Outstanding (in shares) | shares	921
Weighted Average Remaining Contractual Life (in years)	8 years 1 month
Weighted Average Exercise Price (in dollars per share)	$ 39
Aggregate Intrinsic Value | $	$ 0
Number Exercisable (in shares) | shares	224
Weighted Average Remaining Contractual Life (in years)	8 years 1 month
Weighted Average Exercise Price (in dollars per share)	$ 39
Aggregate Intrinsic Value | $	$ 0
Range of Exercise Prices $40.01 & Over [Member]
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]
Minimum price of options outstanding, end of the period (in dollars per share)	$ 40.01
Number Outstanding (in shares) | shares	1,246
Weighted Average Remaining Contractual Life (in years)	9 years 1 month
Weighted Average Exercise Price (in dollars per share)	$ 41
Aggregate Intrinsic Value | $	$ 0
Number Exercisable (in shares) | shares	13
Weighted Average Remaining Contractual Life (in years)	8 years 7 months
Weighted Average Exercise Price (in dollars per share)	$ 41
Aggregate Intrinsic Value | $	$ 0

SHARE-BASED COMPENSATION Non-ve

SHARE-BASED COMPENSATION Non-vested award activity disclosure (Details) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Oct. 31, 2015USD ($)yr$ / sharesshares	Oct. 31, 2014USD ($)shares	Oct. 31, 2013USD ($)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested beginning (in shares) | shares	2,750
Granted (in shares) | shares	955
Vested (in shares) | shares	(1,016)
Forfeited (in shares) | shares	(159)
Change in LTPP shares vested in the year due to performance conditions | shares	(113)
Non-vested ending (in shares) | shares	2,417	2,750
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Non-vested at October 31, 2014 -Weighted Average Grant Price (in dollars per share) | $ / shares	$ 32
Granted - Weighted Average Grant Price (in dollars per share) | $ / shares	42
Vested- Weighted Average Grant Price (in dollars per share) | $ / shares	30
Foreited- Weighted Average Grant Price (in dollars per share) | $ / shares	36
Change in LTPP shares vested in the year due to performance conditions Fair Value | $ / shares	0
Non-vested at October 31, 2015 -Weighted Average Grant Price (in dollars per share) | $ / shares	$ 36
Unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures | $	$ 32
Weighted-average period non-vested restricted stock awards are expected to be amortized over (in years) | yr	2.3
Total fair value of restricted stock awards vested | $	$ 31	$ 54	$ 44

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Operating Loss Carryforwards [Line Items]
Net Discrete Tax Expense (Benefit)	$ (55)
Other Tax Expense (Benefit)	23	$ 13
IRS Audit Settlement and Repatriation of Dividends [Member]
Operating Loss Carryforwards [Line Items]
Other Tax Expense (Benefit)	(32)	$ (33)
De-registration of certain foreign branches [Member]
Operating Loss Carryforwards [Line Items]
Other Tax Expense (Benefit)	(16)
U.S. Research & Development Tax Credit Extension [Member]
Operating Loss Carryforwards [Line Items]
Other Tax Expense (Benefit)	(6)
Discrete tax benefit [Member]
Operating Loss Carryforwards [Line Items]
Other Tax Expense (Benefit)	$ (1)

INCOME TAXES INCOME TAXES- Prov

INCOME TAXES INCOME TAXES- Provision (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Income from continuing operations before income tax
U.S. operations	$ 77	$ (72)	$ 5
Non-U.S. operations	403	301	288
Income from continuing operations before taxes	480	229	293
Provision (benefit) for income taxes
U.S. federal taxes - current	(91)	17	13
U.S. federal taxes - deferred	97	(80)	3
Non-U.S. taxes - current	62	176	88
Non-U.S. taxes - deferred	(27)	(111)	(43)
State taxes, net of federal benefit - current	1	0	2
State taxes, net of federal benefit - deferred	0	(5)	5
Income tax expense (benefit)	42	(3)	68
Effective Income Tax Rate Reconciliation
Profit before tax times statutory rate	167	80	103
State income taxes, net of federal benefit	(8)	(7)	5
Non-U.S. income taxed at different rates	(72)	(39)	(34)
Change in unrecognized U.S. tax benefits	(116)	(111)	0
Repatriation of foreign earnings	68	75	0
Valuation allowances	(2)	2	(8)
Transfer pricing adjustment for prior years	0	0	8
Adjustment to income tax payable	0	(6)	0
Other, net	$ 5	$ 3	$ (6)
Effective tax rate (in hundredths)	8.70%	(1.30%)	23.40%
Impact of the tax holidays decreased in income taxes	$ 65	$ 27	$ 44
The benefit of the tax holidays on net income per share (diluted)	$ 0.19	$ 0.08	$ 0.13

INCOME TAXES INCOME TAXES - Def

INCOME TAXES INCOME TAXES - Deferred Taxes and other(Details) - USD ($) $ in Millions	Oct. 31, 2015	Oct. 31, 2014
Income Tax Disclosure [Abstract]
The cumulative amount of undistributed earnings considered indefinitely reinvested	$ 5,000
Unrecognized deferred tax benefits, stock option plans not yet realized through reduction in income taxes payable	193
Cumulative excess tax benefit realized for shared based awards	28
Components of Deferred Tax Assets
Inventory	13	$ 18
Intangibles	0	0
Property, plant and equipment	17	18
Warranty reserves	11	9
Pension benefits and retiree medical	93	85
Employee benefits, other than retirement	26	27
Net operating loss, capital loss and credit carryforwards	173	176
Unremitted earnings of foreign subsidiaries	0	0
Share-based compensation	39	41
Deferred revenue	41	41
Other	4	9
Subtotal	417	424
Tax valuation allowance	(131)	(134)
Total deferred tax assets	286	290
Components of Deferred Tax Liabilities
Inventory	0	0
Intangibles	95	142
Property, plant and equipment	0	0
Warranty reserves	0	0
Pension benefits and retiree medical benefits	0	0
Employee benefits, other than retirement	0	0
Net operating loss, capital loss and credit carryforwards	0	0
Unremmitted earnings of foreign subsidiaries	33	44
Share-based compensation	0	0
Deferred revenue	0	0
Other	0	3
Subtotal	128	189
Tax valuation allowance	0	0
Total deferred tax liabilities	128	189
Current And Long Term Deferred Tax Assets And Liabilities [Abstract]
Current deferred tax assets (included within other current assets)	84	88
Long-term deferred tax assets (included within other assets)	180	145
Current deferred tax liabilities (included within other accrued liabilities)	(10)	(7)
Long-term deferred tax liabilities (included within other long-term liabilities)	(96)	(125)
Total	158	$ 101
Net Operating loss carryforwards
Federal net operating loss carryforwards	7
Tax credit carryforwards	0
State net operating loss carryforwards	228
State tax credit carryforwards that do not expire	36
Foreign net operating loss carryforwards	358
Portion of this foreign loss which will expire in years beginning 2016 through 2024	234
Balance of this foreign loss with an indefinite life	$ 124

INCOME TAXES INCOME TAXES - Ass

INCOME TAXES INCOME TAXES - Assets and liabilities and Uncertain Tax Positions (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Operating Loss Carryforwards [Line Items]
Income Tax Expense (Benefit)	$ (42)	$ 3	$ (68)
Interest and penalties accrued related to unrecognized tax benefits accrued and reported	24	29
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	269
Current and Long-term Income Tax Assets and Liabilities
Current income tax assets (included within other current assets)	104	82
Long-term income tax assets (included within other assets)	20	45
Current income tax liabilities (included within other accrued liabilities)	(62)	(100)
Long-term income tax liabilities (included within other long-term liabilities)	(227)	(285)
Total	(165)	(258)
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued [Abstract]
Balance, beginning of year	417	512	457
Additions for tax positions related to the current year	33	45	52
Additions for tax positions from prior years	3	11	15
Reductions for tax positions from prior years	156	141	6
Settlements with taxing authorities	(4)	(2)	(3)
Statute of limitations expirations	(4)	(8)	(3)
Balance, end of year	289	417	512
Tax Interest and Penalties [Member]
Operating Loss Carryforwards [Line Items]
Income Tax Expense (Benefit)	$ 2	$ 10	$ 5

INCOME TAXES INCOME TAXES - Tra

INCOME TAXES INCOME TAXES - Transferred to Keysight (Details) - USD ($) $ in Millions	Oct. 31, 2015	Nov. 01, 2014	Oct. 31, 2014
Deferred Tax Assets and Liabilities
Deferred tax assets	$ 417		$ 424
Deferred tax liabilities	128		189
Income tax payable transferred	$ 165		$ 258
Keysight Spin-off [Member]
Deferred Tax Assets and Liabilities
Deferred tax assets		$ 237
Deferred tax liabilities		37
Income tax payable transferred		40
Other long-term liabilities transferred		8
Prepaid taxes transferred		19
prepaid taxes long term transferred		$ 3

INCOME TAXES INCOME TAXES - Tax

INCOME TAXES INCOME TAXES - Tax Examination (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Income Tax Examination [Line Items]
Reductions for tax positions from prior years	$ 156	$ 141	$ 6
Internal Revenue Service (IRS) [Member]
Income Tax Examination [Line Items]
Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority	9
Reductions for tax positions from prior years	119	111
Tax liability on foreign earnings distributions	99	$ 75
Settlement with Taxing Authority [Member]
Income Tax Examination [Line Items]
Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority	12
Prepaid Tax on Settlement [Member]
Income Tax Examination [Line Items]
Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority	$ 3

NET INCOME (LOSS) PER SHARE (De

NET INCOME (LOSS) PER SHARE (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Antidilutive securities excluded from EPS computation
Income from continuing operations	$ 438	$ 232	$ 225
Income (loss) from discontinued operations	(37)	317	509
Net income	$ 401	$ 549	$ 734
Denominator:
Basic weighted average shares	333,000,000	333,000,000	341,000,000
Potential common shares - stock options and other employeee stock plans	2,000,000	5,000,000	4,000,000
Diluted weighted average shares	335,000,000	338,000,000	345,000,000
Total number of share-based awards issued (in shares)	3,000,000	6,000,000	6,000,000
Options with exercise price greater than average market price [Member]
Antidilutive securities excluded from EPS computation
Antidilutive shares excluded from EPS computation (in shares)	1,200,000	1,500	4,200
Stock Options, LTPP and restricted stock combined exercise price, unamortized fair value, excess tax benefits or shortfalls greater than average market price [Member]
Antidilutive securities excluded from EPS computation
Antidilutive shares excluded from EPS computation (in shares)	368,900	383,200	18,300

SUPPLEMENTAL CASH FLOW INFORM74

SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Supplemental Cash Flow Information [Abstract]
Net cash paid for income taxes	$ 129	$ 131	$ 110
Cash paid for interest	$ 71	$ 142	$ 112

INVENTORY (Details)

INVENTORY (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Inventory [Line Items]
Finished goods	$ 362	$ 366
Purchased parts and fabricated assemblies	179	208
Inventory	541	574
Inventory-related excess and obsolescence charges	30	79	$ 48
Continuing Operations [Member]
Inventory [Line Items]
Inventory-related excess and obsolescence charges	$ 30	$ 46	$ 27

PROPERTY, PLANT AND EQUIPMENT76

PROPERTY, PLANT AND EQUIPMENT, NET (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Property, Plant and Equipment [Line Items]
Land	$ 53	$ 58
Buildings and leasehold improvements	705	714
Machinery and equipment	401	443
Software	168	154
Total property, plant and equipment	1,327	1,369
Accumulated depreciation and amortization	(723)	(738)
Property, plant and equipment, net	604	631
Asset impairments other than restructuring	0	0	$ 3
Depreciation expense	98	$ 120	$ 116
NMR [Member]
Property, Plant and Equipment [Line Items]
Asset impairments other than restructuring	$ 7

GOODWILL AND OTHER INTANGIBLE77

GOODWILL AND OTHER INTANGIBLE ASSETS Roll forward (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Goodwill - Rollforward
Beginning Balance	$ 2,507	$ 2,628
Foreign currency translation impact	(196)	(121)
Goodwill arising from acquisitions	55	0
Ending Balance	2,366	2,507
Life Sciences and Applied Markets [Member]
Goodwill - Rollforward
Beginning Balance	668	626
Foreign currency translation impact	(18)	42
Goodwill arising from acquisitions	0
Ending Balance	650	668
Diagnostics and Genomics [Member]
Goodwill - Rollforward
Beginning Balance	1,345	1,546
Foreign currency translation impact	(166)	(201)
Goodwill arising from acquisitions	55
Ending Balance	1,234	1,345
Agilent CrossLab [Member]
Goodwill - Rollforward
Beginning Balance	494	456
Foreign currency translation impact	(12)	38
Goodwill arising from acquisitions	0
Ending Balance	$ 482	$ 494

GOODWILL AND OTHER INTANGIBLE78

GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Other Intangibles (Details) - USD ($) $ in Millions	Oct. 31, 2015	Oct. 31, 2014
Schedule of Other Intangible Assets By Major Class [Abstract]
Gross Carrying Amount	$ 1,117	$ 1,415
Accumulated Amortization	694	784
Total amortizable intangible assets	423	631
Gross Book Value	1,139	1,433
In-Process R&D	22	18
Net Book Value	445	649
Purchased technology
Schedule of Other Intangible Assets By Major Class [Abstract]
Gross Carrying Amount	746	880
Accumulated Amortization	476	475
Net Book Value	270	405
Trademarks/Tradename [Member]
Schedule of Other Intangible Assets By Major Class [Abstract]
Gross Carrying Amount	141	167
Accumulated Amortization	50	52
Net Book Value	91	115
Customer Relationships [Member]
Schedule of Other Intangible Assets By Major Class [Abstract]
Gross Carrying Amount	230	368
Accumulated Amortization	168	257
Net Book Value	$ 62	$ 111

GOODWILL AND OTHER INTANGIBLE79

GOODWILL AND OTHER INTANGIBLE ASSETS Finite-Lived Assets and Future Amortization Expense (Details) $ in Millions	12 Months Ended
	Oct. 31, 2015USD ($)acquisition	Oct. 31, 2014USD ($)	Oct. 31, 2013USD ($)
Goodwill [Line Items]
Goodwill, Impairment Loss	$ 0	$ 0	$ 0
Goodwill arising from acquisitions	$ 55	0
Number of acquisitions or business purchases | acquisition	1
Additions and adjustments to other intangibles	$ 13	0
Foreign exchange translation impact to other intangible assets	(58)
Fully amortized intangible assets removed	246
Impairment of other intangibles related to cancellation of IPRD project	3	4	0
Amortization Expense, Maturity Schedule [Abstract]
Amortization of intangible assets during the period	156	189	$ 190
Future amortization expense for 2016	131
Future amortization expense for 2017	92
Future amortization expense for 2018	61
Future amortization expense for 2019	47
Future amortization expense for 2020	36
Future amortization thereafter	$ 56
NMR [Member]
Goodwill [Line Items]
Impairment of other intangible assets, NMR business		12
NMR Asset impairment
Goodwill [Line Items]
Impairment of other intangible assets, NMR business		$ 12

INVESTMENTS (Details)

INVESTMENTS (Details) $ in Millions	12 Months Ended
	Oct. 31, 2015USD ($)funds	Oct. 31, 2014USD ($)	Oct. 31, 2013USD ($)
Long-Term [Abstract]
Cost method investments	$ 23	$ 25
Trading securities	35	35
Equity Method Investments	28	36
Total	$ 86	96
Number of special funds included in cost method investments | funds	2
Amounts included in other income (expense), net [Abstract]
Equity method investments - share of losses	$ 9	7	$ (2)
Net unrealized gains and losses on trading securities	$ 2	$ 2	$ 6

FAIR VALUE MEASUREMENTS, Fair v

FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Millions	Oct. 31, 2015	Oct. 31, 2014
Assets, Short-term [Abstract]
Cash equivalents (money market funds)	$ 1,411	$ 1,117
Derivative instruments (foreign exchange and interest rate swap contracts)	4	10
Assets, Long-term [Abstract]
Trading securities	35	35
Total assets measured at fair value	1,450	1,162
Liabilities, Short-term [Abstract]
Derivative instruments (foreign exchange contracts)	5	4
Liabilities, Long-term [Abstract]
Deferred compensation liability	35	35
Total liabilities measured at fair value	40	39
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets, Short-term [Abstract]
Cash equivalents (money market funds)	1,411	1,117
Derivative instruments (foreign exchange and interest rate swap contracts)	0	0
Assets, Long-term [Abstract]
Trading securities	35	35
Total assets measured at fair value	1,446	1,152
Liabilities, Short-term [Abstract]
Derivative instruments (foreign exchange contracts)	0	0
Liabilities, Long-term [Abstract]
Deferred compensation liability	0	0
Total liabilities measured at fair value	0	0
Significant Other Observable Inputs (Level 2) [Member]
Assets, Short-term [Abstract]
Cash equivalents (money market funds)	0	0
Derivative instruments (foreign exchange and interest rate swap contracts)	4	10
Assets, Long-term [Abstract]
Trading securities	0	0
Total assets measured at fair value	4	10
Liabilities, Short-term [Abstract]
Derivative instruments (foreign exchange contracts)	5	4
Liabilities, Long-term [Abstract]
Deferred compensation liability	35	35
Total liabilities measured at fair value	40	39
Significant Unobservable Inputs (Level 3) [Member]
Assets, Short-term [Abstract]
Cash equivalents (money market funds)	0	0
Derivative instruments (foreign exchange and interest rate swap contracts)	0	0
Assets, Long-term [Abstract]
Trading securities	0	0
Total assets measured at fair value	0	0
Liabilities, Short-term [Abstract]
Derivative instruments (foreign exchange contracts)	0	0
Liabilities, Long-term [Abstract]
Deferred compensation liability	0	0
Total liabilities measured at fair value	$ 0	$ 0

FAIR VALUE MEASUREMENTS FAIR VA

FAIR VALUE MEASUREMENTS FAIR VALUE MEASURMENTS - Fair value of assets and liabilities measured on non recurring (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-lived assets held and used	$ 3	$ 23	$ 1
Long-lived assets held for sale			3
Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-lived assets held and used	0	0	0
Long lived assets held for use impairment	3	23	1
Long-lived assets held for sale			2
Long lived assets held for sale Impairment	$ 0	0	$ 1
NMR [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long lived assets held for use impairment		19
In Process Research and Development [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long lived assets held for use impairment		$ 4

DERIVATIVES (Details)

DERIVATIVES (Details) $ in Millions	Oct. 20, 2014USD ($)	Oct. 31, 2015USD ($)contracts	Oct. 31, 2014USD ($)	Oct. 31, 2013USD ($)	Jul. 01, 2012USD ($)	Aug. 09, 2011USD ($)contracts	Jul. 13, 2010USD ($)	Nov. 25, 2008USD ($)contracts	Oct. 24, 2007USD ($)
Terminated Interest Rate Swaps
Accelerated amortization of interest rate swap gain		$ 0	$ 22	$ 0
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative, Net Liability Position, Aggregate Fair Value		$ 2
Derivative Contracts [Abstract]
Number Of Foreign Exchange Forward Contracts Designated As Cash Flow Hedge | contracts		53
Number Of Foreign Exchange Forward Contracts Not Designated As Hedges | contracts		170
Treasury Lock [Member] | Cash Flow Hedges
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative, Notional Amount					$ 400
Remaining gain loss to be amortized on derivative		$ 2
Senior Notes 2017 [Member]
Terminated Interest Rate Swaps
Notional Amount of Terminated Interest Rate Swaps								$ 400
Asset Value of Terminated Interest Rate Swaps								$ 43
Terminated Interest Rate Fair Value Hedge Asset Unamortized Amount		2
Senior Notes 2020 [Member]
Terminated Interest Rate Swaps
Notional Amount of Terminated Interest Rate Swaps						$ 500
Asset Value of Terminated Interest Rate Swaps						$ 34
Terminated Interest Rate Fair Value Hedge Asset Unamortized Amount		19
Senior Notes 2020 [Member]
Terminated Interest Rate Swaps
Number of Interest Rate Swap Contracts Designated as Fair Value Hedges Terminated | contracts						5
Terminated Interest Rate Fair Value Hedge Asset Unamortized Amount		19
Debt Instrument, Face Amount						$ 500	$ 500
Senior Notes 2017 [Member]
Terminated Interest Rate Swaps
Number of Interest Rate Swap Contracts Designated as Fair Value Hedges Terminated | contracts								2
Notional Amount of Terminated Interest Rate Swaps								$ 400
Terminated Interest Rate Fair Value Hedge Asset Unamortized Amount		2
Accelerated amortization of interest rate swap gain	$ 14
Extinguishment of Debt, Amount	500
Debt Instrument, Face Amount	$ 600	$ 100							$ 600

DERIVATIVES, Disclosures and de

DERIVATIVES, Disclosures and derivative instrument aggregated notional amounts by currency and designations (Details) $ in Millions	Oct. 31, 2015USD ($)
Buy | Forward Contracts Buy/(Sell) [Member] | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Derivative, Notional Amount	$ 201
Buy | Euro Member Countries, Euro | Forward Contracts Buy/(Sell) [Member] | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Derivative, Notional Amount	186
Buy | Australia, Dollars | Forward Contracts Buy/(Sell) [Member] | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Derivative, Notional Amount	13
Buy | Australia, Dollars | Cash Flow Hedges | Forward Contracts Buy/(Sell) [Member]
Derivative [Line Items]
Derivative, Notional Amount	10
Buy | United States of America, Dollars | Forward Contracts Buy/(Sell) [Member] | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Derivative, Notional Amount	0
Buy | United States of America, Dollars | Forward Contracts DKK [Member] | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Derivative, Notional Amount	33
Buy | United States of America, Dollars | Cash Flow Hedges | Forward Contracts Buy/(Sell) [Member]
Derivative [Line Items]
Derivative, Notional Amount	0
Buy | Malaysia, Ringgits | Forward Contracts DKK [Member] | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Derivative, Notional Amount	0
Buy | Malaysia, Ringgits | Cash Flow Hedges | Forward Contracts Buy/(Sell) [Member]
Derivative [Line Items]
Derivative, Notional Amount	0
Buy | Other Currency | Forward Contracts Buy/(Sell) [Member] | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Derivative, Notional Amount	21
Sell | Forward Contracts DKK [Member] | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Derivative, Notional Amount	46
Sell | Cash Flow Hedges | Forward Contracts Buy/(Sell) [Member]
Derivative [Line Items]
Derivative, Notional Amount	116
Sell | Euro Member Countries, Euro | Forward Contracts DKK [Member] | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Derivative, Notional Amount	60
Sell | Euro Member Countries, Euro | Cash Flow Hedges | Forward Contracts Buy/(Sell) [Member]
Derivative [Line Items]
Derivative, Notional Amount	19
Sell | United Kingdom, Pounds | Forward Contracts Buy/(Sell) [Member] | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Derivative, Notional Amount	10
Sell | United Kingdom, Pounds | Forward Contracts DKK [Member] | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Derivative, Notional Amount	4
Sell | United Kingdom, Pounds | Cash Flow Hedges | Forward Contracts Buy/(Sell) [Member]
Derivative [Line Items]
Derivative, Notional Amount	15
Sell | Canada, Dollars | Forward Contracts Buy/(Sell) [Member] | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Derivative, Notional Amount	0
Sell | Canada, Dollars | Forward Contracts DKK [Member] | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Derivative, Notional Amount	2
Sell | Canada, Dollars | Cash Flow Hedges | Forward Contracts Buy/(Sell) [Member]
Derivative [Line Items]
Derivative, Notional Amount	23
Sell | Australia, Dollars | Forward Contracts DKK [Member] | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Derivative, Notional Amount	3
Sell | Malaysia, Ringgits | Forward Contracts Buy/(Sell) [Member] | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Derivative, Notional Amount	4
Sell | Japan, Yen | Forward Contracts Buy/(Sell) [Member] | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Derivative, Notional Amount	5
Sell | Japan, Yen | Forward Contracts DKK [Member] | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Derivative, Notional Amount	1
Sell | Japan, Yen | Cash Flow Hedges | Forward Contracts Buy/(Sell) [Member]
Derivative [Line Items]
Derivative, Notional Amount	67
Sell | Other Currency | Forward Contracts DKK [Member] | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Derivative, Notional Amount	9
Sell | Other Currency | Cash Flow Hedges | Forward Contracts Buy/(Sell) [Member]
Derivative [Line Items]
Derivative, Notional Amount	$ 2

DERIVATIVES, Fair value of deri

DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details) - USD ($) $ in Millions	Oct. 31, 2015	Oct. 31, 2014
Derivative, Fair Value, Net [Abstract]
Derivative Asset, Fair Value	$ 4	$ 10
Derivative Liability, Fair Value	5	4
Derivatives Designated as Hedging Instrument [Member]
Derivative, Fair Value, Net [Abstract]
Derivative Asset, Fair Value	2	9
Derivative Liability, Fair Value	1	1
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts [Member] | Other Current Assets [Member]
Derivative, Fair Value, Net [Abstract]
Derivative Asset, Fair Value	2	1
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts [Member] | Other Accrued Liabilities [Member]
Derivative, Fair Value, Net [Abstract]
Derivative Liability, Fair Value	4	3
Cash Flow Hedges | Derivatives Designated as Hedging Instrument [Member] | Foreign Exchange Contracts [Member] | Other Current Assets [Member]
Derivative, Fair Value, Net [Abstract]
Derivative Asset, Fair Value	2	9
Cash Flow Hedges | Derivatives Designated as Hedging Instrument [Member] | Foreign Exchange Contracts [Member] | Other Accrued Liabilities [Member]
Derivative, Fair Value, Net [Abstract]
Derivative Liability, Fair Value	$ 1	$ 1

DERIVATIVES, Effect of derivati

DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	$ 11	$ 13
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months	1
Derivatives Not Designated as Hedging Instruments | Other income (expense) [Member]
Derivative [Line Items]
Gain (loss) recognized in income statement	(21)	(20)	$ 10
Cash Flow Hedges | Derivatives Designated as Hedging Instrument [Member] | Foreign Exchange Contracts [Member] | Cost of Sales [Member]
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from OCI into Income, Effective Portion, Net	18	(1)	13
Cash Flow Hedges | Derivatives Designated as Hedging Instrument [Member] | Foreign Exchange Contracts [Member] | Accumulated Other Comprehensive Income (Loss) [Member]
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	$ 11	$ 13	$ 10

RESTRUCTURING AND EXIT OF NMR87

RESTRUCTURING AND EXIT OF NMR BUSINESS - Exit of NMR Business (Details) $ in Millions	12 Months Ended
	Oct. 31, 2015USD ($)Employee	Oct. 31, 2014USD ($)Employee
Restructuring Cost and Reserve
Expected Number of Positions Eliminated | Employee		300
Restructuring Reserve [Abstract]
Beginning Balance	$ 17	$ 0
Income statement expense	6	68
Asset impairment/inventory charges	(2)	(49)
Cash payments	(13)	(2)
Ending Balance	$ 8	17
Number of Employees Pending Termination | Employee	30
NMR [Member]
Restructuring Reserve [Abstract]
Income statement expense	$ 6	68
Ending Balance	8
Workforce Reduction
Restructuring Cost and Reserve
Restructuring Reserve, Accrual Adjustment	(2)
Restructuring Reserve [Abstract]
Beginning Balance	14	0
Income statement expense		16
Asset impairment/inventory charges	0	0
Cash payments	(10)	(2)
Ending Balance	2	14
Impairments of building and other assets
Restructuring Reserve [Abstract]
Beginning Balance	0	0
Income statement expense	0	19
Asset impairment/inventory charges	0	(19)
Cash payments	0	0
Ending Balance	0	0
Special charges related to inventory and other
Restructuring Reserve [Abstract]
Beginning Balance	3	0
Income statement expense	8	33
Asset impairment/inventory charges	(2)	(30)
Cash payments	(3)	0
Ending Balance	$ 6	$ 3

RESTRUCTURING AND EXIT OF NMR88

RESTRUCTURING AND EXIT OF NMR BUSINESS-Summary of restructuring by income statement location (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Income statement expense	$ 6	$ 68
Cost of Sales [Member]
Restructuring Reserve, Accrual Adjustment	(2)
Income statement expense		48
Research and Development
Income statement expense	4	5
Selling, General and Administrative
Income statement expense	$ 4	$ 15

RETIREMENT PLANS AND POST RET89

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Components (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
401(k) and other
Maximum contribution percentage of an employee's annual eligible compensation (in hundredths)	50.00%
The amount of 401(k) plan expense included in income from operations	$ 14	$ 15	$ 13
Fair value of plan assets of the DPSP for US employees	169	520
Defined benefit obligation for DPSP for US Employees	169	520
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]
Net actuarial (gain) loss	90	273
Amortization of net actuarial loss	(35)	(65)
Prior service cost (benefit)	0	0
Amortization of prior service benefit	(17)	(48)
United States Defined Benefit Plans
Net periodic benefit cost (benefit) [Abstract]
Service cost - benefits earned during the period	25	46	44
Interest cost on benefit obligation	14	34	24
Expected return on plan assets	(27)	(64)	(51)
Amortization of net actuarial loss	3	1	13
Amortization of prior service benefit	(5)	(12)	(12)
Total periodic benefit cost (benefit)	10	5	18
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]
Net actuarial (gain) loss	44	86	(122)
Amortization of net actuarial loss	(3)	(1)	(13)
Prior service cost (benefit)	0	0	0
Amortization of prior service benefit	5	12	12
Foreign currency	0	0	0
Total recognized in other comprehensive (income) loss	46	97	(123)
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss	56	102	(105)
Change in fair value of plan assets: [Roll Forward]
Balance, beginning of year	(837)	(782)
Actual return on plan assets	6	64
Employer contributions	15	30
Participants' contributions	0	0
Benefits paid	(21)	(39)
Currency impact	0	0
Balance, end of year	(347)	(837)	(782)
Change in benefit obligation: [Roll Forward]
Balance, beginning of year	(889)	(763)
Service cost	25	46	44
Interest cost	14	34	24
Participants' contributions	0	0
Plan amendment	0	0
Actuarial (gain) loss	23	85
Benefits paid	(22)	(39)
Currency impact	0	0
Balance, end of year	(415)	(889)	(763)
Funded status of plan [Abstract]
Funded status of plan	(68)	(52)
Amounts recognized in the consolidated balance sheet
Net asset (liability)	(68)	(52)
Non-U.S. Defined Benefit Plans
Net periodic benefit cost (benefit) [Abstract]
Service cost - benefits earned during the period	18	36	36
Interest cost on benefit obligation	23	74	68
Expected return on plan assets	(42)	(118)	(97)
Amortization of net actuarial loss	25	48	55
Amortization of prior service benefit	0	(1)	(1)
Total periodic benefit cost (benefit)	24	39	61
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]
Net actuarial (gain) loss	32	173	(85)
Amortization of net actuarial loss	(25)	(48)	(55)
Prior service cost (benefit)	0	(2)	0
Amortization of prior service benefit	0	1	1
Foreign currency	10	(28)	2
Total recognized in other comprehensive (income) loss	17	96	(137)
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss	41	135	(76)
Change in fair value of plan assets: [Roll Forward]
Balance, beginning of year	(2,108)	(2,045)
Actual return on plan assets	53	180
Employer contributions	25	72
Participants' contributions	1	3
Benefits paid	(20)	(62)
Currency impact	(62)	(130)
Balance, end of year	(778)	(2,108)	(2,045)
Change in benefit obligation: [Roll Forward]
Balance, beginning of year	(2,344)	(2,199)
Service cost	18	36	36
Interest cost	23	74	68
Participants' contributions	1	3
Plan amendment	0	(2)
Actuarial (gain) loss	40	236
Benefits paid	(20)	(62)
Currency impact	(77)	(140)
Balance, end of year	(900)	(2,344)	(2,199)
Funded status of plan [Abstract]
Funded status of plan	(122)	(236)
Amounts recognized in the consolidated balance sheet
Net asset (liability)	(122)	(236)
United States Postretirement Benefit Plans
Net periodic benefit cost (benefit) [Abstract]
Service cost - benefits earned during the period	2	3	4
Interest cost on benefit obligation	4	12	12
Expected return on plan assets	(8)	(22)	(20)
Amortization of net actuarial loss	6	14	18
Amortization of prior service benefit	(12)	(35)	(35)
Total periodic benefit cost (benefit)	(8)	(28)	(21)
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]
Net actuarial (gain) loss	16	12	(57)
Amortization of net actuarial loss	(6)	(14)	(18)
Prior service cost (benefit)	0	0	0
Amortization of prior service benefit	12	35	35
Foreign currency	0	0	0
Total recognized in other comprehensive (income) loss	22	33	(40)
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss	14	5	(61)
Change in fair value of plan assets: [Roll Forward]
Balance, beginning of year	(284)	(288)
Actual return on plan assets	2	18
Employer contributions	0	1
Participants' contributions	0	0
Benefits paid	(8)	(23)
Currency impact	0	0
Balance, end of year	(91)	(284)	(288)
Change in benefit obligation: [Roll Forward]
Balance, beginning of year	(309)	(307)
Service cost	2	3	4
Interest cost	4	12	12
Participants' contributions	0	0
Plan amendment	0	0
Actuarial (gain) loss	11	10
Benefits paid	(8)	(23)
Currency impact	0	0
Balance, end of year	(112)	(309)	(307)
Funded status of plan [Abstract]
Funded status of plan	(21)	(25)
Amounts recognized in the consolidated balance sheet
Net asset (liability)	(21)	(25)
Continuing Operations [Member] | United States Defined Benefit Plans
Net periodic benefit cost (benefit) [Abstract]
Total periodic benefit cost (benefit)	10	2	9
Amounts recognized in the consolidated balance sheet
Other assets	0	0
Employee compensation and benefits	(2)	(1)
Retirement and post-retirement benefits	(66)	(28)
Net asset (liability)	(68)	(29)
Continuing Operations [Member] | Non-U.S. Defined Benefit Plans
Net periodic benefit cost (benefit) [Abstract]
Total periodic benefit cost (benefit)	24	27	38
Amounts recognized in the consolidated balance sheet
Other assets	26	22
Employee compensation and benefits	0	0
Retirement and post-retirement benefits	(148)	(147)
Net asset (liability)	(122)	(125)
Continuing Operations [Member] | United States Postretirement Benefit Plans
Net periodic benefit cost (benefit) [Abstract]
Total periodic benefit cost (benefit)	(8)	(14)	(11)
Amounts recognized in the consolidated balance sheet
Other assets	0	0
Employee compensation and benefits	0	0
Retirement and post-retirement benefits	(21)	(6)
Net asset (liability)	(21)	(6)
Discontinued Operations [Member] | United States Defined Benefit Plans
Net periodic benefit cost (benefit) [Abstract]
Total periodic benefit cost (benefit)	0	3	9
Change in fair value of plan assets: [Roll Forward]
Balance, beginning of year	0
Balance, end of year	(490)	0
Change in benefit obligation: [Roll Forward]
Balance, end of year	(514)
Amounts recognized in the consolidated balance sheet
Other assets	0
Employee compensation and benefits	0	(1)
Retirement and post-retirement benefits	0	(22)
Net asset (liability)	0	(23)
Discontinued Operations [Member] | Non-U.S. Defined Benefit Plans
Net periodic benefit cost (benefit) [Abstract]
Total periodic benefit cost (benefit)	0	12	23
Change in fair value of plan assets: [Roll Forward]
Balance, end of year	(1,327)
Change in benefit obligation: [Roll Forward]
Balance, end of year	(1,429)
Amounts recognized in the consolidated balance sheet
Other assets	0	0
Employee compensation and benefits	0	48
Retirement and post-retirement benefits	0	(159)
Net asset (liability)	0	(111)
Discontinued Operations [Member] | United States Postretirement Benefit Plans
Net periodic benefit cost (benefit) [Abstract]
Total periodic benefit cost (benefit)	0	(14)	$ (10)
Change in fair value of plan assets: [Roll Forward]
Balance, beginning of year	0
Balance, end of year	(187)	0
Change in benefit obligation: [Roll Forward]
Balance, beginning of year	0
Balance, end of year	(206)	0
Amounts recognized in the consolidated balance sheet
Other assets	0	0
Employee compensation and benefits	0	0
Retirement and post-retirement benefits	0	(19)
Net asset (liability)	$ 0	$ (19)
Employees hired before November 1, 2014 [Member]
401(k) and other
Maximum employer matching contribution in the 401(k) plan (in hundredths)	4.00%
Employees hired on or after November 1, 2014 [Member]
401(k) and other
Maximum employer matching contribution in the 401(k) plan (in hundredths)	6.00%

RETIREMENT PLANS AND POST RET90

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Financial Statement Location (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
United States Defined Benefit Plans
Amounts recognized in the consolidated balance sheet
Net asset (liability)	$ (68)	$ (52)
Amounts Recognized in Accumulated Other Comprehensive Income (loss): [Abstract]
Actuarial (gains) losses	(73)	(77)
Prior service costs (benefits)	(18)	(55)
Total	55	22
Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract]
Amortization of net prior service cost (benefit)	(5)
Amortization of actuarial net loss (gain)	8
Non-U.S. Defined Benefit Plans
Amounts recognized in the consolidated balance sheet
Net asset (liability)	(122)	(236)
Amounts Recognized in Accumulated Other Comprehensive Income (loss): [Abstract]
Actuarial (gains) losses	(256)	(621)
Prior service costs (benefits)	0	(4)
Total	256	617
Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract]
Amortization of net prior service cost (benefit)	0
Amortization of actuarial net loss (gain)	26
United States Postretirement Benefit Plans
Amounts recognized in the consolidated balance sheet
Net asset (liability)	(21)	(25)
Amounts Recognized in Accumulated Other Comprehensive Income (loss): [Abstract]
Actuarial (gains) losses	(49)	(118)
Prior service costs (benefits)	(40)	(149)
Total	9	$ (31)
Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract]
Amortization of net prior service cost (benefit)	(10)
Amortization of actuarial net loss (gain)	$ 10

RETIREMENT PLANS AND POST RET91

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Target Allocations (Details)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Non-U.S. Defined Benefit Plans | Real Estate Investment [Member]
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets, minimum range	0.00%
Target Allocation Percentage of Plan Assets, maximum range	6.00%
Non-U.S. Defined Benefit Plans | Cash [Member]
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets, minimum range	0.00%
Target Allocation Percentage of Plan Assets, maximum range	7.00%
Non-U.S. Defined Benefit Plans | Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets, minimum range	40.00%
Target Allocation Percentage of Plan Assets, maximum range	60.00%
Non-U.S. Defined Benefit Plans | Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets, minimum range	37.00%
Target Allocation Percentage of Plan Assets, maximum range	60.00%
Deferred Profit Sharing [Member] | Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	40.00%	40.00%	40.00%
Deferred Profit Sharing [Member] | Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	60.00%	60.00%	60.00%
United States Defined Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan Us Portfolio Equity Securities Percentage Of Alternative Investments	5.00%	5.00%	5.00%
Discount rate (in hundredths)	4.00%		3.25%
United States Defined Benefit Plans | Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	20.00%	20.00%	20.00%
United States Defined Benefit Plans | Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	80.00%	80.00%	80.00%
United States Postretirement Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan Us Portfolio Equity Securities Percentage Of Alternative Investments	5.00%	5.00%	5.00%
Discount rate (in hundredths)	4.00%		3.50%
Current medical cost trend rate (in hundredths)	8.00%	8.00%	9.00%
United States Postretirement Benefit Plans | Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	20.00%	20.00%	20.00%
United States Postretirement Benefit Plans | Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	80.00%	80.00%	80.00%
Minimum [Member] | Non-U.S. Defined Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Discount rate (in hundredths)	1.50%	1.50%	1.50%
Minimum [Member] | United States Defined Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Discount rate (in hundredths)		4.00%
Minimum [Member] | United States Postretirement Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Discount rate (in hundredths)		4.00%
Maximum [Member] | Non-U.S. Defined Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Discount rate (in hundredths)	4.00%	4.50%	4.50%
Maximum [Member] | United States Defined Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Discount rate (in hundredths)		4.50%
Maximum [Member] | United States Postretirement Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Discount rate (in hundredths)		4.25%

RETIREMENT PLANS AND POST RET92

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Fair Value of Plan Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
United States Postretirement Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	$ 91	$ 284	$ 288
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]
Balance, beginning of year	8	10
Realized gains/(losses)	(1)	1
Unrealized gains/(losses)	0	1
Purchases, sales, issuances, and settlements	(1)	(2)
Balance, end of year	6	8
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	91	284
Defined Benefit Plan, Benefit Obligation	112	309	307
United States Postretirement Benefit Plans | Cash and Cash Equivalents [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	3	6
United States Postretirement Benefit Plans | Equity Securities [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	62	217
United States Postretirement Benefit Plans | Fixed Income Funds [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	20	53
United States Postretirement Benefit Plans | Other Plan Assets [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	6	8
United States Postretirement Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	23	68
United States Postretirement Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Cash and Cash Equivalents [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	2	3
United States Postretirement Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Equity Securities [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	15	51
United States Postretirement Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Fixed Income Funds [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	6	14
United States Postretirement Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Other Plan Assets [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	0	0
United States Postretirement Benefit Plans | Significant Other Observable Inputs (Level 2) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	62	208
United States Postretirement Benefit Plans | Significant Other Observable Inputs (Level 2) [Member] | Cash and Cash Equivalents [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	1	3
United States Postretirement Benefit Plans | Significant Other Observable Inputs (Level 2) [Member] | Equity Securities [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	47	166
United States Postretirement Benefit Plans | Significant Other Observable Inputs (Level 2) [Member] | Fixed Income Funds [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	14	39
United States Postretirement Benefit Plans | Significant Other Observable Inputs (Level 2) [Member] | Other Plan Assets [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	0	0
United States Postretirement Benefit Plans | Significant Unobservable Inputs (Level 3) [Member]
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]
Transfers in (out)	0	0
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	6	8
United States Postretirement Benefit Plans | Significant Unobservable Inputs (Level 3) [Member] | Cash and Cash Equivalents [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	0	0
United States Postretirement Benefit Plans | Significant Unobservable Inputs (Level 3) [Member] | Equity Securities [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	0	0
United States Postretirement Benefit Plans | Significant Unobservable Inputs (Level 3) [Member] | Fixed Income Funds [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	0	0
United States Postretirement Benefit Plans | Significant Unobservable Inputs (Level 3) [Member] | Other Plan Assets [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	6	8
United States Defined Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	347	837	782
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]
Balance, beginning of year	14	17
Realized gains/(losses)	(1)	1
Unrealized gains/(losses)	2	2
Purchases, sales, issuances, and settlements	(2)	(4)
Balance, end of year	9	14
Projected benefit obligation and fair value of plan assets [Abstract]
Total projected benefit obligation - aggregate benefit obligation	415	889
Total accumulated benefit obligation - aggregate benefit obligation	389	826
Total projected benefit obligation - aggregate fair value of plan assets	347	837
Fair value of plan assets in excess of accumulated benefit obligation - aggregate fair value of plan assets	0
Total accumulated benefit obligation - aggregate fair value of plan assets	347	837
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	347	837
Defined Benefit Plan, Benefit Obligation	415	889	763
United States Defined Benefit Plans | Cash and Cash Equivalents [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	3	9
United States Defined Benefit Plans | Equity Securities [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	258	668
United States Defined Benefit Plans | Fixed Income Funds [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	76	145
United States Defined Benefit Plans | Other Plan Assets [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	10	15
United States Defined Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	84	199
United States Defined Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Cash and Cash Equivalents [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	1	2
United States Defined Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Equity Securities [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	61	156
United States Defined Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Fixed Income Funds [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	22	40
United States Defined Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Other Plan Assets [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	0	1
United States Defined Benefit Plans | Significant Other Observable Inputs (Level 2) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	254	624
United States Defined Benefit Plans | Significant Other Observable Inputs (Level 2) [Member] | Cash and Cash Equivalents [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	2	7
United States Defined Benefit Plans | Significant Other Observable Inputs (Level 2) [Member] | Equity Securities [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	197	512
United States Defined Benefit Plans | Significant Other Observable Inputs (Level 2) [Member] | Fixed Income Funds [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	54	105
United States Defined Benefit Plans | Significant Other Observable Inputs (Level 2) [Member] | Other Plan Assets [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	1	0
United States Defined Benefit Plans | Significant Unobservable Inputs (Level 3) [Member]
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]
Transfers in (out)	0	0
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	9	14
United States Defined Benefit Plans | Significant Unobservable Inputs (Level 3) [Member] | Cash and Cash Equivalents [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	0	0
United States Defined Benefit Plans | Significant Unobservable Inputs (Level 3) [Member] | Equity Securities [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	0	0
United States Defined Benefit Plans | Significant Unobservable Inputs (Level 3) [Member] | Fixed Income Funds [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	0	0
United States Defined Benefit Plans | Significant Unobservable Inputs (Level 3) [Member] | Other Plan Assets [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	9	14
Non-U.S. Defined Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	778	2,108	2,045
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]
Balance, beginning of year	4	0
Realized gains/(losses)	(1)	0
Unrealized gains/(losses)	0	0
Purchases, sales, issuances, and settlements	(5)	0
Balance, end of year	0	4
Projected benefit obligation and fair value of plan assets [Abstract]
Total projected benefit obligation - aggregate benefit obligation	900	2,344
Total accumulated benefit obligation - aggregate benefit obligation	859	2,263
Total projected benefit obligation - aggregate fair value of plan assets	778	2,108
Total accumulated benefit obligation - aggregate fair value of plan assets	778	2,108
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	778	2,108
Defined Benefit Plan, Benefit Obligation	900	2,344	$ 2,199
Non-U.S. Defined Benefit Plans | Cash and Cash Equivalents [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	3	10
Non-U.S. Defined Benefit Plans | Equity Securities [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	396	1,078
Non-U.S. Defined Benefit Plans | Fixed Income Funds [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	379	974
Non-U.S. Defined Benefit Plans | Other Plan Assets [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	0	46
Non-U.S. Defined Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	186	375
Non-U.S. Defined Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Cash and Cash Equivalents [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	1	3
Non-U.S. Defined Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Equity Securities [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	172	335
Non-U.S. Defined Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Fixed Income Funds [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	13	37
Non-U.S. Defined Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Other Plan Assets [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	0	0
Non-U.S. Defined Benefit Plans | Significant Other Observable Inputs (Level 2) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	592	1,712
Non-U.S. Defined Benefit Plans | Significant Other Observable Inputs (Level 2) [Member] | Cash and Cash Equivalents [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	2	7
Non-U.S. Defined Benefit Plans | Significant Other Observable Inputs (Level 2) [Member] | Equity Securities [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	224	743
Non-U.S. Defined Benefit Plans | Significant Other Observable Inputs (Level 2) [Member] | Fixed Income Funds [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	366	937
Non-U.S. Defined Benefit Plans | Significant Other Observable Inputs (Level 2) [Member] | Other Plan Assets [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	0	25
Non-U.S. Defined Benefit Plans | Significant Unobservable Inputs (Level 3) [Member]
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]
Transfers in (out)	0	4
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	0	21
Non-U.S. Defined Benefit Plans | Significant Unobservable Inputs (Level 3) [Member] | Cash and Cash Equivalents [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	0	0
Non-U.S. Defined Benefit Plans | Significant Unobservable Inputs (Level 3) [Member] | Equity Securities [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	0	0
Non-U.S. Defined Benefit Plans | Significant Unobservable Inputs (Level 3) [Member] | Fixed Income Funds [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	0	0
Non-U.S. Defined Benefit Plans | Significant Unobservable Inputs (Level 3) [Member] | Other Plan Assets [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits	0	21
Agilent CrossLab [Member] | United States Postretirement Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	187
Fair value of plan assets [Abstract]
Defined Benefit Plan, Benefit Obligation	206
Agilent CrossLab [Member] | United States Defined Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	490
Fair value of plan assets [Abstract]
Defined Benefit Plan, Benefit Obligation	514
Agilent CrossLab [Member] | Non-U.S. Defined Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	1,327
Fair value of plan assets [Abstract]
Defined Benefit Plan, Benefit Obligation	1,429
Continuing Operations [Member] | United States Postretirement Benefit Plans
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		97
Continuing Operations [Member] | United States Postretirement Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		19
Continuing Operations [Member] | United States Postretirement Benefit Plans | Significant Other Observable Inputs (Level 2) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		70
Continuing Operations [Member] | United States Postretirement Benefit Plans | Significant Unobservable Inputs (Level 3) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		8
Continuing Operations [Member] | United States Defined Benefit Plans
Projected benefit obligation and fair value of plan assets [Abstract]
Projected benefit obligation in excess of plan assets - aggregate benefit obligation	415	375
Accumulated benefit obligation in excess of fair value of plan assets - aggregate benefit obligation	389	9
Fair value of plan assets in excess of accumulated benefit obligation - aggregate benefit obligation	0	340
Projected benefit obligation in excess of fair value of plan assets - aggregate fair value of plan assets	347	347
Accumulated benefit obligation in excess of accumulated benefit obligation - aggregate fair value of plan assets	347	0
Fair value of plan assets in excess of accumulated benefit obligation - aggregate fair value of plan assets		347
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		347
Continuing Operations [Member] | United States Defined Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		73
Continuing Operations [Member] | United States Defined Benefit Plans | Significant Other Observable Inputs (Level 2) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		260
Continuing Operations [Member] | United States Defined Benefit Plans | Significant Unobservable Inputs (Level 3) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		14
Continuing Operations [Member] | Non-U.S. Defined Benefit Plans
Projected benefit obligation and fair value of plan assets [Abstract]
Projected benefit obligation in excess of plan assets - aggregate benefit obligation	771	754
Fair value of plan assets in excess of projected benefit obligation - aggregate benefit obligation	129	161
Accumulated benefit obligation in excess of fair value of plan assets - aggregate benefit obligation	732	714
Fair value of plan assets in excess of accumulated benefit obligation - aggregate benefit obligation	127	158
Projected benefit obligation in excess of fair value of plan assets - aggregate fair value of plan assets	623	607
Fair value of plan assets in excess of benefit obligation - aggregate fair value of plan assets	155	183
Accumulated benefit obligation in excess of accumulated benefit obligation - aggregate fair value of plan assets	623	607
Fair value of plan assets in excess of accumulated benefit obligation - aggregate fair value of plan assets	155	183
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		790
Continuing Operations [Member] | Non-U.S. Defined Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		200
Continuing Operations [Member] | Non-U.S. Defined Benefit Plans | Significant Other Observable Inputs (Level 2) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		586
Continuing Operations [Member] | Non-U.S. Defined Benefit Plans | Significant Unobservable Inputs (Level 3) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		4
Discontinued Operations [Member] | United States Postretirement Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	187	0
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		187
Defined Benefit Plan, Benefit Obligation	206	0
Discontinued Operations [Member] | United States Postretirement Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		49
Discontinued Operations [Member] | United States Postretirement Benefit Plans | Significant Other Observable Inputs (Level 2) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		138
Discontinued Operations [Member] | United States Postretirement Benefit Plans | Significant Unobservable Inputs (Level 3) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		0
Discontinued Operations [Member] | United States Defined Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	490	0
Projected benefit obligation and fair value of plan assets [Abstract]
Projected benefit obligation in excess of plan assets - aggregate benefit obligation	0	514
Accumulated benefit obligation in excess of fair value of plan assets - aggregate benefit obligation	0	5
Fair value of plan assets in excess of accumulated benefit obligation - aggregate benefit obligation	0	472
Projected benefit obligation in excess of fair value of plan assets - aggregate fair value of plan assets	0	490
Accumulated benefit obligation in excess of accumulated benefit obligation - aggregate fair value of plan assets	0	0
Fair value of plan assets in excess of accumulated benefit obligation - aggregate fair value of plan assets	0	490
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		490
Defined Benefit Plan, Benefit Obligation	514
Discontinued Operations [Member] | United States Defined Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		126
Discontinued Operations [Member] | United States Defined Benefit Plans | Significant Other Observable Inputs (Level 2) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		364
Discontinued Operations [Member] | United States Defined Benefit Plans | Significant Unobservable Inputs (Level 3) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		0
Discontinued Operations [Member] | Non-U.S. Defined Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	1,327
Projected benefit obligation and fair value of plan assets [Abstract]
Projected benefit obligation in excess of plan assets - aggregate benefit obligation	0	1,111
Fair value of plan assets in excess of projected benefit obligation - aggregate benefit obligation	0	318
Accumulated benefit obligation in excess of fair value of plan assets - aggregate benefit obligation	0	1,081
Fair value of plan assets in excess of accumulated benefit obligation - aggregate benefit obligation	0	310
Projected benefit obligation in excess of fair value of plan assets - aggregate fair value of plan assets	0	952
Fair value of plan assets in excess of benefit obligation - aggregate fair value of plan assets	0	366
Accumulated benefit obligation in excess of accumulated benefit obligation - aggregate fair value of plan assets	0	952
Fair value of plan assets in excess of accumulated benefit obligation - aggregate fair value of plan assets	0	366
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		1,318
Defined Benefit Plan, Benefit Obligation	$ 1,429
Discontinued Operations [Member] | Non-U.S. Defined Benefit Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		175
Discontinued Operations [Member] | Non-U.S. Defined Benefit Plans | Significant Other Observable Inputs (Level 2) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		1,126
Discontinued Operations [Member] | Non-U.S. Defined Benefit Plans | Significant Unobservable Inputs (Level 3) [Member]
Fair value of plan assets [Abstract]
Defined Benefit Plan, Assets for Plan Benefits		$ 17

RETIREMENT PLANS AND POST RET93

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Expected Benefit Payments (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2014	Oct. 31, 2015
United States Defined Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plans, Estimated Future Employer Contributions in Next Fiscal Year	$ 0
Future benefit payments [Abstract]
2,016		$ 25
2,017		26
2,018		28
2,019		30
2,020		33
2021 - 2025		177
Non-U.S. Defined Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plans, Estimated Future Employer Contributions in Next Fiscal Year	25
Future benefit payments [Abstract]
2,016		21
2,017		22
2,018		24
2,019		26
2,020		27
2021 - 2025		166
United States Postretirement Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plans, Estimated Future Employer Contributions in Next Fiscal Year	$ 1
Future benefit payments [Abstract]
2,016		8
2,017		9
2,018		8
2,019		8
2,020		8
2021 - 2025		$ 40

RETIREMENT PLANS AND POST RET94

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Assumptions (Details)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
United States Defined Benefit Plans
Assumptions used to calculate the net periodic cost
Discount rate (in hundredths)	4.00%		3.25%
Average increase in compensation levels (in hundredths)	3.50%	3.50%	3.50%
Expected long-term return on assets (in hundredths)	8.00%	8.00%	8.00%
Assumptions used to calculate the benefit obligation
Discount rate (in hundredths)	4.20%	4.00%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase	3.50%	3.50%
United States Postretirement Benefit Plans
Assumptions used to calculate the net periodic cost
Discount rate (in hundredths)	4.00%		3.50%
Expected long-term return on assets (in hundredths)	8.00%	8.00%	8.00%
Current medical cost trend rate (in hundredths)	8.00%	8.00%	9.00%
Ultimate medical cost trend rate (in hundredths)	3.50%	3.50%	3.50%
Medical cost trend rate decreases to ultimate rate in year	2,028	2,028	2,027
Assumptions used to calculate the benefit obligation
Discount rate (in hundredths)	4.00%
Current medical cost trend rate - benefit obligation (in hundredths)	7.00%	8.00%
Ultimate medical cost trend rate - benefit obligation (in hundredths)	3.50%	3.50%
Medical cost trend rate decreases to ultimate rate in year - benefit obligation	2,029	2,028
Minimum [Member] | United States Defined Benefit Plans
Assumptions used to calculate the net periodic cost
Discount rate (in hundredths)		4.00%
Minimum [Member] | Non-U.S. Defined Benefit Plans
Assumptions used to calculate the net periodic cost
Discount rate (in hundredths)	1.50%	1.50%	1.50%
Average increase in compensation levels (in hundredths)	2.50%	2.50%	2.50%
Expected long-term return on assets (in hundredths)	4.00%	4.00%	4.00%
Assumptions used to calculate the benefit obligation
Discount rate (in hundredths)	0.77%	1.50%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase	2.25%	2.50%
Minimum [Member] | United States Postretirement Benefit Plans
Assumptions used to calculate the net periodic cost
Discount rate (in hundredths)		4.00%
Assumptions used to calculate the benefit obligation
Discount rate (in hundredths)		3.75%
Maximum [Member] | United States Defined Benefit Plans
Assumptions used to calculate the net periodic cost
Discount rate (in hundredths)		4.50%
Maximum [Member] | Non-U.S. Defined Benefit Plans
Assumptions used to calculate the net periodic cost
Discount rate (in hundredths)	4.00%	4.50%	4.50%
Average increase in compensation levels (in hundredths)	3.25%	3.25%	3.00%
Expected long-term return on assets (in hundredths)	6.50%	6.50%	6.50%
Assumptions used to calculate the benefit obligation
Discount rate (in hundredths)	3.76%	4.00%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase	4.00%	3.25%
Maximum [Member] | United States Postretirement Benefit Plans
Assumptions used to calculate the net periodic cost
Discount rate (in hundredths)		4.25%
Assumptions used to calculate the benefit obligation
Discount rate (in hundredths)		4.00%

GUARANTEES (Details)

GUARANTEES (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2015	Oct. 31, 2014
Summary of standard warranty accrual activity
Beginning balance	$ 30	$ 31
Accruals for warranties including change in estimates	53	44
Settlements made during the period	(52)	(45)
Ending balance	31	30
Standard Product Warranty Accrual, Balance Sheet Classification [Abstract]
Accruals for warranties due within one year			$ 29	$ 26
Accruals for warranties due after one year			2	4
Balance	$ 30	$ 31	$ 31	$ 30

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Future minimum lease payments 2016	$ 35
Future minimum lease payments 2017	31
Future minimum lease payments 2018	23
Future minimum lease payments 2019	15
Future minimum lease payments 2020	11
Future minimum lease payments thereafter	34
Operating Leases, Future Minimum Payments Receivable [Abstract]
Future minimum lease income 2016	9
Future minimum lease income 2017	9
Future minimum lease income 2018	7
Future minimum lease income thereafter	23
Total rent expense	$ 65	$ 55	$ 53

SHORT-TERM DEBT - Credit Facili

SHORT-TERM DEBT - Credit Facility (Details) $ in Millions	12 Months Ended
	Oct. 31, 2015USD ($)
Line of Credit Facility [Abstract]
Credit facility limit increase	$ 300
Line of Credit [Member]
Line of Credit Facility [Abstract]
Credit facility initiation date	Sep. 15, 2014
Initial maximum borrowing capacity - credit facility	$ 400
Line of Credit Facility, Maximum Borrowing Capacity	$ 700
Short-term Debt, Terms	five
Line of credit facility expiration date	Sep. 15, 2019
Line of credit outstanding balance	$ 0

LONG-TERM DEBT - Carrying Value

LONG-TERM DEBT - Carrying Value (Details) - USD ($) $ in Millions	Oct. 20, 2014	Jun. 18, 2013	Sep. 10, 2012	Jul. 13, 2010	Oct. 24, 2007	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013	Aug. 09, 2011
Debt Instrument [Line Items]
Amortized Principal						$ 1,596	$ 1,596
Interest Rate Swap						21	25
Total						1,617	1,621
Repayments of Senior Debt						0	1,000	$ 250
Accelerated amortization of interest rate swap gain						0	22	$ 0
Senior Notes 2017 [Member]
Debt Instrument [Line Items]
Issuance date of Debt					Oct. 24, 2007
Debt Instrument, Repurchase Amount							580
Amortized Principal						100	100
Interest Rate Swap						2	3
Total						102	103
Repayments of Senior Debt	$ 500
Gains (Losses) on Extinguishment of Debt							80
Accelerated amortization of interest rate swap gain	14
Amortization of Financing Costs							2
Interest Paid							15
Debt Instrument, Face Amount	$ 600				$ 600	100
Fixed interest rate per annum (in hundredths)					6.50%
Senior Notes 2020 [Member]
Debt Instrument [Line Items]
Issuance date of Debt				Jul. 13, 2010
Amortized Principal						499	499
Interest Rate Swap						19	22
Total						518	521
Debt Instrument, Face Amount				$ 500					$ 500
Fixed interest rate per annum (in hundredths)				5.00%
Senior Notes 2022 [Member]
Debt Instrument [Line Items]
Issuance date of Debt			Sep. 10, 2012
Amortized Principal						399	399
Interest Rate Swap						0	0
Total						399	399
Debt Instrument, Face Amount			$ 400
Fixed interest rate per annum (in hundredths)			3.20%
Senior Notes 2023 [Member]
Debt Instrument [Line Items]
Issuance date of Debt		Jun. 18, 2013
Amortized Principal						598	598
Interest Rate Swap						0	0
Total						$ 598	$ 598
Debt Instrument, Face Amount		$ 600
Fixed interest rate per annum (in hundredths)		3.875%

LONG-TERM DEBT - Components and

LONG-TERM DEBT - Components and Additional Disclosures (Details) - USD ($) $ in Millions	Sep. 30, 2027	Jun. 18, 2013	Sep. 10, 2012	Jul. 13, 2010	Oct. 24, 2007	Jan. 31, 2014	Oct. 31, 2015	Oct. 20, 2014	Aug. 09, 2011
Debt Instrument [Line Items]
Maturity date						Sep. 30, 2027
Mortgage Loans on Real Estate							$ 38
Senior Notes 2017 [Member]
Debt Instrument [Line Items]
Issuance date of Debt					Oct. 24, 2007
Aggregate face amount of debt					$ 600		$ 100	$ 600
Issue rate percentage of principal amount					99.60%
Maturity date					Nov. 1, 2017
Fixed interest rate per annum (in hundredths)					6.50%
Interest payment frequency					semi-annually
Date payments commenced					May 1, 2008
Senior Notes 2020 [Member]
Debt Instrument [Line Items]
Issuance date of Debt				Jul. 13, 2010
Aggregate face amount of debt				$ 500					$ 500
Issue rate percentage of principal amount				99.54%
Maturity date				Jul. 15, 2020
Fixed interest rate per annum (in hundredths)				5.00%
Interest payment frequency				semi-annually
Date payments commenced				Jan. 15, 2011
Senior Notes 2022 [Member]
Debt Instrument [Line Items]
Issuance date of Debt			Sep. 10, 2012
Aggregate face amount of debt			$ 400
Issue rate percentage of principal amount			99.80%
Maturity date			Oct. 1, 2022
Fixed interest rate per annum (in hundredths)			3.20%
Interest payment frequency			semi-annually
Date payments commenced			Apr. 1, 2013
Senior Notes 2023 [Member]
Debt Instrument [Line Items]
Issuance date of Debt		Jun. 18, 2013
Aggregate face amount of debt		$ 600
Issue rate percentage of principal amount		99.544%
Maturity date		Jul. 15, 2023
Fixed interest rate per annum (in hundredths)		3.875%
Interest payment frequency		semi annually
Date payments commenced		Jan. 15, 2014
Scenario, Forecast [Member] | Other Debt [Member]
Debt Instrument [Line Items]
Interest payment frequency	March, June, September and December of each year

LONG-TERM DEBT - Other (Details

LONG-TERM DEBT - Other (Details) $ in Millions	Aug. 09, 2011USD ($)	Nov. 25, 2008USD ($)contracts	Jan. 31, 2014	Oct. 31, 2015USD ($)
Schedule Of Interest Rate Swaps Regarding Senior Notes Offered [Line Items]
Debt Instrument, Maturity Date			Sep. 30, 2027
Senior Notes 2020 [Member]
Schedule Of Interest Rate Swaps Regarding Senior Notes Offered [Line Items]
Interest Rate Derivatives Terminated Date	August 9, 2011
Notional Amount of Terminated Interest Rate Swaps	$ 500
Asset Value of Terminated Interest Rate Swaps	$ 34
Amount to be amortized on terminated interest rate swaps associated with senior notes				$ 19
Senior Notes 2017 [Member]
Schedule Of Interest Rate Swaps Regarding Senior Notes Offered [Line Items]
Interest Rate Derivatives Terminated Date		November 25, 2008
Number of interest swaps terminated on specified date | contracts		2
Notional Amount of Terminated Interest Rate Swaps		$ 400
Asset Value of Terminated Interest Rate Swaps		$ 43
Amount to be amortized on terminated interest rate swaps associated with senior notes				$ 2

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	Nov. 19, 2015	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013	May. 28, 2015
Share Repurchase Program [Line Items]
Expected total amount of share repurchases in fiscal year		$ 365
Weighted average count of diluted shares		335
Treasury Stock, Shares, Acquired		6	4	20
Remaining authorized repurchase amount		$ 98
Cost to repurchase shares of common stock under share repurchase program		$ 267	$ 200	$ 900
Dividends [Abstract]
Cash Dividends Declared (per common share)		$ 0.400	$ 0.528	$ 0.460
Cash dividends declared		$ 133	$ 176	$ 156
Aggregate cash dividends paid ( per common share)		$ 0.40	$ 0.53	$ 0.46
Aggregate cash dividends paid		$ 133	$ 176	$ 156
2015 Repurchase Program [Member]
Share Repurchase Program [Line Items]
Stock Repurchase Program, Authorized Amount					$ 1,140
Dividend Declared [Member]
Dividends [Abstract]
Cash Dividends Declared (per common share)	$ 0.115
Cash dividends declared	$ 38
Dividends date of record	Jan. 5, 2016
Dividends payment date	Jan. 27, 2016

STOCKHOLDERS' EQUITY -Accumulat

STOCKHOLDERS' EQUITY -Accumulated other comprehensive income (Details) - USD ($) $ in Millions	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Unrealized gain on equity securities, net of $0 and $(3) of tax expense for 2015 and 2014, respectively	$ 0	$ 17	$ 7
Foreign currency translation, net of $(2) and $(86) of tax expense for 2015 and 2014, respectively	(189)	156	425
Unrealized losses on defined benefit plans, net of tax benefit of $126 and $145 for 2015 and 2014, respectively	(204)	(516)
Unrealized gains and (losses) on derivative instruments, net of tax expense of $(2) and $(7) for 2015 and 2014, respectively	2	9	0
Total accumulated other comprehensive income (loss)	(391)	(334)	$ 91
Accumulated other Comprehensive Income (Loss), Tax [Abstract]
Unrealized gain on equity securities, tax	0	(3)
Foreign currency translation, tax	(2)	(86)
Unrealized losses on defined benefit plans, tax	126	145
Unrealized gains (losses) on derivative instruments, tax	$ (2)	$ (7)

STOCKHOLDERS' EQUITY - Changes

STOCKHOLDERS' EQUITY - Changes in accumulated other comprehensive income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Beginning Balance	$ (334)	$ 91
Other Comprehensive Income (Loss), before Reclassifications	(439)	(525)
Amounts Reclassified out of Accumulated Other Comprehensive Income	0	17
Tax (expense) benefit	50	83
Other Comprehensive Income (Loss)	(389)	(425)	$ 202
Ending Balance	(391)	(334)	91
Unrealized Gain (Loss) on Investments [Abstract]
Beginning Balance	17	7
Other Comprehensive Income (Loss), before Reclassifications	0	12
Amounts Reclassified out of Other Comprehensive Income	0	(1)
Tax (expense) benefit	0	(1)
Other Comprehensive Income (Loss)	0	10
Ending Balance	0	17	7
Foreign Currency Translation [Abstract]
Beginning Balance	156	425
Other Comprehensive Income (Loss), before Reclassifications	(360)	(277)
Amounts Reclassified out of Other Comprehensive Income	0	0
Tax (expense) benefit	24	8	8
Other Comprehensive Income (Loss)	(336)	(269)
Ending Balance	(189)	156	425
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit), before Tax [Abstract]
Beginning Balance	255	287
Other Comprehensive (Income) Loss, before Reclassifications	0	0
Amounts Reclassified out of Other Comprehensive Income	(17)	(48)
Tax (expense) benefit	6	16	16
Other Comprehensive (Income) Loss	(11)	(32)	(32)
Ending Balance	161	255	287
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), before Tax [Abstract]
Beginning Balance	(771)	(628)
Other Comprehensive Income (Loss), before Reclassifications	(90)	(273)
Amounts Reclassified out of Other Comprehensive Income	35	65
Tax (expense) benefit	17	65
Other Comprehensive Income (Loss)	(38)	(143)	228
Ending Balance	(365)	(771)	(628)
Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax [Abstract]
Beginning Balance	9	0
Other Comprehensive Income (Loss), before Reclassifications	11	13
Amounts Reclassified out of Other Comprehensive Income	(18)	1
Tax (expense) benefit	3	(5)
Other Comprehensive Income (Loss)	(4)	9
Ending Balance	2	9	$ 0
Continuing Operations [Member]
Beginning Balance	(2)
Ending Balance		(2)
Unrealized Gain (Loss) on Investments [Abstract]
Beginning Balance	0
Ending Balance		0
Foreign Currency Translation [Abstract]
Beginning Balance	147
Ending Balance		147
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit), before Tax [Abstract]
Beginning Balance	172
Ending Balance		172
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), before Tax [Abstract]
Beginning Balance	(327)
Ending Balance		(327)
Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax [Abstract]
Beginning Balance	6
Ending Balance		6
Discontinued Operations [Member]
Beginning Balance	332
Ending Balance		332
Unrealized Gain (Loss) on Investments [Abstract]
Beginning Balance	(17)
Ending Balance		(17)
Foreign Currency Translation [Abstract]
Beginning Balance	(9)
Ending Balance		(9)
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit), before Tax [Abstract]
Beginning Balance	(83)
Ending Balance		(83)
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), before Tax [Abstract]
Beginning Balance	444
Ending Balance		444
Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax [Abstract]
Beginning Balance	$ (3)
Ending Balance		$ (3)

STOCKHOLDERS' EQUITY STOCKHOLDE

STOCKHOLDERS' EQUITY STOCKHOLDERS' EQUITY - Reclassifications out of accumulated other comprehensive income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Unrealized gains and (losses) on sale of securities reclassified to other income (expense)	$ 0	$ 1
Total reclassification of unrealized gains and losses on equity securities before tax	0	1
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax	0	0	$ 0
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax	0	1	0
Derivative Instruments, Gain Reclassified from Accumulated OCI into Income, Effective Portion	18
Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion		(1)
Unrealized gains and losses on derivatives reclassified to cost of products, before tax	18	(1)
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax	(6)	0	(3)
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax	12	(1)	$ 10
Other Comprehensive Income Defined Benefit Plan Amortization Of Net Actuarial Loss	(35)	(65)
Amortization of prior service benefit	(17)	(48)
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, before Tax	(18)	(17)
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, Tax	5	(2)
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, Net of Tax	(13)	(19)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	$ (1)	$ (19)

SEGMENT INFORMATION Profitabili

SEGMENT INFORMATION Profitability (Details) $ in Millions	12 Months Ended
	Oct. 31, 2015USD ($)segment	Oct. 31, 2014USD ($)	Oct. 31, 2013USD ($)
Segment Reporting [Abstract]
Number of operating segments | segment	3
Select income statement components (Loss) [Abstract]
Total net revenue	$ 4,038	$ 4,048	$ 3,894
Income from operations	522	419	386
Depreciation expense	98	120	116
Share-based compensation	54	96	85
Life Sciences and Applied Markets [Member]
Select income statement components (Loss) [Abstract]
Total net revenue	2,046	2,078	2,035
Income from operations	380	369	338
Depreciation expense	27	29	28
Share-based compensation	27	29	27
Diagnostics and Genomics [Member]
Select income statement components (Loss) [Abstract]
Total net revenue	662	663	635
Income from operations	88	93	95
Depreciation expense	37	43	43
Share-based compensation	9	9	4
Agilent CrossLab [Member]
Select income statement components (Loss) [Abstract]
Total net revenue	1,330	1,307	1,224
Income from operations	299	301	299
Depreciation expense	34	33	27
Share-based compensation	18	18	16
Segment Total [Member]
Select income statement components (Loss) [Abstract]
Total net revenue	4,038	4,048	3,894
Income from operations	767	763	732
Depreciation expense	98	105	98
Share-based compensation	$ 54	$ 56	$ 47

SEGMENT INFORMATION Reconciliat

SEGMENT INFORMATION Reconciliation of Reportable Results (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Reconcilitation between statement results and enterprise results [Abstract]
Total reportable segments' income from operations	$ 767	$ 763	$ 732
Restructuring and business exit related costs	(12)	(66)	(34)
Acceleration of depreciation for held and used assets	0	0	0
Asset impairments	(3)	(4)	(2)
Transformational programs	(56)	(29)	(19)
Amortization of intangibles	(156)	(189)	(190)
Acquisition and integration costs	(13)	(11)	(22)
Acceleration of sharebased compensation expense related to workforce reduction	(2)	(1)	(2)
One time and pre separation costs	0	(14)	0
Other	(3)	10	(13)
Interest income	7	9	7
Interest Expense	(66)	(110)	(107)
Other income (expense), net	17	(89)	7
Unallocated corporate charges	0	(40)	(64)
Income from continuing operations before taxes	480	229	293
Segment assets and capital expenditures [Abstract]
Assets	4,574	4,966
Capital expenditures	98	205	$ 195
Segment Total [Member]
Segment assets and capital expenditures [Abstract]
Capital expenditures	98	110
Life Sciences and Applied Markets [Member]
Segment assets and capital expenditures [Abstract]
Assets	1,539	1,663
Capital expenditures	28	33
Diagnostics and Genomics [Member]
Segment assets and capital expenditures [Abstract]
Assets	2,027	2,302
Capital expenditures	33	40
Agilent CrossLab [Member]
Segment assets and capital expenditures [Abstract]
Assets	1,008	1,001
Capital expenditures	$ 37	$ 37

SEGMENT INFORMATION Entity-Wide

SEGMENT INFORMATION Entity-Wide Disclosures (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Entity Wide Disclosure
Concentration Risk, Customer	No customer represented 10 percent or more of our total net revenue in 2015, 2014 or 2013
Revenue by product category
Revenues	$ 4,038	$ 4,048	$ 3,894
Revenue by geography
Revenue, Net	4,038	4,048	3,894
Long-lived assets by geography
Long-Lived Assets	770	830
UNITED STATES
Revenue by geography
Revenue, Net	1,206	1,019	1,077
Long-lived assets by geography
Long-Lived Assets	391	379
Rest Of World [Member]
Revenue by geography
Revenue, Net	2,199	2,486	2,198
Long-lived assets by geography
Long-Lived Assets	379	451
CHINA
Revenue by geography
Revenue, Net	633	543	619
Instrumentation
Revenue by product category
Revenues	1,827	1,839	1,802
Analytical lab services
Revenue by product category
Revenues	843	831	768
Analytical lab consumables
Revenue by product category
Revenues	489	476	456
Diagnostics and genomics solutions
Revenue by product category
Revenues	662	663	635
Informatics and other
Revenue by product category
Revenues	$ 217	$ 239	$ 233

SEGMENT INFORMATION Segment Ass

SEGMENT INFORMATION Segment Assets (Details) - USD ($) $ in Millions	Oct. 31, 2015	Oct. 31, 2014
Segment Reporting Information [Line Items]
Total reportable segments' assets	$ 4,574	$ 4,966
Cash and cash equivalents	2,003	2,218
Short-term restricted cash and cash equivalents	242	0
Prepaid expenses	105	85
Investments	86	96
Long term and other receivables	104	90
Other	365	377
Current and non-current assets of discontinued operations	0	2,983
Total assets	7,479	10,815
Life Sciences and Applied Markets [Member]
Segment Reporting Information [Line Items]
Total reportable segments' assets	1,539	1,663
Diagnostics and Genomics [Member]
Segment Reporting Information [Line Items]
Total reportable segments' assets	2,027	2,302
Agilent CrossLab [Member]
Segment Reporting Information [Line Items]
Total reportable segments' assets	$ 1,008	$ 1,001

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($) $ in Millions	Nov. 02, 2015	Oct. 31, 2015	Oct. 31, 2014
Subsequent Event [Line Items]
Short-term restricted cash and cash equivalents		$ 242	$ 0
Subsequent Event [Member]
Subsequent Event [Line Items]
Acquisition purchase price	$ 242

Schedule II Valuation and Qu110

Schedule II Valuation and Qualifying Accounts (Details) - Valuation Allowance of Deferred Tax Assets [Member] - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Movement in valuation and qualifying accounts [Roll Forward]
Balance at Beginning of Period	$ 134	$ 131	$ 139
Additions Charged to Costs, Expenses or Other Accounts	6	3	0
Deductions Credited to Expenses or Other Accounts	(9)	0	(8)
Balance at End of Period	$ 131	$ 134	$ 131